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Blood donation is central to maintaining adequate blood supply for routine hospital demands and 
ensuring preparedness for emergency situations.  As blood donation is a voluntary activity, it is 
important that blood collection services ensure that blood donor health is not negatively impacted in 
the strive to maintain blood supply. However, health-related consequences of frequent blood 
donation are not fully understood, and the relevance of iron supplementation remains unclear. Thus, 
the aim of this thesis was to investigate different aspects of blood donor health (including quality of 
life, iron levels and symptoms related to iron deficiency) and to summarise key characteristics of 
donors who may be able to safely give blood donations more frequently.  
The INTERVAL trial was a large pragmatic trial conducted to assess whether blood supply in the UK 
could be safely increased by reducing the interval between blood donations. A total of 45,263 UK 
blood donors (50% men and 50% women) were assigned to donate blood more frequently (men: 8 
and 10 weeks; women: 12 and 14 weeks) than routine practice (men: 12 weeks, women 16 weeks). 
Interactions with randomised inter-donation interval were assessed to identify donor subgroups who 
may safely donate more frequently without affecting the trial’s key safety outcome - low haemoglobin 
deferrals. Mediation analyses were performed to assess whether iron supplementation during the 
trial mediated the effect of randomised inter-donation frequency on donor reported symptoms 
potentially associated with iron deficiency, including tiredness, breathlessness, palpitations, and 
fainting. Modelling was performed to assess the effect of more frequent blood donation on donors’ 
physical and mental wellbeing. 
Among 252,528 donor attendances during the 2-year period of the INTERVAL trial, 222,370 (88%) 
resulted in successful donation and 13,099 (5%) resulted in low haemoglobin deferrals. Donors 
randomised to shorter inter-donation intervals were able to give more donations, but also had higher 
frequency of low haemoglobin deferrals. Further interaction analyses conducted in this thesis 
suggested that increased frequency of donations with shorter inter-donation intervals was modified 
by age, donation history, iron multivitamin supplement use, physical and mental health scores and 
ferritin levels. The effect of randomised inter-donation interval on low haemoglobin deferrals was 
modified by baseline donation history, age, haemoglobin level and ferritin level.   
Donors randomised to shorter inter-donation intervals reported higher frequencies of symptoms such 
as tiredness, breathlessness, fainting or feeling faint, and palpitations. Use of iron supplementation, a 
commonly studied therapy for relieving symptoms such as fatigue, also increased during the trial. 
However, the effect of shorter inter-donation intervals on the frequency of symptoms was the same 
irrespective of adjustment for iron supplementation use before or during the trial.  
Donors in the INTERVAL trial had higher physical and mental health component scores (PCS, MCS) than 
the general population. While the PCS and MCS were associated with baseline characteristics such as 
age, weight, and previous diagnosis of anaemia, there was no significant effect of randomised inter-
donation interval on any of PCS, MCS, or the eight sub-components that make up the two summary 
measures. 
The findings from this thesis may help inform future directions for blood donation practice and 
management in the UK and elsewhere. Characteristics of donors able to safely donate blood more 
frequently and those who may be at greater risk of low haemoglobin deferrals were identified. Impact 
on donors’ quality of life appears marginal. Some physical symptoms may be experienced by donors 
who donate more frequently, irrespective of iron supplementation use, suggesting need for further 
study to elucidate other mechanisms of mitigating post-donation symptoms. 
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Blood donation is central to maintaining adequate blood supply for routine hospital demands and 
ensuring preparedness for emergency situations.  As blood donation is a voluntary activity, it is 
important that blood collection services ensure that blood donor health is not negatively impacted in 
the strive to maintain blood supply. However, health-related consequences of frequent blood 
donation are not fully understood, and the relevance of iron supplementation remains unclear. Thus, 
the aim of this thesis was to investigate different aspects of blood donor health (including quality of 
life, iron levels and symptoms related to iron deficiency) and to summarise key characteristics of 
donors who may be able to safely give blood donations more frequently.  
The INTERVAL trial was a large pragmatic trial conducted to assess whether blood supply in the UK 
could be safely increased by reducing the interval between blood donations. A total of 45,263 UK 
blood donors (50% men and 50% women) were assigned to donate blood more frequently (men: 8 
and 10 weeks; women: 12 and 14 weeks) than routine practice (men: 12 weeks, women 16 weeks). 
Interactions with randomised inter-donation interval were assessed to identify donor subgroups who 
may safely donate more frequently without affecting the trial’s key safety outcome - low haemoglobin 
deferrals. Mediation analyses were performed to assess whether iron supplementation during the 
trial mediated the effect of randomised inter-donation frequency on donor reported symptoms 
potentially associated with iron deficiency, including tiredness, breathlessness, palpitations, and 
fainting. Modelling was performed to assess the effect of more frequent blood donation on donors’ 
physical and mental wellbeing. 
Among 252,528 donor attendances during the 2-year period of the INTERVAL trial, 222,370 (88%) 
resulted in successful donation and 13,099 (5%) resulted in low haemoglobin deferrals. Donors 
randomised to shorter inter-donation intervals were able to give more donations, but also had higher 
frequency of low haemoglobin deferrals. Further interaction analyses conducted in this thesis 
suggested that increased frequency of donations with shorter inter-donation intervals was modified 
ii 
 
by age, donation history, iron multivitamin supplement use, physical and mental health scores and 
ferritin levels. The effect of randomised inter-donation interval on low haemoglobin deferrals was 
modified by baseline donation history, age, haemoglobin level and ferritin level.   
Donors randomised to shorter inter-donation intervals reported higher frequencies of symptoms such 
as tiredness, breathlessness, fainting or feeling faint, and palpitations. Use of iron supplementation, a 
commonly studied therapy for relieving symptoms such as fatigue, also increased during the trial. 
However, the effect of shorter inter-donation intervals on the frequency of symptoms was the same 
irrespective of adjustment for iron supplementation use before or during the trial.  
Donors in the INTERVAL trial had higher physical and mental health component scores (PCS, MCS) than 
the general population. While the PCS and MCS were associated with baseline characteristics such as 
age, weight, and previous diagnosis of anaemia, there was no significant effect of randomised inter-
donation interval on any of PCS, MCS, or the eight sub-components that make up the two summary 
measures. 
The findings from this thesis may help inform future directions for blood donation practice and 
management in the UK and elsewhere. Characteristics of donors able to safely donate blood more 
frequently and those who may be at greater risk of low haemoglobin deferrals were identified. Impact 
on donors’ quality of life appears marginal. Some physical symptoms may be experienced by donors 
who donate more frequently, irrespective of iron supplementation use, suggesting need for further 
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Chapter 1 – Introduction  
Summary 
The UK blood services rely on donations from unpaid, voluntary donors. Blood donation in England is 
administered by NHS Blood and Transplant, which requires around 5,000 donations every day to meet 
the demand of hospital emergencies and planned procedures. The donation process lasts between 5-
10 minutes, and each blood unit is separated into component parts which can be administered to 
different patients. The majority of blood is given by donors who are white, older than average, and 
male. The UK donor population is aging more quickly than the general population. 
Despite concerns that the aging population would require more transfusions, transfusion demand has 
been declining globally. However, as it is possible that demand may outstrip supply in the future, and 
for rare blood groups the question of efficiently maximising blood collection from the blood donor 
population remains relevant. Currently in the UK, men can donate every 12 weeks, and women every 
16 weeks.  
The INTERVAL trial was a large multi-centre trial that recruited approximately 45,000 blood donors 
from the UK, who were randomised to give blood at different inter-donation intervals for two years. 
For men, the inter-donation intervals were 8, 10, and 12 weeks, and for women these were 12, 14, 
and 16 weeks. The aims of the trial included the feasibility of use of different donation intervals for 
subgroups of the population.  
The objectives of this chapter are to provide a background to blood donation in the UK and an 
overview of the INTERVAL trial, the primary data source. It also examines recent trends in blood supply 
and demand and how these may change in the future, including how personalised inter-donation 
intervals that are more frequent than current NHS guidelines may become relevant. 
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The overarching aim of my PhD project was to identify donor characteristics associated with the ability 
to safely donate blood more frequently than current NHS guidelines, which could be used to develop 
stratification schemes to personalise the inter-donation intervals of blood donors. 
1.1 Overview of Blood Donation in the UK 
Blood donation in England is managed by the NHS Blood and Transplant (NHSBT). This body was 
formed in 2005 after the merging of the National Blood Service and UK Transplant. NHSBT currently 
needs approximately 5,000 donations a day to meet blood demand in England [1], which amounts to 
400 new donors a day [2]. One donation removes 470ml of blood [3] and this is separated into 
components such as red blood cells, platelets, and plasma (Figure 1.1). These components can then 
be administered separately to patients who need them, allowing one blood donation to benefit 
multiple people [4]. 
 
Figure 1.1: Diagram of key blood components [5]. Blood is made up of 55% plasma and 45% of cells, 
the most common being red blood cells, white blood cells, and platelets. 
Blood donors in the UK must satisfy eligibility and exclusion criteria for blood donation (Table 1.1) [6]. 
In addition, they must satisfy a haemoglobin level screening test. This helps check that donors are not 
already iron deficient and minimises the risk of developing iron deficiency anaemia as a result of 
donation, with a loss of 250mg of iron per donation [7]. It also ensures that the blood collected by the 
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blood service is fit for purpose, and able to be safely used in a transfusion [8]. Currently, the 
haemoglobin cutoff levels for donation are 125g/l for women and 135g/l for men [9] in line with 
European guidelines [10].  
Haemoglobin is a protein present in red blood cells with a primary physiological function for oxygen 
transport from lungs to cells and body tissues. Its molecular structure includes iron ions (Fe), which 
are essential for oxygen binding, and hence the regard of circulating haemoglobin concentration as 
one of key biomarkers of iron status in the blood [11]. However, as haemoglobin concentrations are 
also related to mechanisms that control the red cell mass, size and the plasma volume, haemoglobin 
screening alone may not detect iron deficient donors who should not be giving blood [12]. Ferritin is 
another key protein reflecting total body iron stores, primarily stored in body organs as the liver, 
spleen and muscle, but also present in circulation as a key carrier of iron in the blood [11]. 
Improvements in technology have recently allowed for quantification of haemoglobin concentrations 
in subpopulations of red blood cells, including reticulocyte haemoglobin concentration (i.e. in young 
red blood cells) suggested to be a better indicator of iron deficiency. Mean cell volume (MCV) is 
another iron-related circulating indicator that has been widely used to detect nutritional iron 
deficiency, however MCV values can be low due to other conditions such as thalassaemia and 
inflammation [12]. 
Table 1.1: Inclusion and exclusion criteria for blood donation in the UK 
Inclusion Criteria for Blood Donation Common Exclusion Criteria for Blood Donation 
Weight between 50 and 160kg Receiving medical or hospital treatment 
Aged between 17 and 66, or 70 if a previous donor Taking medication 
Over 70 and have given blood in the last two years Travel outside of the UK 
 Recent tattoo or piercing 
 During and after pregnancy 
 Feeling ill 
 Cancer 
 After receiving blood, blood products, or organs 
 
When a donor arrives at the blood donor centre to donate, they are asked to complete a questionnaire 
and undergo haemoglobin testing. The donor is also provided with 500ml of fluid which they are 
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advised to drink over 5 minutes. Then, a needle is inserted into the donor’s arm to enable donation. 
Donors are advised to perform muscle tension exercises from this point of the donation process to 
maintain blood pressure and make the donation experience a more positive one. The amount of blood 
collected is measured by an agitator scale, and the process of drawing blood is stopped automatically 
when this reaches the required amount. The process of blood donation itself usually takes between 5 
and 10 minutes. 
Post-donation, donors can collect drinks and snacks from a refreshment table. They are advised to 
wait at least 15 minutes in the area and to take at least two drinks. Where possible, the donor is then 
encouraged to book an appointment for their next donation [3]. 
1.2 Low Haemoglobin Deferrals 
One consequence of blood donation is an immediate decrease in iron stores followed by gradual 
recovery in the period thereafter. Low haemoglobin deferral occurs when a blood donor candidate 
fails to meet the haemoglobin threshold for donation. Low haemoglobin deferrals are very de-
motivating for donors: studies have found that a low haemoglobin deferral can significantly reduce a 
donor’s likelihood to return to donate [13, 14]. Even when considering donors who have donated 
regularly some may not return to donate after a low haemoglobin deferral [15]. 
While it is de-motivating for donors to be deferred, it is necessary to protect them from health risks 
associated with anaemia, which include fatigue, restless leg syndrome, and pica [16]. As blood donors 
are particularly at risk of iron deficiency [17], it is important to ensure that allocated inter-donation 
intervals minimise any potential harm to the donor. 
Some donors may be more likely than others to be able to give more blood safely should inter-
donation intervals be varied. There also exist certain donors who are more likely to be deferred with 
the current inter-donation intervals and some for which conclusive information is lacking, as will be 
reviewed in Chapter 2. It is possible that some of these subgroups could be more susceptible to low 
haemoglobin deferrals, as could others not yet apparent in UK populations. It is essential that these 
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aspects are rigorously assessed before implementation of a policy varying the inter-donation intervals 
for donors. 
1.3 Blood Donor Motivations 
With the United Kingdom’s blood service relying on voluntary blood donors, it is important to 
understand donors’ motivations as the demand for blood changes. Efforts to increase the donor base 
may be required as the current population of committed donors from the baby boomer generation 
become ineligible to donate [18]. 
Studies have been performed in the UK and elsewhere that have identified several motivating factors 
for donors to donate (Table 1.2) [13]. These include emotional and bond driven motivations, such as 
knowing others who donate, events such as natural disasters, and personal factors such as a feeling 
of accomplishment [19-21]. Some of these motivations vary by gender. More women respond to direct 
appeals for donation from blood services [22], while more men than women will come to donate in 
response to natural disasters, such as earthquakes, when more people are admitted to hospital hence 
more blood is needed [23, 24]. Men also have more external motivations to giving blood. These 
include personal benefits such as infectious disease testing [25] and general health screening [26]. In 
addition, more men than women report that they are influenced by friends and family, who encourage 
them to donate [25, 27]. This trend can also be seen in rural areas [19], where donors are proud to tell 
their village that they have donated, and blood donation is a part of the donor’s identity. This would 
then encourage other donors to donate. However, donors who donate blood for reasons of reputation 
and recognition by peers, can be viewed as an example of “impure altruism” [28], which is described 
as a “warm glow” that donors experience – feeling good about themselves for donating because they 
believe they have done something good and altruistic. This is evident in both men and women and is 
in contrast to the traditional depiction of blood donation as a purely altruistic act i.e. donors are 
donating purely for the wellbeing of others. One study [29], reported that there has been a decline in 
altruism, which may partly explain the decline in new donor numbers. 
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Consideration of the impact of preceding motivations to donate blood need necessarily be taken into 
account when assessing the generalisability of findings from randomised trials in blood donors. While 
randomisation and analysis under the intention-to-treat principle provides unbiased estimates of the 
effects of the randomised intervention when there is no differential loss to follow up across 
randomised groups, the findings would still only generalise to the donor population similar in 
characteristics to the sample that participated in the trial.  In the trial setting donors are expected to 
actively sign up to participate and comply with demanding trial protocols, such as donating blood at 
specific inter-donation intervals and completing questionnaires, which may skew recruitment to more 
altruistic and motivated donors than the general population. Consequently, it may be possible that 
the intervention effects estimated in a randomised trial may be of a higher magnitude than would be 
observed in practice, due to the variety of likely donor motivations that may impact recruitment into 
a randomised trial setting. Furthermore, substantial outcome-related differential losses to follow up 
across trial arms would bias the trial results. 
Table 1.2: Motivators to donate blood by sex 
Motivates Men Motivates Women Motivates Both 
Natural Disaster Response Direct Appeals Impure Altruism 
Infectious Disease Testing Social Motivations Social Responsibility 
Health Screening Need for Blood Altruism 
Influence of Friends and Family Religious Reasons  
Small Gifts Concern for Others  
 
1.4 The UK Blood Donor Population 
The blood donor population in the UK is aging more quickly than the general population (Figure 1.2); 
the median (IQR) age of the UK general population and the UK donor population was 40 (31-51) and 
45 (32-61) years in 2001 respectively, which rose to 44 (30-54) and 46 (31-62) years in 2011 [30]. A 
similar trend has been observed in other countries, for example, the over 65 donor population more 
than doubled between 1999 and 2009 in Japan [31]. In the USA, changes to the donor eligibility criteria 
increased the prevalence of donors aged 65 years and over [32]. The UK has an over-representation 
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of donors in the 40-60 year old age group [30]. The transfusion needs in the UK population are low, 
until ages 45-50 years, after which point red blood cell use increases exponentially [30]. Similar 
findings were observed in Switzerland [33], and Germany [18] with >60% of blood use occurring in 
those over 65 years old. 
 
 
Figure 1.2: Age distribution of the general population and donor population in years in 2001 (– – –) 
and 2011 (—) in the Netherlands, USA, UK, and Singapore. Proportionally, the donor population is 




1.5 Donor Return Rates  
Retention rates for new donors are low with only 55.2% of new donors in a UK study returning after 
18 months [34]. There are many factors that affect whether a donor is likely to return to donate. A 
large Norwegian study found men significantly more likely to return to donate after 6 months than 
women (OR 1.09, 95% CI 1.08-1.11), although a more recent but smaller study found no significant 
difference (p=0.16) [35]. Other factors that affect blood donors returning to donate include adverse 
events and vasovagal reactions such as fainting, loss of breath, dizziness, and nausea [36], which can 
account for a drop of between 24% and 34% in return rates [8, 37-39]. Other individual level factors 
that reduce return rates are fear of needles, dizziness, and worries about the healthcare system and 
donation process [25, 40, 41]. Another key indicator of donor lack of return is missing an appointment 
[35]. Donors are more likely to continue to donate if they have a positive experience of or attitude to 
blood donation [33, 42, 43]. Another strategy that has proven effective in retaining donors is helping 
them to plan future donation, for example, by reminding them of donation appointments [43].  
A key aim of donor retention should be to create blood donation as a part of a donor’s routine, and 
the aforementioned systematic reminders can help donors to schedule donation into their lives as a 
routine activity. One study found that it takes four donations for blood donation to form a part of the 
donor’s identity [44]. Another study established that donors are more likely than not to tell family and 
friends, and encourage them to donate [45].  
1.6 Trends in Blood Donation  
In the UK over 2 million donations per year are given by over 1 million donors [46], although donation 
rates per donor are falling [34]. The UK’s donor population is reliant more on donors who are white, 
older, and male [34]. Donor numbers in London are significantly lower than elsewhere in the UK. This 
is in concordance with international studies that found that donors in urban areas are more likely to 
lapse from donating blood (cease donation) than those who live in rural and suburban areas [39, 43]. 
Ethnic diversity is increasing in the UK, with a rise from 11% of the UK population identifying as an 
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ethnic minority in 2001, to 20% in 2011 [47]. Despite this, ethnic minorities are under-represented in 
the donor population [34] and ethnic minority donors donate less frequently than white donors [34, 
48, 49], and retention rates for ethnic minority donors, as well as first time donors, are low [34]. 
1.7 Changes in Transfusion Demand 
Despite the aging population, transfusion demand is falling globally. All Western countries have found 
a reduction in the demand for blood [33, 50-53]. In the UK, there was a 7.3% decrease of RBC 
transfusions between 2011 and 2013, alongside a 12.1% decrease in collections [32]. Transfusion rates 
per 1000 of the population have fallen from 45.5 in 1999 to 36 in 2009 [51, 52]. In Germany, the 
number of transfusions fell by 13% between 2010 and 2015 [54], and in the wider time frame between 
2005 and 2015, the largest reduction in transfusion demand came from the 20-45 and 65-80 year old 
age groups [18]. Like in the UK, donor numbers are falling, with a 12.4% decrease in donation rates for 
women. A Dutch study found decreased transfusions, with a 20% reduction in RBCs issued between 
1996 and 2005, and a continued decrease of 9%, between 2012 and 2013 [53]. In addition, the number 
of hospital inpatients who did not require a transfusion increased from around 30% in 2002 to over 
40% in 2011 [55]. There are several possible explanations for the decline in transfusion demand. The 
first is a change in the demographics of hospital procedures, particularly a large decrease in surgical 
patients requiring transfusion. Studies have found that surgical transfusion RBC use decreased by 40% 
or more [18, 51], and those without quantifiable results also stated that the surgical transfusion rate 
is falling [51-53, 56]. Noteworthy is that this is the type of procedure that affects the oldest 
populations most, and so counteracts fears of the aging population requiring more transfusions [18, 






Figure 1.3: Observed changes in blood demand in the 2010 decade in the UK, Germany, the 
Netherlands, Japan, and Switzerland. All countries have seen a fall in demand in the 2010 decade. 
1.7.1 Patient Blood Management 
Another explanation for falling transfusion rates is the growing focus on patient blood management 
(PBM) techniques. PBM aims to optimise the haemoglobin concentration of patients, and to minimise 
blood loss [57]. Successful PBM reduces unnecessary transfusion and side effects, ensures blood 
products are available when needed, improves patient outcomes, and reduces costs [58]. A wide 
variety of PBM techniques can be used, including parenteral iron supplementation, oral iron 
supplementation, topical/systemic haemostatic agents, restrictive use of phlebotomy and restrictive 
transfusion practices [32], all of which have seen a significant increase in usage recently in the UK, 
despite inconsistent implementation amongst UK hospitals [58]. One hospital studied in Manchester, 
that implemented a wider range of PBM initiatives when compared with other hospitals in Europe, 
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had a lower numbers of transfusions per bed (14.9) and low proportion of transfused surgical patients 
(2.5) [56].  
PBM has also been credited with declining blood use in the USA [59-62], with one study finding that 
giving less blood through more restrictive haemoglobin triggers (reducing the threshold at which a 
transfusion is performed) gave the same or better outcomes for most patients. This, used alongside 
other PBM techniques, contributed to a fall in RBC use per 1000 patients from 338 pre PBM to 228 
post PBM. The effect was further pronounced in the over 65s, with these numbers being 547 vs 313 
[63]. A change in haemoglobin thresholds advised before transfusion has also been implemented in 
the UK [52]. In the Netherlands, a reduction of 10-15% in the use of the overall blood supply has been 
achieved in the past decade due to increasing awareness of blood conservation techniques and 
reduced preoperative allogenic transfusion [64-66]. Another study found that the number of 
procedures which required just one unit per transfusion increased from 4 to 8%, and for medical 
procedures the use of three or more decreased [53]. A single unit transfusion policy was named as 
one of the PBM priorities for the UK hospital in a European PBM study [56] and as such, it is possible 
that future transfusion demand will decrease further if this practice is adopted more generally. 
An additional explanation for more efficient transfusion practices is a large decrease in wasted blood 
products. A study from the USA found that outdated blood fell by 17.3% between 2011 and 2013 [67]. 
In another study, this figure was 19.8%. In particular, when examining platelet use in the same study, 
platelet collections and total distribution were not significantly different, but hospital use increased. 
Combining this with fewer outdated platelet donations suggests hospitals are using products more 
efficiently, and that this improved product management may have a greater effect than PBM 
initiatives [32].  
1.8 Predictions for the Future of Blood Donation 
Due to increased life expectancy, the aging of the baby boomer generation, and a decrease in birth 
rates coupled with increasing affluence, the demographics of the United Kingdom’s blood donor 
12 
 
population may be expected to change in the coming decades [34]. This shift in demographics could 
lead to an increased demand for blood [30, 68-70]. The aforementioned faster aging of the donor 
population compared to the general population [30] could expediate such a problem. While there is a 
current surplus of blood for transfusions, this may change in the future. The primary cause for concern 
in the next 10-15 years is that the current set of donors from the baby boomer generation, who are 
currently most committed and give the most donations, become ineligible to donate because of age 
or other health problems [18], and new donor levels will not match the shortfall caused by these 
donors becoming ineligible to donate. It has been suggested that a way to mitigate this is to encourage 
repeat donationas soon as possible, as well as to encourage repeat donors to persuade peers to 
donate. As such, maximising the blood supply from the current donor base may become a relevant 
question for in the future. 
The future of blood supply and demand remains uncertain throughout the world. Due to the aging 
population worldwide, studies predict  that there will soon be large shortfalls in blood supply in many 
countries [33], some stating these could occur as soon as 2020 [70]. However, a study from Japan 
incorporated advances in medical technology into their models, and found that, after a slight increase 
in demand in 2022 to outstrip supply, demand would fall due to technological progress by 2027 and 
would be met by predicted supply [31]. However, Japan permits 200ml blood donations in addition to 
400ml donations, and this could increase supply as donors unable to endure a full 400ml donation can 
still donate blood. Despite this, it is possible that these technological advances will be seen in other 
countries, thus similarly reducing demand for blood. 
1.9 Blood Donation Intervals in the UK and Europe 
The minimum length of time between blood donations (i.e. inter-donation interval) in England and 
Wales is twelve weeks for men and sixteen weeks for women [71]. These are some of the longest 
inter-donation intervals in Europe (Table 1.3). In other countries, the donation interval can be as little 
as eight weeks for both sexes, e.g. in the USA [72], and some countries in Europe. In Austria, Germany, 
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France and Finland, men can donate every eight weeks, and in Austria and Ireland women can donate 
every ten weeks [7]. Decreasing the donation interval for blood donors in the UK could be an answer 
to the declining number of new donors. 
Table 1.3: Inter-donation intervals (in weeks) in England and selected countries from the rest of the 
world 
Country Men Women 
England 12 16 
USA 8 8 
Austria 8 10 
France 8 12 
Ireland 10 10 
Denmark 12 12 
Slovenia 12 16 
Scotland 16 16 
 
1.10 The INTERVAL Trial 
The INTERVAL trial was a large randomised trial that assigned men and women to donate more 
frequently than current NHS guidelines, with a control arm donating at the current inter-donation 
intervals. The shorter inter-donation intervals trialled were 8 and 10 weeks for men, and 12 and 14 
weeks for women [7]. The trial aimed to identify those who were able to safely donate blood more 
frequently than current guidelines, maximising the number of units of blood collected from the UK’s 
decreasing donor population.  
The trial ran for two years between 2014 and 2016, and randomised 45,263 donors, 22,466 men and 
22,797 women, to donate blood at one of the donation intervals, in a 1:1:1 split between donation 
groups [73]. Donors had to donate in one of the 25 fixed donation centres in the UK during the trial 
period. 
The primary outcome was the number of units of blood collected during the trial period. Quality of 
life, as measured by the Physical Component Score (PCS) and Mental Component Score (MCS)  of the 
SF-36 questionnaire, was a key secondary outcome, and was assessed at baseline and end of trial 




The INTERVAL cohort was around 4% of the UK’s total donor population at the time. The sample of 
donors included in the trial was largely similar to the general donor population aside from having a 
higher mean age, lower proportion of men, and a longer and more active donation history [73].  
 
Figure 1.4: Distribution of INTERVAL participants (NHSBT general population in brackets), red dots are 
the donor centres. Darker shades of green indicate where more INTERVAL participants were located 
[73]. 
Previously published results from the trial have shown that for both sexes, donors on the shorter inter-
donation intervals gave significantly more units of blood but also had a significantly higher frequency 
of low haemoglobin deferrals, as well as lower haemoglobin and ferritin concentrations at 2 years 
than those on the longer intervals. Men on the 8 week interval had a 33% higher mean difference in 
units of blood donated during the study. For women on the 10 week interval, this was a 24% increase. 
In addition, there was no impact on the overall quality of life scores due to increased donation, but 
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those on shorter donation intervals did experience more post-donation symptoms such as tiredness, 
restless leg syndrome, and feeling faint, especially men [74]. An extension study of the INTERVAL trial 
involved participants agreeing to continue donating blood at allocated intervals for up to four years. 
While donors in the extension study were older and more committed donors, with fewer deferrals 
and symptoms observed during the main trial, they had decreased haemoglobin concentrations and 
more self-reported symptoms compared with the initial two years of the trial. Furthermore, there was 
an increase in reported frequency of iron supplements prescription or use, particularly in the shorter 
inter-donation intervals [75]. 
1.11 PhD Project Rationale 
While some studies have retrospectively assessed how prolonging the inter-donation interval would 
affect the blood supply in the USA [76], before INTERVAL there was yet to be a randomised trial to 
find the optimal inter-donation intervals at which individuals or groups should donate blood to 
maximise the amount of blood collected while minimising deferrals and effects on quality of life to 
donors.  
The objectives of this PhD project are to identify donor characteristics associated with ability to safely 
donate blood more frequently than current NHS guidelines, which can then be used to develop 
stratification schemes to personalise the inter-donation intervals of blood donors. 
The thesis is structured as follows: 
• In Chapter 2, I present a systematic review of factors that influence a donor’s inability to meet 
pre-donation haemoglobin thresholds. 
• Chapter 3 describes the INTERVAL trial and data used for analysis in the remaining chapters. 
• In Chapter 4, I assess interactions with randomised inter-donation intervals to identify 
characteristics of donors that may potentially inform personalised donation in relation to the 




• Chapter 5 presents the association between donation frequency and the risk of symptoms 
related to iron deficiency, including tiredness, breathlessness, palpitations and fainting. 
Mediation analyses are performed to assess whether iron supplementation mediated the 
effect of donation frequency on health-related outcomes.  
• In Chapter 6, I perform analyses to quantify the effect of more frequent inter-donation 
interval on wellbeing, measured by the physical and mental component scores of the Sf-36 
and Sf-12 questionnaires and the sub-components that comprise these.   
• Chapter 7 provides a general discussion, conclusions, and future directions of research arising 





Chapter 2 – Donor Deferral due to Low Haemoglobin – a Systematic Review 
Update 
Summary 
Blood donors attending a donation session may be deferred from donating blood due to a failure to 
meet low haemoglobin (Hb) thresholds. This costs the blood donor service, and donors, valuable time 
and resources. In addition, return rates of donors deferred for low haemoglobin are lower, even 
amongst repeat donors. Moreover, even when donors do return, they take a long time to do so. It is 
therefore vital that low haemoglobin deferral is minimised to maintain the donor population. A 
systematic review of these factors was conducted in 2012. The current update further synthesised the 
growing evidence base, including quality assessment of relevant studies. 
Studies were identified by searching MEDLINE, EMBASE, The Cochrane Library and the WHO 
International Clinical Trials Registry from 2012 onwards, and the results were added to the previous 
review. Demographic characteristics, donor history, haematological/biological factors and the primary 
outcome of deferral due to low Hb were extracted. Descriptive and quantitative analyses were 
conducted; pooled odds ratios (ORs) were obtained by meta‐analysis.  
Following re-assessment of the studies in the original review, 116 studies met the inclusion criteria 
between this and the previous search. A consistently higher rate of low Hb deferral was reported in 
females compared with males. Meta‐analysis showed a significantly higher odds of deferral due to low 
Hb in females compared with males in studies with universal Hb thresholds for males and females (OR 
14·42, 95% confidence interval (CI) 12·24–16.97) and those with sex‐specific thresholds (OR 5.98, 95% 
CI 4·46–8.02). Other characteristics associated with increased rates of deferral due to low Hb included 
increasing age in men, low body weight, shorter inter‐donation interval, donors of Hispanic or African 
descent, higher ambient temperature, donors with low ferritin levels, donation in a fixed donor centre, 
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and geographical location. There was conflicting evidence on the association of new and repeat donor 
status, and blood group with low Hb deferral.  
This work has strengthened the evidence of the previous systematic review by further identifying key 
characteristics that may be considered in studies of donor deferral. The current review has also 
highlighted areas in need of further study, including blood group, previous platelet donation, diet, 





Faced with dwindling numbers of new donors, blood services globally need to be able to better 
understand how to retain donors. One of the main reasons why donors may stop donating blood is 
because they received a temporary deferral for low haemoglobin (Hb) [15]. While it is widely 
understood that women are more likely to be deferred for low Hb than men, there is limited evidence 
on the contribution of other donor characteristics to low Hb deferral including demographics, or 
physical and environmental factors.  
A previous systematic review from 2013, which included 55 studies, identified a variety of 
characteristics associated with a higher risk for low Hb deferral (LHD) in blood donors [77]. These 
included female gender, the season of donation (spring and summer), older male donors, non-white 
ethnicity, and new donors [77]. Other potential factors identified from individual studies were difficult 
to evaluate due to the small number of studies reporting each factor.  
The objective of this review was to identify new research findings after the publication of the previous 
review and re-assess the previous review. This review also included a formal quality assessment of all 
studies. The information obtained in this review expands the evidence base of factors that influence 
low haemoglobin deferral in blood donors, and helps to inform criteria that should be considered in 
trials of donor management. 
2.2 Materials and Methods 
The protocol for this review was prospectively registered on PROSPERO (CRD42017071105). The 
review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [78]. Full details of the search strategy, eligibility, data extraction 
and quality assessment are provided in the Appendix A. Briefly, literature searches were carried out 
up to March 2019 with eligible studies identified and summarised in Figure 2.1. Screening for eligibility 
and data extraction was performed independently in duplicate by two reviewers.  
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Extracted data included characteristics of study participants (sex, age, ethnicity, weight, number of 
donations during study, season of donation, type of donor etc.), Hb thresholds for deferral from 
donation, outcome data (number of donors deferred and/or number of donation attempts resulting 
in LHD) and any other reported factors which may affect donation. Quality assessment methods were 
adapted from the RTI Item Bank for assessing risk of bias and confounding in observational studies 
[79]. 
The primary outcome was deferral due to low Hb. Both qualitative syntheses and quantitative analyses 
were performed. Random effects meta-analyses were used to account for the expected clinical and 
statistical heterogeneity between studies and provide pooled association estimates based on 
unadjusted count data, which should be interpreted with caution. Summary measures were presented 
as unadjusted odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was assessed using 
the I2 statistic which measures the percentage of variance in a meta-analysis which can be attributed 
to heterogeneity [80]. Statistical analysis was carried out in R v3.4.2 (http://www.r‐project.org/) and 
Review Manager 5.3 [81]. 
2.3 Results of Literature Search 
2.3.1 Study Selection 
The PRISMA study flow diagram is shown in Figure 2.1. After de-duplication, 2,518 records were 
initially screened. Of these, 102 eligible records contributed to 76 independent studies. Thus, together 
with 40 studies from the previous review, 116 studies were included in this update.  
2.3.2 Description of Included Studies  
A summary of the characteristics of the studies can be found in Appendix B.  Of the 116 included 
studies, the majority (n=80) included single unit red blood cell (RBC)/whole blood donations only. 
Other donation types included platelets, double red cell and multicomponent donations (Table 2.1). 
The studies were carried out in 35 countries across six continents. 
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Hb deferral thresholds were reported in 85 studies, and four studies used haematocrit (HCT) levels. A 
universal threshold of 125 g/L was used in 31 studies, while sex-specific thresholds were used in the 
remaining studies, where reported. The threshold for men was between 120 and 135 g/L, and for 
women between 110 and 125 g/L. A variety of screening methods for Hb levels were used, including 
gravimetric estimation, involving a drop of blood into a copper sulphate solution, Hb measurement in 
venous or capillary blood samples, spectrophotometric estimation of haemoglobin (Hemocue), and 
automated analyser (for example Sysmex or Coulter analysers). 
2.3.3 Quality Assessment 
The risk of selection bias was low in the majority of included studies. A moderate risk of attrition bias 
was observed due to some studies failing to report the number of successful donations or deferrals 
due to other reasons. Few studies adequately reported baseline characteristics of donors. The risk of 
attrition bias was lower in new studies, as was the risk of confounding, however few studies performed 






Figure 2.1: PRISMA flow diagram of study selection. 76 new studies were identified and added to the 










Figure 2.2: Comparison of Risk of Bias observed in original and new studies. A: studies new to this 
review update; B: studies included in the previous version of this review. Bias was similar in both the 
original review studies and those in the updated review. 
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2.4 Factors Associated with Low Haemoglobin Deferral (LHD) 
2.4.1 Sex 
Sex specific LHD rates were reported by 64 studies. The male to female ratio varied widely across 
studies, with the percentage of female participants ranging from 1.7% [82] to 100% [83]. Studies from 
India had significantly fewer female participants (3.96 - 20.2%), whereas studies performed in Europe 
and the USA generally had more equal proportions of male and female participants. LHD rates were 
higher in females in all studies. Studies which used universal Hb thresholds for both male and female 
donors showed a 14-fold higher odds of LHD for females (OR 14.62, 95%CI 12.43-17.19).  An increased 
risk of LHD in females remained for those studies which applied lower Hb thresholds for female donors 
(OR 5.73, 95%CI 4.36-7.53) (Figure 2.3). High heterogeneity between studies was observed in both 
analyses (I2>95%). 
Studies that reported male and female deferral numbers separately were stratified by geographical 
location of study, and results of these meta-analyses are presented in Figure 2.4. Notably, differences 
between studies performed in different geographical settings were observed even when similar Hb 
thresholds were applied. For example, the increased risk of LHD in females compared with males was 
significantly higher in studies from Africa (OR 5.24, 95%CI 4.07-6.74) than in studies from Europe (OR 
2.85, 95%CI 2.21-3.68) despite both sets of studies using predominantly sex-specific Hb thresholds 
(where reported). The greatest difference in the risk of LHD between men and women was observed 





Figure 2.3: Meta-analyses of low Hb deferral for females compared with males stratified by whether 
the studies used universal or sex-specific deferral thresholds. There was a higher rate of low Hb 





Figure 2.4: Meta-analyses of low Hb deferral for females compared with males stratified by study 




Nine studies reported LHD by ethnicity, although there was a lack of consistency in the groups studied 
[72, 84-90]. In four studies, [72, 84, 85, 89] the non-white ethnicities reported were Asian, Black, 
Hispanic and not stated, whereas in one study [90] donors were categorized as White, Asian, African, 
unknown and “coloured” and in another study [88], donors were defined as African-American, 
Hispanic, White and “other”. Another study [87] reported deferral rates for Black, Asian, Mixed, Native 
America, and Native Hawaiian. One study only compared white donors with non-white donors. Five 
studies reported Hb deferrals by ethnicity separately for male and female donors. 
For male donors, four out of five studies observed a significantly higher risk of LHD in African-
American/Black donors compared with White donors, with meta-analysis showing an approximate 
two-fold increased risk (OR 1.94, 95%CI 1.14-3.31) associated with African-American/Black ethnicity. 
In female donors, the risk of LHD associated with African-American/Black ethnicity was higher and 
found in all five studies (OR 2.82, 95%CI 1.71-4.65) (Figure 2.5A). In the comparison of Asian and White 
male donors, the combined risk across four studies was not significant (OR 1.17, 95%CI 0.77-1.78).  
However, a significantly higher risk of LHD was found in female Asian donors compared with female 
white donors, with an overall 63% increased risk associated with Asian ethnicity (OR 1.63, 95%CI 1.31-
2.03) (Figure 2.5B). A similar increased risk of LHD was found in female Hispanic donors compared 
with female White donors (OR 1.43, 95%CI 1.22-1.68). However, in male donors, there was no 
evidence that Hispanic ethnicity was associated with an increased risk of LHD (OR 0.74, 95%CI 0.53-
1.03) (Figure 2.5C). However, it should be noted that the degree of heterogeneity across studies was 










Figure 2.5: Meta-analysis of low haemoglobin deferral by ethnicity. A: Black or African-American vs 
White; B: Asian vs White; C: Hispanic vs White. White women had a lower deferral rate than other 




LHD was reported by age groups in 19 new studies [72, 84, 87, 90-105]. In 14 studies which reported 
results separately for men and women, the general trend across studies for men was for LHD rates to 
increase with age in men and to mostly decrease with age in women after 50 years (Figure 2.6). Some 
studies reported that the youngest groups of women had the highest deferral rates [84, 90] while 
others saw a higher deferral rate for women aged 30-50 [92, 101, 102].  
 
Figure 2.6: Graphs of deferral by age for men and women. Each tile represents a study, red lines 
indicate deferral percentage for men, and blue deferral percentage for men. In most studies, women 
were deferred less often as age increased, while the reverse was true of men. 
One study from Africa [100] reported deferral rates by age for men and women separately but these 
were universally very high, with the lowest rate of LHD in any one age group being 27% (in men in 
their 30s) and the highest 71.4% (in women under 20). Two European studies found that male donors 
who were deferred for low Hb had a higher mean age (years) than those not deferred, (47 vs 43) [93] 
(50 vs 46) [94]. In contrast, both studies reported a lower mean age in female deferred donors (38 vs 
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41) [93], (39 vs 43) [94].  A study from the Netherlands [97] showed via a multivariable logistic 
regression model an increased risk of LHD for older men and younger women. A US study [72] 
compared different age groups to those aged 40-49 and found that older men were more likely to be 
deferred (50-59: OR 1.56; 60+: OR 2.96), and younger men less likely (<30: OR 0.57; 30-39: OR 0.74), 
with an inverse trend for women (<30: OR 1.09; 30-39: OR 1.00; 50-59: OR 0.73; 60+: OR 0.72). Finally, 
an Indian study [99] reported that more younger than older donors of both sexes were deferred. 
2.4.4 Seasonality 
Seven studies reported the relationship between seasonal or temperature changes and LHD [93, 94, 
97, 100, 106-108]. Three of these, two European [93, 94] and one African study [100], reported 
deferral numbers by season. Meta-analyses of the three studies showed no significant difference in 
LHD rates between spring and summer months. One other European study noted a significant increase 
in the LHD rate of donors from 2% in January to 3.5% in July [106]. In addition, a US study [107] 
reported a deferral rate of approximately 8% when the temperature was above 12 degrees Celsius, 
compared with 6% in winter. A Dutch study [97] performed logistic regression and found that higher 
LHD was associated with spring and summer compared with autumn and winter, which was more 
pronounced in men. 
In studies that reported deferral numbers separately by sex [93, 94, 100], meta-analysis of each season 
versus winter showed no significant differences by season in male donors (Figure 2.7). In female 
donors, evidence from three studies showed a significantly higher risk of LHD in summer compared 
with winter (OR 1.18, 95%CI 1.07-1.30) (Figure 2.7), but no differences associated with either spring 
or autumn seasons. 
An additional study from the USA [108] reported percentages of low Hb deferrals for men and women 
between 2002 and 2004. It found an overall increase in LHD in other seasons compared with winter, 
which was most pronounced in summer. Looking at sex and age specific deferral rates, older women 
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had a higher increase in deferrals by season compared to younger women, as did older men compared 







Figure 2.7: Meta-analysis of low haemoglobin deferral by season. A: Spring vs Winter; B: Summer vs 
Winter; Autumn vs Winter. Only for women in winter compared to summer were deferral rates 




Four studies [72, 84, 85, 109] reported ORs for LHD by weight and sex. One US study [72] found that, 
compared to people who weighed between 150 and 174lbs (68.0 to 79.3 kg), lighter men (OR 1.38) 
and women (OR 1.13) were deferred at a higher frequency, as were the heaviest women (equal to or 
over 200lbs weight (equal to or over 90.7 kg), OR 1.04), although no CIs were reported. Men who were 
between 175 and 199lbs (79.4 and 90.6 kg) (OR 0.79) and above 200lbs (equal to or over 90.7 kg) (OR 
0.72) were less likely to be deferred, as were women between 175 and 199lbs (79.4 and 90.6 kg) (OR 
0.98), although the statistical significance of these ORs were not reported. One US study [84] used the 
same weight categories as the previous study and showed a marginally significant increase in LHD for 
the heaviest women (>200lbs) (over 90.7 kg) (OR 1.5, 95%CI 1.0 -2.2). In a US study [85], the heaviest 
age group (>200lbs) (over 90.7 kg) was used as the reference group, and logistic regression showed 
significantly higher deferral rates for both sexes for donors in all lighter weight categories with the 
exception of female donors who weighed between 150 and 174lbs (68.0 to 79.3 kg),  who had a 
marginally lower deferral rate (OR 0.95, 95%CI 0.93-0.97), and females between 175-199lbs (79.4 and 
90.6 kg) (OR 0.92, 95% 0.89-0.94). A Dutch study [109] used age adjusted ORs and found that, 
compared to those in the lightest weight category (<60kg), deferral risk decreased with increasing 
weight, with the lowest risk for male donors over 100kg (OR 0.22, 95%CI 0.18-0.27). 
2.4.6 Donation Characteristics 
Donation history was reported using a number of different methods including donation intensity, 
inter-donation interval and repeat versus new donors (Table 2.1). Evaluation of the association of 
donation characteristics with low Hb deferral is difficult as there is an effect of selection and also an 
opposite effect of lowering of iron stores with repeated donation. 
Twelve studies reported deferral by donation intensity, either the number of previous donations the 
donor had made in the past two years expressed as a categorical [72, 84, 85, 96, 110] or continuous 
[93, 94, 97, 111] variable, or the time since the donor’s previous donation [93, 94, 96, 112-114].  
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Two European studies found that the number of previous donations was associated with lower LHD 
risk in both men and women, with a stronger association in men [93, 94]. However, the third study 
concluded that for men, LHD deferral increased as the number of donations increased. One US study 
[84] found no effect of donation history, while the other [72] reported ORs below 1 for donors who 
had seven or more donations in the past two years. A Brazilian study [92] found that, for women in 
particular, the percentage of donation attempts that resulted in low HCT deferrals increased to above 
0.3% for those with seven donations in the past, compared with a proportion of around 0.1% or less 
for those with one or two previous donations. These results for women were in particular contrast 
with the earlier US studies, which found that women who donated more often were at a lower risk of 
deferral, and that only men who had donated once or twice in the past year had a significantly reduced 
risk of deferral  [85, 96]. 
Eight studies reported an association between LHD and time since previous donation [84, 92-94, 96, 
112-114]. Four European studies found that men had a reduced chance of LHD the longer they waited 
to donate, however the results for women were inconsistent [93, 94, 112, 114]. A US study [96] 
reported no significant association for donors who had returned to donate 24 weeks or less since their 
previous donation compared with those who returned between 24 and 36 weeks, however those who 
waited longer between donations were significantly less likely to be deferred. A South African study 
[113] found no significant effect of donation interval.  A Brazilian study [92] found that in male donors 
aged >44y, the time since previous donation had little effect on LHDs, whilst younger male donors saw 
a decrease in low HCT deferrals until around 10 months since their previous donation. Results for 
female donors were similar, although the proportion of low HCT deferrals was higher for all age groups 
than for men. A US study [84] found that donors who waited 13 weeks or less were significantly more 
likely to be deferred for low Hb than those who waited 26 weeks or longer. 
Two studies [115, 116] reported the effect of minimum inter-donation interval on LHDs. A US study 
[115] found that, after increasing the minimum inter-donation interval from eight to twelve weeks, 
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the LHD rate was reduced from 12.5% to 10.2% (p<0.0001). A Canadian study [116] also found that 
after raising its minimum donation interval from 56 to 84 days, deferral rates fell from 13% to 9.5%. 
 
Figure 2.8: Meta-analysis of low haemoglobin deferral, repeat versus new donors. The pooled effect 
was non-significant, indicating that there is no difference in deferral rates by donor status. 
Fifteen studies [87, 90, 95, 96, 104, 105, 117-125] reported LHD for new and repeat donors. Meta-
analysis of 13 studies which reported LHD rates found no difference in the risk of LHD between new 
and repeat donors (OR 0.80, 95%CI 0.58-1.10) (Figure 2.8). In addition, a study from Thailand [121] 
reported only deferral percentages for repeat and new donors and found a higher percentage of LHDs 
for regular donors than new donors, whereas a study from the Caribbean [124] observed the opposite 
effect. The risk of LHD in new and repeat donors is likely to be confounded by the number and intensity 





Table 2.1: Deferral results by donation characteristics. 
Study Donation Group Hb Deferral Rate (%) 
(males/females) 
OR (95% CI) (male/female) 
Donation Intensity    
Baart 2012 Number of whole blood donations in past two years 
 Continuous n/r 1.14 (1.12-1.15)/0.92 (0.9-0.93) 
Baart 2014 Number of whole blood donations in past two years 
 Continuous n/r 0.97/0.9 
Baart 2016 Number of whole blood donations in past two years 
 Continuous n/r 0.97/0.9 
Cable  2012 Number of whole blood donations in past two years 
 1-3 12.26 1 
 4-6 11.23 0.9 (0.7-1.3) 
 7-9 9.07 1 (0.8-1.3) 
 10+ 5.17 1 (0.9-1.4) 
Custer et al 2012 and Number of whole blood donations during previous 12 months 
Mast et al 2010 0 1·3/18·2 1 
 1 1·1/17·5 0·72 (0·67–0·77)/0·99 (0·98–1·01) 
 2 1·5/18·1 0·84 (0·79–0·90)/1·07 (1·05–1·09) 
 3 2·1/18·1 1·04 (0·97–1·11)/1·09 (1·06–1·12) 
 4 2·3/16·4 1·08 (1·01–1·15)/0·97 (0·94–1·00) 
 5 2·6/13·4 1·07 (0·99–1·16)/0·76 (0·73–0·80) 
 ≥6 2·8/8·8 1·00 (0·89–1·13)/0·45 (0·40–0·51) 
De Kort 2019 Number of whole blood donations in past two years 
 Continuous n/r 0.025/0.015 
Spencer 2016 Number of whole blood donations in past two years 
 0 n/r 1 
 1-3 n/r 1.02 
 4-6 n/r 1 
 7-9 n/r 0.83 
 10+ n/r 0.59 
Zanella et al 1989 Annual Rate of Donation 
 M: <2/year M: trend is to fall over the 16 donations. 
 F: <1.5/year F: trend is to rise over the 18 donations. 
 M: 2–3/year M: trend is to fall over 23 donations (slight rise in 18-21 year olds). 
 F: 1·5–2·5/year F: stable over 11 donations then varies. 
 M: >3/year M: falls over the 22 donations. 
 F: >2·5/year F: falls to 12 donations then rises. 
Inter-donation Interval  
Baart 2014 Time since previous donation per month smaller than one year 
 Continuous n/r 0.89/0.9 
Baart 2016 Time since previous donation per month smaller than one year 
 Continuous n/r 0.87/1.11 
Custer 2014 Time since previous donation in weeks 
 8-16 n/r 1.5 (1.4-1.6) 
 16-20 n/r 1.2 (1.05-1.3) 
 20-24 n/r 1.2 (1.1-1.3) 
 24-36 n/r 1 
 36-52 n/r 0.8 (0.7-0.9) 
 52+ n/r 0.7 (0.7-0.8) 
Muon 2018 Interdonation Interval 
 <3 months 4.4/40.4 3.58 (3.22-3.99)/8.48 (7.95-9.06) 
 3-4 months 1.8/13 1.39 (1.26-1.54)/1.87 (1.76-1.99) 
 4-5 months 1.6/9.9 1.23 (1.12-1.36)/1.38 (1.32-1.43) 
 5-6 months 1.5/8.9 1.16 (1.07-1.25)/1.22 (1.18-1.26) 
 ≥6 months 1.3/7.4 1/1 
Van den Berg 2019 Interdonation Interval 
 ≤3 months 1.98/13.95 1.18 (0.52-2.69)/0.94 (0.63-1.41) 
 3 to 6 months 2.37/16.88 1.41 (0.65-3.05)/1.14 (0.83-1.56) 
 >6 months 1.68/14.78 1/1 
Zeimann et al 2006 Interdonation Interval 
 <6 months 6·3 0·70 (0·56–0·87) 
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 6 to 11 months 6·2 0·68 (0·54–0·86) 
 12 to 23 months 7·7 0·87 (0·67–1·13) 
 ≥24 months 8·8 1 
New vs Repeat  
Afzal 2016 New 1.04/41.99 1/1 
 Repeat 4.77/37.82 4.58 (3.8-5.52)/0.85 (0.9-0.95) 
Al Shaer 2017 New 14.27 1 
 Repeat 6.68 0.47 (0.45-0.49) 
Bakrim 2018 New 9.69 1 
 Repeat 8.6 0.89 (0.79-1) 
Custer 2004 New 0·7/12·6 1/1 
 Repeat 0·5/10·3 0·69 (0·47–1·03)/0·80 (0·76–0·85) 
Custer 2012 New 8·8 1 
 Repeat 8·1 0·87 (0·86–0·88) 
Goncalez 2013 New 7·9 1 
 Repeat 3·9 0·47 (0·47–0·48) 
Klausa 2013 New 38.46 1 
 Repeat 39.58 1.03 (0.46-2.29) 
Kouao 2012 New 2·6 1 
 Repeat 4·0 1·61 (1·23–2·11) 
Ngoma 2013 New 14.14 1 
 Repeat 7.29 0.52 (0.49-0.55) 
Ngoma 2014 New 10.54 1 
 Repeat 12.5 1.09 (0.99-1.19) 
Perez 2018 New 1/14 1/1 
 Repeat 2.76/15.27 2.75 (2.6/2.91)/1.09 (1.07/1.11) 
Van den Berg 2019 New 1.55/19.01 1/1 
 Repeat 1.98/13.28 1.28 (0.31-5.34)/0.65 (0.46-0.93) 
Wilkinson 1982 New 1·2/17·6 1/1 
 Repeat 1·0/13·2 0·78 (0·75–0·81)/0·71 (0·70–0·72) 
 
2.4.7 Previous Haemoglobin Levels 
Six studies reported the relationship between a donor’s previous Hb or HCT level and the likelihood of 
LHD [92-94, 96, 110, 126]. Two European studies [93, 94] applied logistic regression and showed a 
reduced risk of LHD in donors who were not deferred at their previous visit. A third study [111] found 
that men whose Hb increased between visits were less likely to be deferred than those whose Hb 
levels had decreased. In another study from the Netherlands [126] there was a higher risk of LHD for 
donors whose Hb levels were stable across visits, while donors in classes III and IV (whose initial Hb 
levels were higher but experienced a sharper decline) had a lower risk of deferral. In a US study [96], 
donors who had previous Hb levels below the reference group of ≥145 g/L had a higher risk of LHD, 
while previously deferred donors (Hb <125 g/L) were more likely to be deferred due to low Hb. This 
relationship held across all three blood donation types (RBC, double RBC and multicomponent). Finally, 
a Brazilian study [92] compared initial HCT levels with those in the visit immediately before a low HCT 
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deferral over a maximum 11 years of study and found that women whose initial HCT was <41 were 
three times more likely to be deferred than those who had initial HCT>43, and men with low initial 
HCT were almost six times more likely to be deferred. There was a similar relationship when examining 
the donor’s HCT level at their previous visit. 
2.4.8 Iron Status Interventions 
Four interventional studies [127-130] investigated whether interventions to improve a donor’s iron 
status affected their likelihood to be deferred for low Hb. 
One Indian study [127] gave deferred donors information on diet, and recommended oral iron 
supplementation. Of the 68.8% of donors who returned to donate, 85% were successful. A Danish 
study [128] directed iron supplementation to those that were considered to potentially benefit and 
saw a significant decrease in the male LHD percentage from 0.92 to 0.55 (p=0.03).  
A randomized trial from the USA of iron intervention strategies [129] found that the LHD rate in donors 
who received daily oral iron (19mg or 38mg) was lower (2.7%) than in those who received placebo 
(6.1%). Furthermore, the LHD rate in donors who received a ferritin status letter which either 
recommended they continue donation (Ferritin>26ug/L) or took iron supplementation/delayed 
donation (Ferritin≤26ug/L) was lower (4.1%) than in those who received a letter with no such 
information/advice (9.8%). 
Another randomized trial from Germany [130] comparing 50mg iron, 20mg food supplement or no 
iron found a higher rate of LHD in those who did not take iron supplements compared to those who 
did (OR 5.03, 95%CI 1.52-16.69). A significant effect was found from the combined treatment groups 
(OR 6.56, 95%CI 2.32-18.53). 
2.4.9 Donation Setting 
Four studies [96, 131-133] compared donor deferral rates at fixed and mobile collection points. A 
study from the UAE [133] reported LHD rates for fixed centres versus mobile sites of 25.3% and 14.4% 
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respectively. Meta-analysis of the remaining three studies showed a significant increase in the risk of 
LHD for those who donated at fixed compared to mobile sites (OR 1.14, 95%CI 1.03-1.27) (Figure 2.9).  
 
Figure 2.9: Meta-analysis of low haemoglobin deferral, fixed versus mobile donation sites. There was 
a significantly higher deferral rate in fixed sites compared to mobile sites. 
Three studies [72, 84, 105] reported deferral by donor centre. The US studies found that in some 
centres the deferral rates were significantly different, with a maximum adjusted odds ratio of 1.87 
[72]. The Japanese study [105] reported deferral numbers by centre and an odds ratio for low 
haemoglobin deferrals in Miyagi compared with Fukushima was calculated as 1.71 (95% CI 1.65–1.77). 
Variation in deferral rates by location was also reported in a Brazilian study [120]. In addition, another 
Brazilian study [134] found that people resident in larger cities were less likely to be accepted for 
donation (p<0.0001). 
2.4.10 Blood Group 
LHD by blood group was analysed in three studies [87, 97, 100]. An African study [100] found a 
significant association between LHD and AB blood group (AB vs O: OR 4.12, 95%CI 1.81-9.4) but not A 
or B blood groups. A US study [87] reported ORs by blood group compared to O negative, both before 
and after changes to the criteria for blood donation in the USA. In both time periods, there was a 
significantly higher risk of deferral for those in blood group A+, while blood groups AB+ and B+ had a 
lower risk of deferral. Finally, a Dutch study [97] analysed blood group O- compared to others and did 
not find a significant difference in deferral rates. 
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2.4.11 Other Factors 
There were additional factors that were analysed by only one study in the review. One study [126] 
found a relationship between donors’ haemoglobin recovery time (defined as constant and non-
constant) affected the likelihood of low haemoglobin deferral. For both men (OR 6.99 95% CI 5.05-
9.67) and women (OR 2.35 95% CI 2-2.76), there was a significant increase in the number of donors 
with at least one low haemoglobin deferral amongst those who had a non-constant haemoglobin 
recovery time compared to those with a constant recovery time. 
Another study [135] looked at deferral numbers of voluntary and replacement donors and found an 
odds ratio of 10.2 (95% CI 8.23-12.65) of deferral for replacement donors compared to voluntary 
donors.  
A Dutch study [106] examined the relationship between the time of day and low haemoglobin deferral. 
It found that more donors who donated in the afternoon and evening were deferred than those who 
donated in the morning. 
A study from Denmark [136] developed a low haemoglobin deferral prediction model including 
genetic data, and found that in 6 SNPs, for each additional copy of the C-allele in the HFE rs1799945 a 
male donor’s risk of low haemoglobin deferral increased (OR 1.3 95% CI 1.1-1.76), and for women 
there was an increase of a smaller magnitude (OR 1.2 95% CI 1.02-1.41). As well as this, each additional 
G allele in HFE rs1800562 increased the risk of deferral for male donors by 50% (OR 1.52 95% CI 1.07-
2.17), and the T-allele TMPRSS6 increased the risk of deferral in female donors (OR 1.21 95% CI 1.08-
1.35).  
Other factors which were investigated but not found to be significantly associated with LHD included 
smoking [84], diet [122], and Rh-positive blood group [100]. 
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2.4.12 Publication Bias 
As there was strong evidence of heterogeneity in the odds of low Hb deferral in females as compared 
to males by geographic regions, with studies in Europe generally showing smaller associations than 
other regions (Figure 2.4), region-specific funnel plots were used to further assess potential 
publication bias. There was little overall evidence of publication bias within each geographic region 
(Figure 2.10). 
 
Figure 2.10: Funnel plots of studies used in meta-analysis stratified by study setting to highlight the 
geographical differences in effect size. While there are differences, there is no evidence of 
publication bias by region. 
 
2.5 Discussion 
This review has identified 116 published studies that investigated the association of various variables 
with deferral of donors from donation due to failure to meet minimum Hb thresholds. Random effects 
meta-analyses and qualitative syntheses of results have shown that female sex, ethnicity, age, weight, 
seasonality, donation intensity, iron interventions and historical Hb levels can all affect a donor’s risk 
of being deferred for low Hb.  
All blood donor deferrals have cost and healthcare implications and have a negative effect on donor 
motivation to donate in the future. If blood collection services can reduce deferral rates, especially 
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those due to low Hb, they may maximize donor return and reduce costs. It is well known that clear 
differences exist in the rates of deferral of donors due to low Hb between men and women, with 
women significantly more likely to be deferred than men. Our meta-analysis confirms that clear 
differences exist in deferral rates between male and female donors irrespective of whether minimum 
Hb thresholds for donation are defined universally for male and female donors, or whether sex-
specific thresholds are used.  Reasons for these differences in deferral rates between males and 
females have been suggested to include both physiological and social causes. There are also 
differences in deferral rates by sex among geographical regions. The odds ratio for deferral of females 
compared to males was highest in developing countries, which could reflect differences in healthcare 
systems, practices, or guidance afforded to blood donors. 
Premenopausal female donors have lower iron stores than post-menopausal resulting from the effects 
of menstruation and pregnancy [137]. In contrast, men have increased testosterone levels which are 
associated with higher Hb levels [138]. In most populations, males are also more likely to be cigarette 
smokers [139] and cigarette smoking increases carboxyhaemoglobin resulting in increased Hb levels 
[140]. The need for different Hb donation thresholds for male and female donors therefore is clearly 
warranted.  Indeed, the US Food and Drug Administration recently changed the Hb threshold for 
donation from a universal threshold of 125 g/L to sex-specific thresholds of 130 g/L for men and 125 
g/L for women [141]. However, sex-specific Hb thresholds only provide a benchmark and cannot 
account for the many other factors may be differentially associated with LHD between male and 
female donors. The associations of other factors therefore can only reliably be evaluated by 
stratification of donors by sex. However, the lack of consistent reporting within individual studies 
prohibits accurate quantification of the magnitude of sex-specific associations. Separate analyses for 
male and female donors are clearly needed in future studies, as is controlling for other risk factors, for 
example by adjustment or stratification in multivariable analyses.  
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2.5.1 Ethnicity and sex as major risk factors for Low Hb Deferral 
The association of ethnicity and low Hb deferral has been described previously [72, 84-90]. Our results 
confirm that both male and female African-American donors are at higher risk of LHD than White 
donors, although the differential risk of deferral appears to be higher in female than male donors.  
Female donors of either Asian or Hispanic ethnicity are also at higher risk of LHD than their white 
counterparts, although the evidence in male Asian or Hispanic donors is inconclusive. The low 
haemoglobin deferral rates observed across different populations show wide variation (Appendix B). 
Although these absolute rates are not directly comparable due to the different Hb thresholds applied 
and other differences in eligibility criteria, the LHD rates in female donors compared to males in 
studies that use identical Hb thresholds show wide variation according to the country of study, again 
suggesting that a donor’s ethnicity may affect their ability to meet minimum Hb thresholds for 
donation. Differences in Hb levels between Black and White populations are well established [142]. 
Different minimum Hb thresholds for male and female donors according to ethnic origin have also 
been suggested [143].  
2.5.2 Factors Affecting Low Hb Deferrals 
Genetic factors may explain some of the differences between donors of different ethnic groups in 
their susceptibility to LHD, although few studies have investigated the effect of genotypes on LHD. 
Different Hb genotypes which occur at varying frequencies in different populations may be associated 
with lower Hb levels, for example α-thalassemia traits that occur at high frequencies of 20% or more 
in some populations [144]. Polymorphisms in the HFE and TMPRSS6 genes have been shown to be 
associated with higher and lower Hb levels [136] and ethnic variation in the frequency of mutations in 
both genes has been identified [145, 146]. Ethnic variation may also arise from nutritional differences. 
For example, a vegetarian diet has been suggested to occur more often in the Indian population [147] 
with particularly high frequencies in certain religious groups. The European Vegetarian Union have 
reported vastly different proportions of vegetarians in different countries [148]. The effect of blood 
43 
 
group on LHD is inconclusive with conflicting results obtained from three trials. However, analysis of 
low Hb deferral by blood group is confounded by different frequency of donation as many blood 
services recall donors with RH negative groups and O and A ABO groups more often than RH positive 
and A and AB ABO blood group donors.  In addition, the study populations were diverse and so may 
not be directly comparable. 
2.5.3 Age 
There is considerable evidence that increasing age is associated with a higher risk of LHD deferrals in 
males. Some explanation can be gained from the decreasing testosterone levels and thus reduced Hb 
levels with age [138, 149, 150]. The effect of age of LHD in women is less clear, with some studies 
reporting high LHD rates in younger women whilst others found an association between LHD and age.  
This is likely explained by the combined effects of menstruation and pregnancy in younger women 
alongside menopausal effects in older women.  A large population-based US study found a 
pronounced increase in the prevalence of anaemia with increasing age and suggested that key causes 
for this were likely to be nutritional deficiencies and chronic disease [149]. 
2.5.4 Seasonality 
The increased risk of LHD observed in warmer months observed in several studies may be attributed 
to transient haemodilution as blood flow to the skin increases as an element of the heat balance 
mechanism [151]. Other indirect factors influencing Hb level have been proposed, including nutrition, 
physical activity and viral infections [109]. It may be that a change in minimum Hb thresholds for 
donation according to ambient temperature could be possible, but a detailed understanding of the 
degree of change in Hb associated with different seasons/temperatures and the relationship between 




A lower risk of LHD has also been observed with increasing body weight [72, 84, 85, 109].  It has been 
suggested that heavier individuals might be expected to have a greater absolute blood volume and so 
would donate proportionally less of their total iron stores than a lighter person, with a lesser impact 
of loss of iron through donation [85]. However, the effect of weight on LHD is likely to be confounded 
by gender and age as well as lower iron stores as BMI increases [74] which may explain some 
inconsistency in the findings of individual studies.  
2.5.6 Donation Characteristics 
Donation characteristics associated with LHD include previous donation [87, 95, 96, 104, 105, 113, 
117-125], frequency of donations [92-94, 96, 112, 114-116], and previous deferral due to low Hb [93, 
94] although results are conflicting and apparent differences exist between male and female donors. 
Evaluation of the association of donation characteristics with low Hb deferral is difficult as there may 
be confounding related to selection biases related to donation frequency and an opposite 
consequence of lowering of iron stores with repeated donation. Shorter inter-donation intervals have 
been associated with higher frequency of iron deficiency, lower Hb, and higher rates of deferral [72, 
152, 153]. As males have typically two to four times greater iron stores than females [137], it would 
be expected that males are better suited to high intensity donation than women. The historical 8-
week inter-donation interval used in the USA has recently been brought into question. An AABB 
Association Bulletin recommended that consideration should be given to increasing inter-donation 
intervals in some circumstances, in particular for young and/or female donors, in order to reduce iron 
deficiency in blood donors [154], although no formal change has been implemented [141]. INTERVAL 
randomized donors to 8, 10, or 12 week (men) or 12, 14, or 16 week (women) inter-donation intervals 
over two years found that although shorter inter-donation intervals increased the risk of LHD, shorter 
inter-donation intervals were associated with a higher mean number of successful donations in both 




Interpretation of the factors that determine LHD in relation to age, donation frequency and total 
number of units donated is confounded by many differences that may exist between the study 
populations selected. For example, donors who have given blood at higher than average frequencies 
over many years are a selected population and may have; genetic or environmental factors that 
predispose to high iron stores and/or rapid loading of iron; and/or learnt behaviour to maintain 
donations at higher than average frequency without breaching the haemoglobin threshold; and/or 
taken over-the-counter iron supplementation. These confounding factors add to the difficulty of 
comparing and combining studies of low haemoglobin deferral and suggest that large-scale studies 
incorporating measurement and analysis of these factors may be required for each donor population.  
2.5.8 Iron Supplementation 
Oral iron supplementation has been shown to reduce the risk of LHD, elevating Hb and iron stores in 
blood donors [155]. However, the prospect of implementing iron supplementation in blood donors is 
a matter of some controversy [156, 157].  Depleted iron stores are more common in female and young 
donors as well as those who donate regularly [158], and it has been suggested that low iron is 
associated with cognitive impairment [159], although there was no evidence of any cognitive 
impairment in the INTERVAL study across randomised groups donating a different intervals and with 
different proportions of donors with iron deficiency [74]. Targeted iron supplementation in these high 
risk groups has been recommended [160]. However, this comes with cost implications, associated 
adverse effects and compliance issues as well as possible health risks associated with regular iron 
intake [157]. Alternative strategies have been suggested [160]. These include extending inter-
donation intervals, limiting donations in young donors (as implemented in Australia where the 
minimum age for donation has been increased from 16 to 18 years [161], and introducing serum 
ferritin testing as part of donor eligibility to donate in order to identify those individuals with low iron 
stores, as implemented in donors aged 16-18 years by Vitalant and the American Red Cross in the US 
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[162, 163]. It remains to be seen which approach can best balance the health of donors against 
maintaining adequate blood supplies. This will be further investigated in Chapter 5. 
2.5.9 Limitations of the Analysis 
This analysis has a number of key limitations. Firstly, the association estimates presented in this review 
are unadjusted for potential confounding factors. The random-effects meta-analyses results are 
therefore only average estimates and should be interpreted with caution. Clearly, individually-tailored 
inter-donation criteria will be most effective when considering a number of characteristics 
simultaneously.   A number of studies have performed multivariable analysis and report results 
adjusted for a range of potential confounding factors including age, sex, ethnicity, weight, season, 
ambient temperature, blood group, inter-donation interval, number of prior donations and use of iron 
supplementation [72, 74, 84, 85, 87, 93, 97, 108, 109, 136, 164]. However, the disparity in 
characteristics adjusted for between these individual studies precluded meta-analysis of these 
adjusted results. A more flexible approach might be gained through meta-regression, allowing 
individual study characteristics to be included as covariates, thus assessing the effect of study level 
characteristics on effect size estimates. Adjustment for confounding factors at study level can be 
incorporated into the regression model, thus allowing interpretation of the extent to which such 
factors affect the effect size.  However, the most powerful approach is the large trial which measures 
a wide range of factors to be evaluated in a multivariate analysis approach. The factors identified in 
this review provide a basis for the design of such trials, giving due attention given to gender, age and 
ethnicity in particular. 
Secondly, a high degree of heterogeneity exists across studies and care should be taken over the 
interpretation and reporting of summary estimates given this high heterogeneity. Key sources of 
heterogeneity include minimum Hb donation thresholds and differences in the ratio of male to female 
donors in individual studies. The determination of Hb levels in prospective donors included a variety 
of methods which included both venous and capillary blood measurements, leading to varying levels 
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of imprecision and bias across studies. Thirdly, the differential number of donations included in each 
study, as well as donation and deferral history, is likely to introduce further heterogeneity in the 
likelihood of deferral at the point of study. Multiple donation attempts, whether successful or 
unsuccessful, could lead to differences in the underlying distribution of Hb levels, and thus the risk of 
LHD. Moreover, it is possible that there is a variation in the amount of blood collected in one donation 
session between countries. Finally, despite the clear evidence for differences in the risk of LHD 
between male and female donors, many studies reported results for male and female donors 
combined, limiting the ability to assess the sex-specific effect of other factors.  
2.5.10 Personalised Eligibility Criteria 
Given the vast number of characteristics which appear to affect a donor’s ability to meet Hb thresholds, 
individually tailored donation criteria may help improve the retention of donors and increase blood 
supply overall. However, tailoring inter-donation frequency will require the development of 
sophisticated mathematical models in prospective studies and this could be an important area for 
donor research in the future. We suggest that future prospective studies of LHD should incorporate 
the factors identified in this study, and appropriate statistical modelling methods should be used. This 
may lead to the identification of specific sub-groups of prospective donors which can then be subject 
to tailored donation criteria and/or iron supplementation. 
2.5.11 Conclusions 
This systematic review has highlighted a number of factors which affect a donor’s ability to meet 
minimum Hb donation thresholds. A donor’s sex, age, ethnicity, weight, donation history and inter-
donation interval as well as ambient temperature and donation setting affect the risk of LHD. Other 
potential factors which may influence LHD include diet, smoking, blood group and genetic factors but 
further evidence is required. In conclusion, large prospective studies are needed, with an emphasis on 
collecting a wide spectrum of data on participant demographics, ethnicity and donation characteristics 
and using appropriate statistical models to establish the combined effect of these multiple factors on 
48 
 
LHD in blood donors. Further analyses of these factors, including an assessment of the combined effect 




Chapter 3 - Data Sources 
Summary 
The primary data source for the analyses in this thesis was the INTERVAL trial [7, 73, 74], a large multi-
centre trial which randomised 45,267 blood donors to different inter-donation intervals for two years 
at one of the 25 static blood donation centres in the UK. My aim is to identify characteristics of donors 
able to safely give blood more frequently than current NHS guidelines.  
Data were collected from participants via self-reported questionnaires at baseline and every six 
months for two years, and haemotology analysis of blood samples provided at baseline and after two 
years of follow-up. Additional data were obtained from the PULSE database of all blood donors 
registered with NHSBT. 
This chapter describes the INTERVAL trial’s design and methodology, as well as the data that were 
collected and used in my subsequent analyses. The INTERVAL data were used to examine associations 
between donor characteristics (demographics, dietary and lifestyle factors, and biomarkers) and 
several outcomes including the number of blood donations, low haemoglobin deferrals, and 
haemoglobin and ferritin levels. Randomisation of donors to different inter-donation intervals 
throughout the trial enabled the assessment of the effect of inter-donation interval on these 
outcomes including identifying characteristics of donors who may be able to safely donate more 
frequently than current NHSBT guidelines without compromising their wellbeing, as well as an 




3.1 The INTERVAL Trial 
INTERVAL was a large, randomised trial that assigned men and women to donate at various inter-
donation intervals – some being more frequently than current NHS guidelines, with a control group 
donating at the current inter-donation intervals. The shorter donation intervals trialled were 8 and 10 
weeks for men, and 12 and 14 weeks for women. The trial aimed to maximise the blood supply and 
maintain donor wellbeing by determining optimal inter-donation intervals, and to explore how donor 
characteristics such as demographics, lifestyle traits, and genetics may be useful in the assignment of 
an optimal inter-donation interval [7].  
The trial ran for two years, between 2014 and 2016, and randomised 45,263 donors (22,466 men and 
22,797 women) to donate blood at one of the donation intervals in a 1:1:1 split between donation 
groups. Randomisation was designed to balance key donor characteristics such as age, weight, and 
new donor status. Donors donated in one of the 25 fixed donation centres in England (UK) during the 
trial period. 
Participants were recruited initially by post, with invitations sent only to those registered at one of the 
fixed blood donation centres. However additional recruitment strategies were adopted in 2013 to 
include those donating in mobile centres who had expressed a willingness to give platelets at a static 
donor centre, lived within ten miles of one, and later who lived within 30 miles, as it was thought that 
these sets of people may be more willing to attend a fixed donation centre for the trial despite not 
using one at the time of recruitment. Information was also given to donors at blood donation 
appointments.  
Inclusion criteria for the trial were that participants had to be at least 18 years old, fulfil normal criteria 
for blood donation, be willing to be allocated any of the three possible donation intervals, and attend 
a static donor centre for the duration of the trial. The main exclusion criteria were related to data 
collection, namely that those without a stable internet connection, or those unwilling or unable to 
provide a contact e-mail address, could not participate as questionnaires sent via e-mail were a key 
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method of data collection [7]. A flowchart of the recruitment process can be seen in Figure 3.1. Once 
recruited, donors were randomised into one of three inter-donation groups using a minimisation 
algorithm to balance key characteristics at baseline between the inter-donation interval groups, 
including weight, age, and new/repeat donor status [7]. This was stratified by donation centre and 
gender and attempts to minimise confounding due to key variables on the observed effect of inter-
donation interval. 
Data quality control (QC) in the trial was ensured through the Independent Data Monitoring 
committee, the Research Ethics Committee, Trial Steering Committee, and the Trial Management 
Group. The trial data manager and statistician oversaw the daily accrual of data and periodically 
reported to the preceding trial management groups. Furthermore, of relevance to the current work 
were QC conducted on Sysmex haematology measurements to monitor and correct for any drift in 
analysers, which involved a team of lab technicians, statisticians, and haematology experts. The 
INTERVAL trial sample size calculations aimed to have 80% power to detect a 5% difference in the 
number of donations given over two years, and a 3% difference or more change in quality of life 




Figure 3.1: INTERVAL Recruitment flowchart, taken from [74]. Roughly 50% of those invited to 
participate in the trial enrolled, and completeness of data was not differential by inter-donation 
interval group. 
3.2 The INTERVAL Trial Participants 
Compared to the general NHSBT population, which consists of all donors who give blood in England 
and Wales, the INTERVAL trial sample had a higher proportion of men than the general donor 
population (50% vs 44%), and the sample were older in age (mean age 43.1 versus 42.3 years). There 
were also differences in past donation history, with the INTERVAL sample both having a longer history 
of donation (mean of 10.7 years vs 8.6 years) and a higher number of donations given in the previous 
two years (mean of 3.2 donations vs 2.1 donations) than the general NHSBT donor population. There 
was also a lower proportion of new donors in INTERVAL (3% vs 22%). Aside from these differences, 
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there was broad similarity between the INTERVAL donors and the general donor population, so results 
should be generalisable to the NHSBT donor population. However, it is possible that the effect of 
different inter-donation intervals on donation rates could be greater in INTERVAL than the general 
population of blood donors, owing both to the trial setting and the fact that the donors in the trial 
were already a more committed group of donors. On the other hand, as NHSBT aims to have a greater 
proportion of donations made at static donor centres by 2020/21 (rising from 15% to 25%), it is 
possible that the INTERVAL cohort may be more representative of future NHSBT blood donor 
populations [73]. 
3.3 Data Collection in INTERVAL 
3.3.1 Self-Reported Data Collection in INTERVAL 
Information on INTERVAL participants was mainly collected with self-reported questionnaires. 
Participants were e-mailed the baseline questionnaire a few days after enrolment, which contained 
the following sections: 
1. Compulsory questions on month and year of birth, sex, height, and weight, to verify that the 
intended person was the one who completed the questionnaire. 
2. Well-being assessments using the SF-36v2 questionnaire. This comprises 36 questions that are 
used to generate summary scores of a participant’s physical and mental well-being. It has been 
reported to differentiate well between health benefits produced my treatments in trials, 
regardless of age, disease condition, and treatment group [165-168]. 
3. History of iron deficiency such as whether the participant had ever been diagnosed with 
anaemia by a doctor. 
4. Lifestyle information including diet, alcohol and smoking status, and physical activity. 
Participants were also asked to complete follow-up questionnaires every six months during the trial. 
These questionnaires asked the following: 
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1. Compulsory questions on month and year of birth, sex, height, and weight, to verify that the 
intended person was the one who completed the questionnaire. 
2. Well-being assessments using the abbreviated Sf-12v2. This was chosen over the full Sf-36v2 
because it takes just five minutes to complete, reducing the time burden on participants. 
3. Reporting of adverse events and serious adverse events. These included heart problems, falls, 
accidents when driving, new illnesses, diagnoses of low iron, low haemoglobin, and 
prescriptions of iron supplements, as well as nine post-donation symptoms: tiredness, 
dizziness, feeling faint, fainting, fit or seizure, breathlessness, palpitations, chest pain, and 
restless leg syndrome [169]. 
A final questionnaire was sent to participants upon their two-year anniversary of involvement in the 
trial (and thus completion). This was a longer questionnaire which asked: 
1. Month and year of birth, and sex, to validate the person completing the questionnaire was 
the participant 
2. The Sf-36v2 questionnaire 
3. Reporting of adverse events and serious adverse events as above, with additions – severity of 
breathlessness, palpitations and chest pain, headaches, sleep disturbances, irritability, 
concentration, restlessness, and pica. 
4. Medication and supplement use such as glucose-lowering, antihypertensive, and lipid-
lowering supplements, as well as over the counter dietary supplements, with an additional 
question as to whether these contained iron. 
5. Cognitive function tests, designed to measure a range of attributes: attention and reaction 
times (using Stroop Test), executive function (using Trail Making Test), episodic memory (using 
Pairs Test), and intelligence (using Reasoning Test). These are a series of tests designed for 
cognitive testing in an epidemiological setting [170], and also contain a mood questionnaire 
to adjust for effects that may skew these tests [171, 172]. 
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6. Beliefs on blood donation, and particularly questions asking if increased donation frequency 
raised difficulties or concerns. 
7. An invitation to take part in physical activity monitoring 
8. Recent physical activity questionnaire which measures activity in the past four weeks across 
a participant’s leisure time, occupation, commuting, and domestic life [173, 174]. 
3.3.2 The PULSE database 
An additional source of data collection in INTERVAL is the PULSE database. PULSE is an electronic 
database that covers all aspects of blood donation and donor management, with codes added to 
donor records describing the type of donation they gave, and communications sent to donors. Special 
codes were added to the records of INTERVAL donors in PULSE during the trial to facilitate 
identification and exchange of information with the trial academic co-ordinating centre. The PULSE 
database includes information on donors’ sex, age, ethnicity, ABO and Rhesus D blood groups, and 
information on donation history from donors which were used in INTERVAL analyses. These data were 
confidentially retrieved by NHSBT the day after donors enrolled into INTERVAL and were securely 
transferred to the academic coordinating centre. 
3.3.3 Biomarker Data Collection in INTERVAL 
Research blood samples were collected from donors at their baseline donation visit. A full blood count 
was performed on these using a SYSMEX XN-2000 haemotology analyser (Sysmex UK Limited, Milton 
Keynes, UK). Indices obtained included haemoglobin levels, red and white blood cell counts, and mean 
corpuscular volume and haemoglobin. In addition, one of the research samples collected was used to 
create buffy coat, from which DNA was extracted using a Kleargene method (LGC Genomics, 
Teddington UK). Ferritin concentrations were also measured using an immunoturbidimetric assay 
(Roche/Hitachi chemistry analyser, Stichting Huisartsen Laboratorium, Etten-Leur, Netherlands). This 
research blood sample collection was then repeated during a participant’s final donation before their 
two-year involvement in the trial. 
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3.4 INTERVAL Primary and Secondary Outcomes 
3.4.1 Primary Outcome of the INTERVAL Trial 
The primary outcome of the trial was the number of blood donations given during the two years of 
the trial. This was defined as donating one full unit of blood of 470 mL [74].  
3.4.2 Secondary Outcomes of the INTERVAL Trial 
3.4.2.1 Low Haemoglobin Deferrals 
Before donating blood, all donors must pass a haemoglobin test, to both protect them from iron 
deficiency and associated consequences, and to ensure that any blood collected is fit for purpose. In 
the UK, haemoglobin cut-off points are 135 g/L for men and 125g/L for women. At the time of the 
INTERVAL trial, haemoglobin was measured using the copper sulphate test only. The exception to this 
was during the donor’s baseline donation visit. On this occasion, if a donor failed the copper sulphate 
test they had their haemoglobin concentration measured using a Hemocue test [7]. 
3.4.2.2 Haemoglobin and Ferritin Concentrations 
Haemoglobin and ferritin levels in donors were measured at their two year involvement in the trial. 
3.4.2.3. Self-reported symptoms  
Every six months during the trial, and upon the trial’s completion, participants were asked if they 
had experienced the following symptoms: being more tired than usual, feeling more breathless than 
usual, palpitations, dizziness, chest pain, fainting or feeling faint, restless legs syndrome, and pica 
(the desire to eat non-nutritious foods, usually ice) [74]. 
3.4.2.4 PCS and MCS Quality of Life Measures 
The trial’s key secondary outcomes included well-being (quality of life) measures, in particular the 
physical and mental component scores of the Sf-36 questionnaire (PCS and MCS). These are summary 
scores taken from either the Sf-36 or Sf-12 questionnaire, and are used to measure the person’s well-
being. They give a numerical value, with higher indicating a better score, as a measure of the 
57 
 
participant’s physical and mental well-being. The PCS and MCS are reported on a population-norm 
standardised scale, with mean 50, standard deviation 10, transformed from a raw score of 0-100 [175]. 
This has the advantage that the mean and standard deviation of these scores is always known and so 
they are easier to interpret. 
The scores are constructed from the answers to questions in the questionnaire which fall under multi-
item dimensions of health: physical functioning (10 items) social functioning (2 items) role limitations 
due to physical problems (4 items), role limitations due to emotional problems (3 items), mental 
health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items) [176]. 
There is also a question on general health assessment (“Compared to one year ago, how would you 
rate your health in general now?”) [177]. The PCS and MCS are then derived from these results [176]. 
Studies have shown that there is a gender difference in PCS and MCS scores, with women having lower 
scores than men in all aspects of the questionnaire aside from self-reported health [176, 177]. There 
was also found to be a difference in scores by age [177]. 
3.5 INTERVAL Results 
3.5.1 Descriptive Statistics of Key Baseline Characteristics  
Baseline variables had similar distributions and levels of missingness across all randomised groups in 
both sexes. A much higher proportion of women than men indicated a diagnosis of anaemia (24% vs 
4%), and women had lower haemoglobin and ferritin levels than men. Dietary variables were 
comparable between sexes, as were the baseline PCS and MCS scores. Women were more likely to 
have had previous low haemoglobin deferrals and had donated less than men in the past two years 
(Tables 3.1 and 3.2).  
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Table 3.1: Summary of the key baseline variables for men by trial arm, presented as mean (standard deviation) or frequency (%), and level of missingness 
 Trial arm: 8 weeks N = 7456 Trial arm: 10 weeks N = 7446 Trial arm: 12 weeks N =7452 
Variable Mean (SD) or N (%) Missing (%) Mean (SD) or N (%) Missing (%) Mean (SD) or N (%) Missing (%) 
Demographics       
Height (m) 1.79 (0.08) 0 1.79 (0.079) 0 1.79 (0.08) 0 
Weight (kg) 85.2 (16.42) 0 85.16 (16.67) 0 85.15 (16.47) 0 
Ethnicity – White British (Y/N)1 5840 (78%) 902 (12) 5861 (79%) 910 (12) 5819 (78%) 901 (12) 
Age (years approx.) 45.22 (14.14) 92 (1) 45.24 (14.22) 96 (1) 45.22 (14.19) 108 (1) 
PCS 56.79 (4.61) 58 (1) 56.89 (4.54) 52 (1) 56.84 (4.51) 39 (1) 
MCS 54.62 (6.02) 58 (1) 54.48 (6.26) 51 (1) 54.53 (6.07) 36 (1) 
Iron Status       
Anaemia Ever (Y/N) 319 (4%) 111 (1) 325 (4%) 105 (1) 327 (4%) 124 (2) 
Iron Prescription Use (Y/N) 8 (<1%) 109 (1) 13 (<1%) 117 (2) 27 (<1%) 117 (2) 
Iron Multivitamin Use (Y/N) 922 (12%) 118 (2) 937 (13%) 120 (2) 950 (13%) 105 (1) 
Iron Supplement Use (Y/N) 53 (1%) 144 (2) 79 (1%) 140 (2) 70 (1%) 153 (2) 
Diet/Lifestyle       
Non-Vegetarian (Y/N) 7177 (96%) 49 (1) 7167 (96%) 46 (1) 7148 (96) 49 (1) 
Liver (Portions per Week) 0.19 (0.72) 158 (2) 0.2 (0.93) 162 (2) 0.19 (0.81) 173 (2) 
Red Meat (Portions per Week) 2.59 (1.84) 69 (1) 2.58 (1.82) 67 (1) 2.58 (1.88) 73 (1) 
Poultry (Portions per Week) 2.43 (1.62) 76 (1) 2.46 (1.64) 73 (1) 2.42 (1.62) 78 (1) 
White Fish (Portions per Week) 1.19 (1.07) 94 (1) 1.21 (1.06) 83 (1) 1.22 (1.09) 92 (1) 
Oily Fish (Portions per Week) 0.81 (1.03) 123 (2) 0.82 (1.14) 106 (1) 0.81 (1.02) 119 (2) 
Vegetable Consumption (Y/N) 7216 (97%) 64 (1) 7225 (97%) 58 (1) 7197 (97%) 63 (1) 
Fruit Consumption (Y/N) 6560 (88%) 82 (1) 6542 (88%) 72 (1) 6541 (88%) 81 (1) 
Juice Consumption (Y/N) 4723 (63%) 117 (2) 4706 (63%) 88 (1) 4771 (64%) 108 (1) 
Smoothie Consumption (Y/N) 989 (13%) 172 (2) 922 (12%) 152 (2) 1012 (14%) 154 (2) 
Tea Consumption (Y/N) 5664 (76%) 65 (1) 5570 (75%) 70 (1) 5552 (75%) 65 (1) 
Alcohol Ever (Y/N) 7214 (97%) 54 (1) 7211 (97%) 48 (1) 7208 (97%) 61 (1) 
Smoking Ever (Y/N) 3100 (41%) 96 (1) 3065 (41%) 90 (1) 3173 (43%) 95 (1) 
Donation History       
Donations in Past 2 Years (n) 3.58 (1.87) 0 3.59 (1.86%) 0 3.57 (1.85) 0 
Low Hb Deferral Rate in Past 2 Years 1.09 0 1.03 0 1.03 0 
Other Deferrals in Past 2 Years (n) 0.32 (0.69) 0 0.32 (0.68) 0 0.32 (0.69) 0 
Under-Donations in Past 2 Years (n) 0.045 (0.22) 0 0.048 (0.23) 0 0.043 (0.22) 0 
Biomarkers       




423 (6)  468 (6) 
Haemoglobin (g/dL) 14.98 (1.01) 118 (2) 14.96 (0.99) 131 (2) 14.98 (0.99) 131 (2) 
Mean Corpuscular Haemoglobin (g/dL) 29.72 (1.71) 118 (2) 29.72 (1.68) 131 (2) 29.76 (1.79) 131 (2) 
Mean Corpuscular Volume (fL) 92.24 (4.63) 118 (2) 92.27 (4.66) 131 (2) 92.31 (4.67) 131 (2) 
Red Blood Cell Count (1012/L) 5.05 (0.39) 118 (2) 5.04 (0.38) 131 (2) 5.04 (0.38) 131 (2) 
White Blood Cell Count (109/L) 6.17 (1.68) 118 (2) 6.17 (1.53) 131 (2) 6.18 (1.52) 131 (2) 
Platelet Count (109/L) 230.02 (56.78) 118 (2) 230.96 (57.13) 131 (2) 229.99 (57.72) 131 (2) 
 
1 Y/N – indicates yes/no, with the table corresponding to “yes” responses 
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Table 3.2: Summary of the key baseline variables for women by trial arm, presented as mean (standard deviation) or frequency (%), and level of missingness 
 Trial arm: 12 weeks N = 7567 Trial arm: 14 weeks N = 7565 Trial arm: 16 weeks N =7548 
Variable Mean (SD) or N (%) Missing (%) Mean (SD) or N (%) Missing (%) Mean (SD) or N (%) Missing (%) 
Demographics       
Height (m) 1.65 (0.073) 0 1.65 (0.076) 0 1.65 (0.075) 0 
Weight (kg) 71.33 (14.43) 0 71.94 (18.87) 0 71.83 (14.85) 0 
Ethnicity – White British (Y/N)1 6479 (86%) 788 (10) 6474 (86%) 811 (11) 6460 (86%) 790 (11) 
Age (years approx.) 41.29 (14.02) 122 (2) 41.38 (13.88) 133 (2) 41.45 (13.98) 136 (2) 
PCS 57.03 (4.69) 61 (1) 57 (4.69) 52 (1) 57 (4.61) 54 (1) 
MCS 53.49 (6.68) 59 (1) 53.51 (6.61) 51 (1) 53.51 (6.53) 51 (1) 
Hormone Replacement Therapy 199 (3%) 1901 (25) 236 (3) 1858 (25) 245 (3) 1814 (24) 
Contraceptive Pill Use 1668 (22%) 432 (6) 1649 (22%) 448 (6) 1600 (21%) 459 (6) 
Menopause – Yes 1796 (24%) 85 (1) 1786 (24%) 70 (1) 1802 (24%) 68 (1) 
Iron Status       
Anaemia Ever (Y/N) 1804 (24%) 215 (3) 1813 (24%) 229 (3) 1793 (24%) 223 (3) 
Iron Prescription Use (Y/N) 47 (1%) 208 (3) 42 (1%) 156 (2) 43 (1%) 204 (3) 
Iron Multivitamin Use (Y/N) 1384 (18%) 140 (2) 1314 (17%) 124 (2) 1352 (18%) 139 (2) 
Iron Supplement Use (Y/N) 211 (3%) 254 (3) 191 (3%) 216 (3) 201 (3%) 248 (3) 
Diet/Lifestyle       
Non-Vegetarian (Y/N) 7098 (94%) 69 (1) 7106 (94%) 50 (1) 7081 (94%) 46 (1) 
Liver (Portions per Week) 0.11 (0.58) 208 (3) 0.11 (0.64) 178 (2) 0.1 (0.63) 200 (3) 
Red Meat (Portions per Week) 1.97 (1.54) 95 (1) 1.98 (1.57) 73 (1) 1.96 (1.54) 72 (1) 
Poultry (Portions per Week) 2.3 (1.52) 96 (1) 2.27 (1.55) 74 (1) 2.32 (1.56) 74 (1) 
White Fish (Portions per Week) 1.16 (1.04) 124 (2) 1.14 (1.04) 108 (1) 1.14 (1.04) 103 (1) 
Oily Fish (Portions per Week) 0.81 (1.05) 137 (2) 0.78 (0.97) 131 (2) 0.81 (1.01) 117 (2) 
Vegetable Consumption (Y/N) 7373 (97%) 87 (1) 7376 (98%) 62 (1) 7381 (98%) 54 (1) 
Fruit Consumption (Y/N) 6888 (91%) 94 (1) 6887 (91%) 75 (1) 6912 (92%) 73 (1) 
Juice Consumption (Y/N) 3922 (52%) 124 (2) 3897 (52%) 97 (1) 39.35 (52%) 98 (1) 
Smoothie Consumption (Y/N) 1128 (15%) 161 (2) 1060 (14%) 150 (2) 1094 (14%) 143 (2) 
Tea Consumption (Y/N) 5502 (73%) 89 (1) 5540 (73%) 65 (1) 5529 (73%) 61 (1) 
Alcohol Ever (Y/N) 7312 (97%) 72 (1) 7331 (97%) 53 (1) 7327 (97%) 51 (1) 
Smoking Ever (Y/N) 3035 (40%) 121 (2) 3070 (41%) 110 (1) 2948 (39%) 99 (1) 
Donation History       
Donations in Past 2 Years (n) 2.87 (1.69) 0 2.88 (1.64) 0 2.85 (0.34) 0 
Low Hb Deferral Rate in Past 2 Years 3.58 0 3.51 0 3.7 0 
Other Deferrals in Past 2 Years (n) 0.36 (0.68) 0 0.34 (0.68) 0 0.34 (0.68) 0 
Under-Donations in Past 2 Years (n) 0.052 (0.23) 0 0.051 (0.23) 0 0.056 (0.24) 0 
Biomarkers       





Haemoglobin (g/dL) 13.39 (0.94) 180 (2) 13.4 (0.91) 164 (2) 13.38 (0.9) 170 (2) 
Mean Corpuscular Haemoglobin (g/dL) 29.38 (1.93) 180 (2) 29.38 (1.83) 164 (2) 29.35 (1.86) 170 (2) 
Mean Corpuscular Volume (fL) 93.16 (5) 180 (2) 93.22 (4.96) 164 (2) 93.18 (5.07) 170 (2) 
Red Blood Cell Count (1012/L) 4.57 (0.36) 180 (2) 4.57 (0.35) 164 (2) 4.57 (0.35) 170 (2) 
White Blood Cell Count (109/L) 6.76 (1.68) 180 (2) 6.77 (1.69) 164 (2) 6.83 (1.75) 170 (2) 
Platelet Count (109/L) 261.48 (66.75) 180 (2) 261.86 (66.47) 164 (2) 263.93 (67.4) 170 (2) 
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3.5.2 Outcome Summary Statistics 
The main results from the INTERVAL trial showed that allocation of donors to shorter inter-donation 
intervals increased units of blood collected during the trial period for both sexes. No difference in 
quality of life, physical activity, or cognitive function was observed across randomised groups, 
however those on shorter inter-donation intervals experienced an increase in symptoms and low 
haemoglobin deferrals, and a decrease in their two year haemoglobin and ferritin levels. 
3.5.3 Number of Donations and Low Haemoglobin Deferrals  
The maximum number of donations possible during two years of follow-up were 12, 10, and 8 for men 
allocated to the 8, 10, and 12 respectively, and were 6, 7, and 8 donations for women in the 16, 14, 
and 12 week groups respectively. However, around 2,750 men (12%) of men and 5,000 women (22%) 
did not return to donate during the trial. Most participants, regardless of sex, received no low 
haemoglobin deferrals during the trial. (Figures 3.2 and 3.3). 
Considering these outcomes by randomised trial arm (Table 3.3), one can see that the mean number 
of donations decreased as the randomised inter-donation interval lengthened in both sexes, although 
this effect was less pronounced in women than in men. The number of low haemoglobin deferrals 
decreased as the interval was lengthened, with the male 12 week group having a particularly low 
number, and the two-year haemoglobin and ferritin levels were also higher for donors on the longer 
intervals. This is likely due to the longer intervals allowing the body more time for recovery before 
donating again, and cumulatively losing less during the trial than those on shorter inter-donation 
intervals (Table 3.3).  
3.5.4 Haemoglobin and Ferritin Levels 
Men generally had higher 2-year haemoglobin and ferritin levels than women (Figures 3.2 and 3.3). In 
both sexes, those in the shortest randomised group had the lowest haemoglobin and ferritin, and 




Figure 3.2: Histograms of the number of donations over the two year trial period, low hb deferrals, 





Figure 3.3: Histograms of  number of donations over the two-year trial period, low hb deferrals, and 
haemoglobin and ferritin levels at the end of the trial for women (ferritin capped at 100) 
 
Table 3.3: Mean (SD) by donation group of the two-year number of donations, low hb deferrals, and 
haemoglobin and ferritin levels. 
Gender Group (N) Donations Low Hb Deferrals Haemoglobin (g/dL) Ferritin (µg/L) 
Men 8 weeks (7456) 6.88 (3.75) 0.44 (0.77) 14.13 (1.21) 40.61 (53.17) 
 10 weeks (7446) 5.97 (3.18) 0.25 (0.58) 14.46 (1.16) 44.49 (40.01) 
 12 weeks (7452) 5.19 (2.66) 0.14 (0.45) 14.64 (1.14) 51.1 (64.63) 
Women 12 weeks (7567) 4.28 (2.63) 0.40 (0.73) 13.07 (1.13) 31.98 (33.34) 
 14 weeks (7565) 3.9 (2.34) 0.30 (1.15) 13.16 (1.15) 33.72 (36.3) 
 16 weeks (7548) 3.45 (2.07) 0.20 (0.51) 13.21 (1.1) 36.85 (36.02) 
 
3.5.5 PCS and MCS 
The individual participants’ two year PCS and MCS scores were mostly in the range of 55-60 (Figure 
3.4) indicating better physical and mental well-being in relation to the population mean of 50. This 
may have been expected, as blood donors are typically healthier than the general population (Figure 
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3.4). For approximately one third of male respondents, the outcome PCS and/or MCS score was 
missing. This was anticipated in the trial design, and INTERVAL was designed to account for this while 
retaining statistical power [3]. There were slightly more missing data for women than men (Table 3.4). 
It is possible that those with lower PCS and MCS scores in the intermediate Sf-12 surveys given at 
baseline, 6, 12, and 18 months were more likely to not complete the final survey. 
The frequency of missing data was comparable across the randomised inter-donation groups and thus 
assessment of the effect of inter-donation frequency on well-being measures would be unbiased (i.e. 
limited selective attrition). In men, the median PCS was 57.7 (IQR 54.7 – 59.8, and the median MCS 
was 55.7 (IQR 51.6 – 58.2). In women, the median PCS was 57.7 (IQR 54.3 – 60.0), and the median 
MCS was 54.8 (IQR 49.9 – 57.6). In all of these summary scores, there was a negative skew. The 
assigned inter-donation group had little impact on the PCS and MCS 2-year outcomes.  
Table 3.4: Summary statistics by donation group of the outcome PCS and MCS scores in INTERVAL 
  PCS MCS 
Gender Group (N) Mean (SD) Missing (%) Mean (SD) Missing (%) 
Men 8 weeks (7456) 56.51 (5.20) 2531 (33.65) 53.96 (6.87) 2530 (33.58) 
 10 weeks (7446) 56.59 (4.99) 2503 (33.62) 53.89 (6.79) 2500 (33.58) 
 12 weeks (7452) 56.52 (5.07) 2483 (33.32) 53.82 (6.83) 2482 (33.31) 
Women 12 weeks (7567) 56.48 (5.54) 2823 (37.31) 52.47 (7.65) 2822 (37.29) 
 14 weeks (7565) 56.48 (5.56) 2826 (37.36) 52.63 (7.55) 2824 (37.33) 





This chapter has described the design and procedures of the INTERVAL trial, the main data source 
used for further analyses presented in subsequent chapters. It has described the trial’s protocol and 
Figure 3.4: Histograms of the PCS and MCS scores in men and women. Scores were centred between 50 and 
60, indicating above average physical and mental wellbeing in INTERVAL participants. 
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aims. INTERVAL randomised donors to donate blood at different inter-donation intervals, and is the 
first trial of its kind. It provides a powerful basis for conducting unbiased inferences on the effects of 
randomised inter-donation intervals. Furthermore, given the breadth of information collected and 
randomisation, it enables further detailed study of blood donor health than previously done. 
The strengths of INTERVAL are that, by design as a randomised control trial, results are not as 
susceptible to uncontrolled confounding which may be present in observational studies. The large 
sample size of 45,000 participants also gives high statistical power for inferences, including subgroup 
analyses. The trial was successful in randomising donors to different inter-donation intervals and had 
excellent follow up outcomes and other assessments, with a clear difference shown in the number of 
donations given in each group. In addition, recruitment spanned the geographical breadth of England 
and as such results should be more generalisable to the English blood donor population as a whole 
[74].  
There are, however, limitations. Data were self-reported, and this can be unreliable and susceptible 
to bias. The main biases inherent to self-reported questionnaire data include misclassification bias 
from participants having a subjective view of the questions, particularly for post-donation symptoms, 
and recall bias due to the questionnaires only being given every six months, so it is possible that donors 
may not remember all symptoms that they experienced. In addition, the differing length of the 
questionnaires could induce bias as participants may stop answering longer questionnaires to the best 
of their ability. Moreover, it is possible that the repeated Sf-12 questionnaires and their corresponding 
questions in the Sf-36 could be subject to learned answers, as participants may fill them in on autopilot 
after multiple times answering in the same format.  
As well as this, the results may also not be generalisable to the entire English blood donor population 
as one of the trial’s requirements was regular internet access. Furthermore, it is likely that the trial 
only attracted more motivated donors from the NHSBT population, and the structured trial setting 
with more regular reminders about donation than routine practice could result in the trial 
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overestimating the potential impact of reducing inter-donation intervals on the blood supply in 
practice. The trial also may not be generalisable to countries outside of England, which can have 
different administrative systems for blood donation to the UK, such as non-scheduled appointments. 
INTERVAL analyses previously published have been limited in scope, focussing on a subset of key 
variables on the outcome of number of donations. A comprehensive analysis of low haemoglobin 
deferrals, haemoglobin and ferritin levels, symptoms experienced during the trial, and donor 




Chapter 4 – Effect of Randomised Inter-Donation Intervals on Blood 
Donations, Low Haemoglobin Deferrals, and Iron-Related Biomarkers: 
Extended Analyses of Main Effects and Interactions 
Summary 
Previous published results from the INTERVAL trial assessing interactions with randomised inter-
donation interval focused on a small subset of pre-specified key variables including age and HFE carrier 
status, in relation to the primary outcome of donations given during the trial. Interactions in relation 
to the number of low haemoglobin deferrals experienced, and the associated biomarkers have not 
been assessed, yet could be informative for personalised assignment of inter-donation intervals.  
In this chapter I performed variable selection on a larger subset of baseline variables including 
demographics, dietary and lifestyle variables, donation history and biomarkers with two key aims: (i) 
to assess associations of baseline characteristics with outcomes post-randomisation, and (ii) to assess 
interactions of baseline characteristics and randomised inter-donation interval on outcomes. Four 
outcomes were analysed: number of donations, low haemoglobin deferral, and levels of haemoglobin 
and ferritin.  
For both sexes, inter-donation interval had a significant effect on all four outcomes, with a stronger 
effect in men, likely due to the shorter intervals to which they were assigned. Higher baseline ferritin 
and haemoglobin, and more donations in the two years preceding the trial were all associated with 
more donations given during the trial. Number of previous donations and baseline ferritin had 
differential effects by randomised group for both sexes. Baseline haemoglobin was significantly 
associated with higher haemoglobin after two-years for both sexes, with a significant interaction with 
inter-donation interval for both sexes. For haemoglobin, other significant interactions were due to 
biomarkers in men and donation history in women. Concerning ferritin, for both sexes there were 
significant interactions between inter-donation interval and baseline log ferritin and red blood cell 
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count, and previous donations. Donation history and blood group were differentially associated with 
the number of low haemoglobin deferrals during the trial by randomised inter-donation interval in 
both sexes. For men there were also interactions between inter-donation interval and age, baseline 
haemoglobin and ferritin in relation to low haemoglobin deferrals. 
These analyses suggest that there exist variables with convincing evidence of associations with the 
four outcomes studied, including variables significantly modifying the effect of randomised inter-
donation interval on the outcomes. These four outcomes have routinely been of interest to the blood 
service, and thus the current results may be useful to inform personalisation of inter-donation 
intervals to maximise blood collection safely. A few blood-based biomarkers not routinely collected, 
particularly ferritin, were also identified as important, often with a higher magnitude of association 




The UK’s blood service relies on donations from unpaid, voluntary donors. New donor numbers are 
falling [71, 178], and while the current demand for blood is steadily decreasing [179] owing to better 
transfusion practices, it is possible that this demand could increase in the future for a variety of 
reasons, such as the aging population [71]. 
Currently, the minimum length of time between blood donations in England and Wales is twelve 
weeks for men and sixteen weeks for women [71] (Chapter 3). Decreasing the length of time between 
blood donations (i.e. inter-donation interval) could be one approach to mitigate shortfalls in blood 
supply related to the declining number of new donors. Furthermore, assignment to different inter-
donation intervals based on the individual donor characteristics constitutes a more personalised 
donation experience, which could make donors feel more engaged with the service. 
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4.1.2 The INTERVAL Trial 
As detailed in Chapter 3, the INTERVAL trial was a large randomised trial conducted between June 
2012 and June 2016 that assigned 45,263 donors (22,466 men and 22,797 women) to donate more 
frequently than existing NHS guidelines, with a control group donating at the usual inter-donation 
intervals. The shorter donation intervals trialled were 8 and 10 weeks (vs. 12 weeks usual) for men, 
and 12 and 14 weeks (vs. 16 weeks usual) for women [7]. The trial aimed to identify characteristics of 
donors who were able to safely donate blood more frequently than existing guidelines, maximising 
the number of units of blood collected from the decreasing donor population in England.  
Donors had to donate in one of the 25 fixed donation centres in England (Chapter 3). Recruitment was 
staggered by centre between June 2012 and June 2014, and participants were individually randomised 
to the sex-specific inter-donation intervals in the ratio 1:1:1, stratified by centre and minimising 
differences in age, weight, and new donor status. Participants were followed for outcomes over two 
years ending in June 2016 [73].  
4.1.3 Outcomes of Interest 
Four outcomes were investigated in this chapter, namely the number of donations given by donors 
during the trial, the number of low haemoglobin deferrals experienced, and donors’ two year 
haemoglobin and ferritin levels. The number of donations given was the INTERVAL trial’s primary 
outcome, and the number of low haemoglobin deferrals was a secondary outcome. As low 
haemoglobin deferrals depend on an individual’s haemoglobin levels, monitoring would be of interest. 
Ferritin is a measure of iron stores, and quantification of the effect of more frequent donation on 
ferritin levels, including potential moderators, could be useful in monitoring a donor’s risk of iron 
deficiency and associated symptoms. 
4.1.4 Donor Characteristics of Interest 
The analyses in this chapter looked beyond the characteristics that were prioritised for analyses in the 
INTERVAL trial main paper [74]. Based on findings of the INTERVAL trial main paper [74], donor age, 
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baseline haemoglobin, baseline log ferritin, weight, and number of donations in the previous two 
years were expected to be important covariates for the number of donations given in the trial and low 
haemoglobin deferrals. From the systematic review conducted in Chapter 2, the donor’s status as a 
new or returning donor, donor centre, ethnicity and blood group were also identified as potentially 
important characteristics. However, there have been few or no studies providing evidence on the 
association of many other variables collected in the INTERVAL trial and four outcomes prioritised for 
evaluation in this chapter, thus a wide range of variables assessed at baseline were considered for 
analyses (Table 4.1) on the basis of their potential relevance to the prioritised outcomes, including 
components of dietary and lifestyle habits advised or followed by donors. 
Table 4.1: List of variables considered for inclusion in each model. Asterisked variables were 
considered for women only. 







Iron Prescription Use 
Iron Supplement Use 
Iron Multivitamin Use 
Contraceptive Pill Use* 
Menopausal Status* 
O Blood Group 
Rare Blood Group 
Smoking Status 
Alcohol Status 




Liver Consumption Per Week 
Red Meat Consumption Per 
Week 
Poultry Consumption Per 
Week 
White Fish Consumption Per 
Week 







Red Blood Cell Count 
White Blood Cell Count 
Platelet Count 
Mean Corpuscular Volume 
Mean Corpuscular Baseline 
Haemoglobin 
Baseline Log Ferritin 
 
 
4.2 Statistical Methods 
Cross-sectional correlates of baseline haemoglobin and log-transformed ferritin levels were assessed 
using a linear model adjusted for age, sex, and centre. Continuous explanatory variables were divided 
into groups based on sex-specific distributions.  This approach allowed assessment of the shape of any 
association with haemoglobin without imposing any particular shape on the association a priori [180, 
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181]. Categorical variables were modelled similarly to the risk-factor groups, except that dummy 
variables were used since there was no natural monotonic ordering of the categories. All other models 
were adjusted for age, sex, weight, new donor status, and donor centre. From each fitted linear model, 
overall adjusted mean values and 95 percent confidence intervals for each outcome by sex and 
categories of explanatory variables (ie tenths of continuous markers, or within category for categorical 
variables), were obtained with age fixed at 50 years. These adjusted mean values were used to 
summarise the shape of the association by plotting the mean outcome level against the mean marker 
value within each category.  
Linear regression models were used to assess the associations between baseline donor characteristics 
and the post-baseline outcome variables including (i) number of donations given over 2 years, (ii) 2-
year haemoglobin deferrals (iii) 2-year haemoglobin levels, and (iv) 2-year ferritin levels. Ferritin 
values were loge transformed and presented as geometric means and relative differences (i.e. taking 
exponents of estimated regression coefficients). Linear regression was chosen as the outcomes were 
continuous and a Gaussian distribution could be assumed due to the large sample size by the central 
limit theorem, including in the case of counts of number of donations given [182]. A Poisson model 
was used to assess the associations between baseline characteristics and number of post-baseline low 
haemoglobin deferrals over 2 years as low haemoglobin deferrals were relatively uncommon and thus 
more appropriately modelled as discrete count data. The Poisson distribution assumption of equal 
mean and variance could be relaxed with use of robust standard errors, which often gives similar 
inferences as alternative statistical models as negative binomial regression that include modelling of 
over-dispersion. Data for men and women were analysed separately by the intention-to-treat 
principle according to their randomised inter-donation interval. All models were adjusted for inter-
donation interval, age, sex, weight, and new donor status.  
Donor characteristics investigated further as potential modifiers of the effect of randomised inter-
donation interval on outcomes were first prioritised on the basis of having shown significant 
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associations with outcomes using a backwards-forwards selection procedure with p-value thresholds 
for exclusion and inclusion set to 0.1 and 0.09 respectively.  
Interactions between the selected baseline donor characteristics and the randomised inter-donation 
interval were then assessed in the regression models for the four post-baseline outcomes. Only the 
interaction effects between inter-donation interval and the prioritised donor characteristics were 
included as candidate variables. Interactions retained in the final multivariable adjusted models were 
identified using a backwards-forwards selection procedure with p-value thresholds for exclusion and 
inclusion set to 0.05 and 0.049 respectively. Those characteristics without a significant interaction 
effect were removed from the final model. 
Throughout analyses, inter-donation interval was analysed as a continuous, rather than a categorical 
variable as was the case in previous analyses of the INTERVAL trial [74]. This has the advantage of 
greater statistical power when the assumption of linear trend is reasonable, as well as allowing 
inference of the effect per one week shorter donation interval, which allows interpolation over a 
possible range of inter-donation intervals to be investigated than assigned during the trial (i.e. 
inferences between 8 and 12 weeks for men, and between 12 and 16 weeks for women). To facilitate 
graphical visualisation of interaction effects in the final multivariable models, the models were refitted 
with interacting continuous variables divided into quintiles one at a time and the interaction with 
inter-donation interval modelled as a categorical variable to calculate group-specific marginal means 
of the outcomes, which were then plotted against mean values of the covariates to visualise. These 
plots are referred to as marginal effect plots in the results. Statistical significance was based on p < 





4.3.1 Number of Donations 
4.3.1.1 Baseline Variable Associations with Number of Donations 
Randomisation to shorter inter-donation intervals significantly increased the number of donations 
given over 2 years of the trial in both men and women, with quantitatively twice as large an effect in 
men than women per week shorter inter-donation interval (Table 4.1). Other baseline covariates 
significantly associated with number of donations given after adjusting for the randomised inter-
donation interval and randomisation minimisation variables (i.e. age, weight, centre and new donor 
status) included, in both men and women, positive associations with age, PCS, MCS, iron multivitamin 
supplement use, red meat consumption, vegetable consumption, current alcohol consumption, 
number of donations given in the past two years, and four iron-related biomarkers (i.e. ferritin, 
haemoglobin, MCH, MCV). In women only, donations were also higher with higher reported levels of 
leisure activity. In men only, donations were higher with higher weight and in non-smokers compared 
to smokers.  
Significant negative associations were found in both men and women for first time donor status 
compared to returning donor, Asian ethnicity compared to white ethnicity, and two biomarkers (white 
blood cell count and platelet count), moreover, donations were also lower in part time workers and 
the unemployed compared to full time workers, and in those with a previous diagnosis of anaemia 
compared to those without. Compared to engagement in sitting work, engagement in other types of 
work (standing/walking, manual labour, heavy manual labour, and not working) was also associated 
with decreased units of blood collected during the trial. Ethnic differences were only evident in men, 




Table 4.2: Univariate associations with number of donations over two years adjusted for baseline 
age, weight, centre and new donor status 
 Men Women 
Variable Coefficient (SE) P Coefficient (SE) P 
Inter-donation interval (1 week decrease) 0.42 (0.013) <0.001 0.21 (0.0090) <0.001 
Demographics     
Height (m)2  0.048 (0.023) 0.034 0.075 (0.015) <0.001 
Weight (kg)2  0.089 (0.021) <0.001 0.0043 (0.015) 0.77 
Ethnicity (compared to White)  <0.001   
      Mixed  -0.40 (0.20) 0.048 -0.26 (0.13) 0.041 
      Asian  -1.12 (0.14) <0.001 -0.87 (0.14) <0.001 
      Black -0.64 (0.24) 0.009 -0.28 (0.17) 0.094 
      Chinese 0.67 (0.40) 0.096 -0.091 (0.26) 0.73 
      Other -0.30 (0.34) 0.39 -0.42 (0.29) 0.15 
Age (years)2 0.60 (0.022) <0.001 0.72 (0.015) <0.001 
PCS (score)2 0.23 (0.022) <0.001 0.18 (0.015) <0.001 
MCS (score)2 0.20 (0.021) <0.001 0.15 (0.015) <0.001 
Non-O Blood Group vs O -0.13 (0.043) 0.002   
Contraceptive Pill Use (Y vs N) - - 0.22 (0.40) <0.001 
Menopause – Yes vs No - - 0.17 (0.055) 0.003 
Menopause – Unsure vs No - - 0.064 (0.073) 0.32 
Iron Status     
Anaemia Ever (Y vs N) -0.98 (0.10) <0.001 -0.42 (0.035) <0.001 
Iron Prescription Use (Y vs N) -0.74 (0.45) 0.10 -0.28 (0.19) 0.15 
Iron Multivitamin Use (Y vs N) 0.20 (0.063) <0.001 0.25 (0.039) <0.001 
Iron Supplement Use (Y vs N) -0.0043 (0.22) 0.98 0.18 (0.092) 0.052 
Diet/Lifestyle     
Vegetarian (Y vs N) -0.47 (0.12) <0.001 -0.25 (0.065) <0.001 
Liver (Portions per Week) 2 -0.042 (0.022) 0.06 -0.060 (0.015) <0.001 
Red Meat (Portions per Week) 2 0.076 (0.022) <0.001 0.069 (0.015) <0.001 
Poultry (Portions per Week) 2 0.022 (0.022) 0.31 0.019 (0.016) 0.22 
White Fish (Portions per Week) 2 -0.025 (0.021) 0.25 0.12 (0.015) 0.45 
Oily Fish (Portions per Week) 2 -0.018 (0.022) 0.41 -0.17 (0.016) 0.27 
Vegetable Consumption (Y vs N) 0.70 (0.14) <0.001 0.41 (0.12) 0.001 
Fruit Consumption (Y vs N) 0.10 (0.067) 0.13 0.14 (0.056) 0.014 
Juice Consumption (Y vs N) -0.035 (0.044) 0.42 0.015 (0.030) 0.63 
Smoothie Consumption (Y vs N) -0.10 (0.064) 0.12 -0.14 (0.043) 0.001 
Tea Consumption (Y vs N) -0.13 (0.50) 0.008 -0.12 (0.034) <0.001 
Alcohol Status – Ex vs Never 0.21 (0.12) 0.075 0.031 (0.078) 0.69 
Alcohol Status – Current vs Never 0.71 (0.085) <0.001 0.32 (0.057) <0.001 
Smoking Status – Ex vs Never -0.24 (0.046) <0.001 -0.079 (0.033) 0.017 
Smoking Status – Current vs Never -0.067 (0.079) <0.001 -0.18 (0.054) 0.001 
Lifestyle     
Type of Work (compared to sitting)  <0.001   
      Standing/Walking -0.44 (0.062) <0.001 -0.28 (0.038) <0.001 
      Manual Labour -0.40 (0.065) <0.001 -0.26 (0.053) <0.001 
      Heavy Manual Labour -0.49 (0.11) <0.001 -0.55 (0.13) <0.001 
      Do Not Work -0.63 (0.069) <0.001 -0.22 (0.048) <0.001 
Leisure Activity (compared to very inactive)  0.015   
      Moderately Inactive 0.043 (0.21) 0.84 0.36 (0.14) 0.008 
      Moderately Active 0.21 (0.21) 0.30 0.57 (0.13) <0.001 
      Very Active 0.28 (0.21) 0.18 0.67 (0.14) <0.001 
Occupation – Part Time vs Full Time -0.54 (0.074) <0.001 -0.097 (0.037) 0.009 
Occupation – Do Not Work vs Full Time -0.71 (0.056) <0.001 -0.25 (0.040) <0.001 
Donation History     
New Donor vs Returning Donor -1.16 (0.079) <0.001 -0.65 (0.49) <0.001 
Donations in Past 2 Years (n) 2 0.69 (0.024) <0.001 0.55 (0.017) <0.001 
Low Hb Deferrals in Past 2 Years (n)2 -0.25 (0.021) <0.001 -0.14 (0.015) <0.001 
Biomarkers     
Ferritin (µg/L) 2 0.27 (0.023) <0.001 0.29 (0.016) <0.001 
Haemoglobin (g/dL) 2 0.33 (0.022) <0.001 0.28 (0.015) <0.001 
Mean Corpuscular Haemoglobin (g/dL) 2 0.32 (0.021) <0.001 0.27 (0.015) <0.001 
Mean Corpuscular Volume (fL) 2 0.21 (0.022) <0.001 0.19 (0.015) <0.001 
Red Blood Cell Count (1012/L) 2 0.025 (0.022) 0.25 0.025 (0.015) 0.11 
White Blood Cell Count (109/L) 2 -0.17 (0.022) <0.001 -0.048 (0.016) 0.002 
Platelet Count (109/L) 2 -0.18 (0.021) <0.001 -0.096 (0.015) <0.001 
 
2 Per standard deviation increase. SDs reported in Table 3.1 and Table 3.2 
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Variable selection amongst men resulted in the selection of seven baseline variables with significant 
associations with number of donations, including baseline MCS, MCV, haemoglobin, ferritin, iron 
multivitamin use, occupation status, and the number of donations in the previous two years, their 
corresponding interaction effects with inter-donation interval, adjusted for age, inter-donation 
interval, weight, donor status, and donor centre (Table 4.3). The selection procedure (Section 4.2) 
initially resulted in red blood cell count, MCH and haemoglobin selected for men, but examination of 
regression model diagnostics (specifically, variance inflation factors) indicated high collinearity, and 
thus the variable selection procedure was repeated to force retaining of haemoglobin only on the 
basis of its clinical relevance. The significant associations with an increase in blood donations were (in 
order of magnitude) higher number of donations in the past two years, inter-donation interval, age, 
baseline log ferritin, haemoglobin, MCS and MCV. Conversely, occupation status (part time or not 
working vs full time work), and first time donor status, were significantly associated with fewer 
donations (Table 4.3).  
Variable selection amongst women resulted in the selection of five baseline variables with significant 
associations with number of donations, including baseline log ferritin, the number of donations in the 
previous two years, baseline white blood cell count, PCS, and red blood cell count. The significant 
associations with more donations were (in order of magnitude) higher number of donations in the 




Table 4.3: Coefficients from the final selected model for number of donations in the trial for men (N 
= 20353). 
Main Effects 
Variable Coefficient (95% CI) P Value 
Inter-donation interval (1 week decrease) 0.44 (0.41, 0.47) <0.001 
2-Year Donations (n, 1 SD higher) 0.67 (0.59, 0.75) <0.001 
Age (years, 1 SD higher) 0.42 (0.37, 0.47) <0.001 
Occupation – Part Time vs Full Time -0.26 (-0.49, -0.032) 0.025 
Occupation – Do Not Work vs Full Time -0.45 (-0.62, -0.28) <0.001 
Donor Status (New vs Returning) -0.19 (-0.36, -0.014) 0.034 
Iron Multivitamin Use (Yes vs No) -0.10 (-0.30, 0.093) 0.31 
MCS (score, 1 SD higher) 0.073 (0.0058, 0.14) 0.033 
Weight (kg, 1 SD higher) -0.041 (-0.084, 0.0024) 0.064 
Log Ferritin (µg/L, 1 SD higher) 0.18 (0.096, 0.26) <0.001 
Haemoglobin (g/dL, 1 SD higher) 0.12 (0.054, 0.19) 0.10 
MCV (fL, 1 SD higher) 0.059 (-0.011, 0.13) 0.001 
Interaction with Inter-donation interval 
Iron Multivitamin Use (Yes vs No) 0.12 (0.048, 0.20) 0.001 
2-Year Donations (n, 1 SD higher) 0.11 (0.078, 0.14) <0.001 
Occupation – Part Time vs Full Time -0.10 (-0.19, -0.015) 0.021 
Occupation – Do Not Work vs Full Time -0.11 (-0.18, -0.045) 0.001 
MCS (score, 1 SD higher) 0.041 (0.015, 0.067) 0.002 
Log Ferritin (µg/L, 1 SD higher) 0.14 (0.10, 0.17) <0.001 
Haemoglobin ((g/dL, 1 SD higher) 0.055 (0.029, 0.082) <0.001 
MCV (fL, 1 SD higher) 0.026 (-0.0007, 0.053) 0.056 
 
Table 4.4: Coefficients from the final selected model for number of donations in the trial for women 
(N = 20886) 
Main Effects 
Variable Coefficient (95% CI) P Value 
Inter-donation interval (1 week decrease) 0.21 (0.19, 0.22) <0.001 
2-Year Donations (n, 1 SD higher) 0.53 (0.47, 0.58) <0.001 
Age (years, 1 SD higher) 0.39 (0.34, 0.45) <0.001 
PCS (score, 1 SD higher) 0.093 (0.046, 0.14) <0.001 
Donor Status (New vs Returning) 0.020 (-0.087, 0.13) 0.72 
Weight (kg, 1 SD higher) -0.0081 (-0.039, 0.023) 0.61 
Log Ferritin (1 SD higher) 0.27 (0.22, 0.32) <0.001 
White Blood Cell Count (109/L, 1 SD higher) -0.11 (-0.16, -0.065) <0.001 
Red Blood Cell Count (1012/L, 1 SD higher) -0.0015 (-0.048, 0.046) 0.95 
Interaction with Inter-donation interval 
Age (years, 1 SD higher) 0.050 (0.030, 0.070) <0.001 
2-Year Donations (n, 1 SD higher) 0.052 (0.033, 0.072) <0.001 
PCS (score, 1 SD higher) 0.028 (0.0010, 0.046) 0.003 
Log Ferritin (µg/L, 1 SD higher) 0.075 (0.056, 0.093) <0.001 
White Blood Cell Count (109/L, 1 SD higher) 0.033 (0.015, 0.051) <0.001 
Red Blood Cell Count (1012/L, 1 SD higher) 0.020 (0.0018, 0.038) 0.031 
77 
 
4.3.1.2 Effect Modification by Randomised Group  
The final multivariable model for men retained seven baseline characteristics as significant modifiers 
of the average positive effect of randomised inter-donation interval on the number of donations over 
two years (Table 4.3). These interactions included significantly more donations than average with 
higher values of iron multivitamin supplement use, higher number of donations in the two years prior 
to baseline, MCS, log ferritin, and haemoglobin (Table 4.3, Figure 4.1). Conversely the model indicated 
significantly fewer donations than average with working part-time or not at all as compared to full 
time employment (Table 4.3, Figure 4.1). Comparing the standardised coefficients, the strongest 
effect modifier among the continuous variables was baseline log ferritin levels which was more than 
twice as large as the estimated independent interaction effects of other standardised continuous 
variables. Considering the categorical variables, the difference according to iron multivitamin use and 
inter-donation interval was mostly apparent in the eight week group (Figure 4.1). The interaction with 
MCV had been selected in the smaller complete-case dataset of all variables considered (n = 20,231), 
but was not as convincing when refitted in the larger complete-case dataset of the seven retained 
variables (n = 20,353). In women, all of the interaction effects with inter-donation interval, namely 
higher age, baseline PCS, red blood cell count, white blood cell count, number of donations in the 














Figure 4.1: Marginal effects of number of donations in the past two years, occupation status, iron 
multivitamin use, baseline MCS, baseline MCH, haemoglobin levels, and log ferritin levels on number 
of donations for men. Green lines indicate the eight week group, red the 10 week group, and blue the 






Figure 4.2: Marginal effects of age, baseline PCS, red blood cell count, white blood cell count, number 
of previous donations and baseline log ferritin on number of donations for women. Green lines 




4.3.1.3 Performance of Models for Number of Donations 
Considering the performance of the models, the proportion of variance explained, as measured by the 
R2 values, increased marginally (<1%) when interaction effects were added to the model containing 
selected main effects with biomarkers, implying that the addition of interactions did not explain much 
variation in the number of donations given by donors during the trial. Comparing the models with and 
without biomarkers, there was a difference of approximately 3%. The results for women were similar 
although biomarkers provided less of an increase to the R2 values (Table 4.5).  
Table 4.5: R2 values for models of number of donations in the trial for men 
 Men (N=16004) Women (N=14605) 
No Biomarkers R2 R2 Difference R2 R2 Difference 
Saturated Model 15.98% - 18.94% - 
Selected Main Effects & Interactions 13.77% 2.21% 16.62% 2.32% 
Selected Main Effects Only 13.57% 0.02% 16.36% 0.026% 
Add Biomarkers R2 R2 Difference R2 R2 Difference 
Saturated Model 18.97% - 21.82% - 
Selected Main Effects & Interactions 17.01% 1.96% 19.5% 1.32% 
Selected Main Effects Only 16.09% 0.093% 19% 0.050% 
 
4.3.2 Haemoglobin Levels 
4.3.2.1 Cross-Sectional Correlates of Haemoglobin 
Examining the cross-sectional correlates of baseline haemoglobin, for all variables women had an 
equal or lower baseline haemoglobin than men. There was a positive association between baseline 
red blood cell count and baseline haemoglobin, and a negative association between the number of 
previous low haemoglobin deferrals and baseline haemoglobin. There was no association between 
other variables and baseline haemoglobin (Figure 4.3). For both sexes, black donors had the lowest 
baseline haemoglobin of all ethnic groups, and donors who had never been previously diagnosed with 
anaemia had higher haemoglobin than those who had reported history of anaemia diagnosis. There 





Figure 4.3: Cross-sectional correlates of baseline haemoglobin and continuous variables (partial R2 
difference in brackets). Panels indicate a separate continuous variable, plotted against haemoglobin 
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Figure 4.4: Cross-sectional correlates of baseline haemoglobin and categorical variables (partial R2 
difference in brackets). Panels indicate a separate categorical variable, with levels plotted against 
mean haemoglobin.  
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4.3.2.2 Baseline Variable Associations with 2-Year Haemoglobin 
Variable selection amongst men resulted in the selection of three baseline variables with significant 
associations with two-year haemoglobin – haemoglobin, platelet count, and MCV, their corresponding 
interaction effects with inter-donation interval, adjusted for age, inter-donation interval, weight, 
donor status, and donor centre (Table 4.6). The significant associations with higher haemoglobin after 
two years were (in order of magnitude) higher baseline haemoglobin, weight, and MCV. Conversely, 
inter-donation interval, platelet count, age, and new donor status were significantly associated with 
lower haemoglobin (Table 4.6).  
Table 4.6: Coefficients from the final selected model for two year haemoglobin in the trial for men 
(N=15,431) 
Main Effects 
Variable Coefficient (95% CI) P Value 
Inter-donation interval (1 week decrease) -0.085 (-0.095, -0.075) <0.001 
Weight (kg, 1 SD higher) 0.098 (0.081, 0.11) <0.001 
Age (years, 1 SD higher) -0.050 (-0.069, -0.030) <0.001 
Donor Status (New vs Returning) -0.049 (-0.13, 0.032) 0.24 
Haemoglobin (g/dL, 1 SD higher) 0.58 (0.55, 0.61) <0.001 
Platelet Count (109/L, 1 SD higher) -0.052 (-0.078, -0.025) <0.001 
MCV (fL, 1 SD higher) 0.013 (-0.014, 0.041) 0.33 
Interaction with Inter-donation interval 
Haemoglobin (g/dL, 1 SD higher) -0.048 (-0.058, -0.037) <0.001 
Platelet Count (109/L, 1 SD higher) 0.011 (0.0004, 0.021) 0.041 
MCV (fL, 1 SD higher) 0.010 (0.0001, 0.021) 0.048 
 
Variable selection amongst women resulted in two baseline variables with significant associations with 
two-year haemoglobin: baseline haemoglobin and the number of donations in the previous two years. 
The significant associations with higher two-year haemoglobin were (in order of magnitude) higher 
baseline haemoglobin, number of donations in the previous two years, weight, and age. Only inter-




Table 4.7: Coefficients from the final selected model for two year haemoglobin in the trial for 
women (N=14652) 
Main Effects 
Variable Coefficient (95% CI) P Value 
Inter-donation interval (1 week decrease) -0.032 (-0.042, -0.021) <0.001 
Age (years, 1 SD higher) 0.036 (0.017, 0.054) <0.001 
Weight (kg, 1 SD higher) 0.048 (0.031, 0.065) <0.001 
Donor Status (New vs Returning) 0.037 (-0.033, 0.11) 0.30 
Haemoglobin (g/dL, 1 SD higher) 0.49 (0.46, 0.52) <0.001 
2-Year Donations (n, 1 SD higher) 0.16 (0.13, 0.19) <0.001 
Interaction with Inter-donation interval 
Haemoglobin (g/dL, 1 SD higher) -0.029 (-0.040, -0.019) <0.001 
2-Year Donations (n, 1 SD higher) -0.019 (-0.029, -0.0089) <0.001 
 
4.3.2.3 Effect Modification by Randomised Group 
The only significant selected interaction effect in the model for men was with baseline haemoglobin. 
Higher baseline haemoglobin was associated with less of an increase in haemoglobin at two years on 
shorter inter-donation intervals (Table 4.6). In addition, higher platelet count and MCV were 
associated with a higher haemoglobin level after two years on shorter inter-donation intervals. The 
marginal effect plots show that higher baseline haemoglobin was associated with a higher two year 
haemoglobin level, most apparent in those with higher baseline haemoglobin levels (Figure 4.5). 
Both interaction effects selected in women – baseline haemoglobin and the number of donations 
given in the past two years - were negative with a low magnitude, indicating that the effect of these 






Figure 4.5: Marginal effects of baseline haemoglobin, platelet count, and MCV on two year 
haemoglobin for men. Green lines indicate the eight week group, red the 10 week group, and blue 




Figure 4.6: Marginal effects of baseline haemoglobin and number of previous donations on two year 
haemoglobin for women. Green lines indicate the 12 week group, red the 14 week group, and blue 




4.3.2.4 Performance of Models for Haemoglobin 
Considering the performance of the models, the proportion of variance explained, as measured by the 
R2 values, increased marginally (<1%) when interaction effects were added to the model containing 
selected main effects with biomarkers, implying that the addition of interactions did not explain much 
variation in the number of donations given by donors during the trial. Comparing the models with and 
without biomarkers, there was a difference of approximately 13% in women and 17% in men. (Table 
4.8).  
Table 4.8: R2 values for the haemoglobin models for men and women 
 Men (N=11369) Women (N=9773) 
No Biomarkers R2 R2 Difference R2  R2 Difference 
Saturated Model 7.09% - 7.79% - 
Selected Main Effects & Interactions - - 3.32% 4.47% 
Selected Main Effects Only 5.01% 2.08% 3.25% 0.07% 
Add Biomarkers R2 R2 Difference R2 R2 Difference 
Saturated Model 24.27% - 20.65% - 
Selected Main Effects & Interactions 21.2% 3.07% 18.04% 2.61% 
Selected Main Effects Only 20.65% 5.5% 17.78% 0.26% 
 
4.3.3 Ferritin Levels 
4.3.3.1 Cross-Sectional Correlates of Ferritin 
Examining the cross-sectional correlates of baseline ferritin, for most variables women had a lower 
baseline haemoglobin level than men. There was a positive association between height, weight, white 
blood cell count, baseline haemoglobin, MCV, and MCH and baseline ferritin, and a negative 
association between the number of previous donations and low haemoglobin deferrals and baseline 
ferritin. There was no association between other variables and baseline ferritin (Figure 4.7). For both 
sexes, first time donors had higher ferritin than repeat donors. In addition, those without a previous 
diagnosis of anaemia had higher baseline ferritin than those with a diagnosis. There was no difference 






Figure 4.7: Cross-sectional correlates of baseline ferritin and continuous variables (partial R2 
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Figure 4.8: Cross-sectional correlates of baseline ferritin and categorical variables (partial R2 




4.3.3.2 Baseline Variable Associations with Ferritin Levels 
Variable selection amongst men resulted in four main effects, baseline log ferritin, MCH, and red blood 
cell count, and the number of donations in the previous two years and their corresponding interaction 
effects with inter-donation interval, the interaction effect between age and inter-donation interval, 
and fixed effects of age, inter-donation interval, weight, donor status, and donor centre. Log ferritin 
was used as the outcome, with geometric means presented to show the multiplicative change in two 
year ferritin levels. Characteristics associated with proportionally higher ferritin were (in order of 
magnitude) higher baseline log ferritin, the number of donations in the previous two years, and weight. 
Conversely, new donor status, inter-donation interval, higher red blood cell count and MCH were 
significantly associated with lower ferritin at two years (Table 4.9).  
Table 4.9: Proportional changes from the final selected model for two year log ferritin in the trial for 
men. (N=13,402) 
Main Effects 
Variable Coefficient P Value 
Inter-donation interval (1 week decrease) 0.92 (0.91,0.93) <0.001 
2-Year Donations (n, 1 SD higher) 1.15 (1.13, 1.18) <0.001 
Weight (kg, 1 SD higher) 1.05 (1.03, 1.06) <0.001 
Donor Status (New vs Returning) 0.88 (0.83, 0.93) <0.001 
Age (years, 1 SD higher) 0.99 (0.97, 1.01) 0.342 
Log Ferritin (µg/L, 1 SD higher) 1.70 (1.65, 1.74) <0.001 
Red Blood Cell Count (1012/L, 1 SD higher) 0.94 (0.92, 0.97) <0.001 
MCH (g/dL, 1 SD higher) 0.97 (0.95, 1.00) 0.062 
Interaction with Inter-donation interval 
2-Year Donations (n, 1 SD higher) 0.98 (0.97, 0.99) <0.001 
Age (years, 1 SD higher) 1.01 (1.01, 1.02) 0.001 
Log Ferritin (µg/L, 1 SD higher) 0.96 (0.95, 0.97) <0.001 
Red Blood Cell Count (1012/L, 1 SD higher) 0.98 (0.97, 0.99) <0.001 
MCH (g/dL, 1 SD higher) 0.98 (0.97, 0.990 <0.001 
 
Variable selection amongst women resulted in four main effects and their corresponding interaction 
effects added to the model, including baseline log ferritin, the number of donations in the previous 
two years, baseline red blood cell count, and iron supplement use. The significant associations with 
higher ferritin at two years (in order of magnitude) were higher baseline log ferritin, donations in the 
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previous two years, weight, and age. Conversely, higher baseline red blood cell count was significantly 
associated with lower ferritin at two years (Table 4.10). 
Table 4.10: Proportional changes from the final selected model for two year log ferritin in the trial 
for women (N=12,409) 
Main Effects 
Variable Coefficient P Value 
Inter-donation interval (1 week decrease) 0.96 (0.95, 0.97) <0.001 
2-Year Donations (n, 1 SD higher) 1.14 (1.11, 1.16) <0.001 
Donor Status (New vs Returning) 0.95 (0.90, 1.01) 0.113 
Weight (kg, 1 SD higher) 1.04 (1.03, 1.06) <0.001 
Iron Supplement Use (Yes vs No) 0.97 (0.85, 1.10) 0.621 
Age (years, 1 SD higher) 1.02 (1.00, 1.04) 0.01 
Log Ferritin (µg/L, 1 SD higher) 1.60 (1.56, 1.63) <0.001 
Red Blood Cell Count (1012/L, 1 SD higher) 0.97 (0.94, 0.99) 0.003 
Interaction with Inter-donation interval 
Iron Supplement Use (Yes vs No) 1.06 (1.01, 1.11) 0.023 
2-Year Donations (n, 1 SD higher) 0.99 (0.98, 0.99) 0.001 
Log Ferritin (µg/L, 1 SD higher) 0.97 (0.96, 0.98) <0.001 
Red Blood Cell Count (1012/L, 1 SD higher) 0.99 (0.98, 1.00) 0.006 
 
4.3.3.3 Effect Modification by Randomised Group 
In men, the rises in two year ferritin associated with two-year donations and baseline log ferritin were 
less on the shorter inter-donation intervals, and there was a greater negative association with red 
blood cell count and MCH on shorter inter-donation intervals (Table 4.9). The marginal effect plots 
showed that there was little difference between two-year ferritin levels at the lowest levels of 
donations in the past two years, baseline ferritin, red blood cell count and MCH, and amongst the 




Figure 4.9: Marginal effects of number of donations in the previous two years, age at baseline, 
baseline red blood cell count, MCH and baseline ferritin on two year ferritin levels for men. Green 
lines indicate the eight week group, red the 10 week group, and blue the 12 week group. 
 
In women, those who used iron supplements had 6% higher two year ferritin per week shorter inter-
donation interval than those who did not take supplements. Similarly to men, for women the decrease 
in ferritin levels with shorter inter-donation intervals was attenuated in those with a higher baseline 
log ferritin or red blood cell count, and more donations in the previous two years, had lower ferritin 
proportionally on shorter inter-donation intervals (Table 4.10). Only for women with baseline ferritin 
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above the median was there a notable difference in two year ferritin levels by inter-donation interval 
(Figure 4.10). 
 
Figure 4.10: Marginal effects of iron supplement use, number of donations in the previous two years 
baseline red blood cell count and log ferritin on two year ferritin for women. Green lines indicate the 
12 week group, red the 14 week group, and blue the 16 week group. 
 
4.3.3.4 Performance of Models for Ferritin 
Considering the performance of the models, the proportion of variance explained, as measured by the 
R2 values, increased marginally (<1%) when interaction effects were added to the model containing 
selected main effects with biomarkers, implying that the addition of interactions does little to explain 
variation in two-year ferritin levels. Comparing the models with and without biomarkers, in men 
adding biomarkers contributed an extra 19% to R2. The R2 values were lower for the models in women 
containing biomarkers, however addition of biomarkers still added 10% to the R2 values (Table 4.11).  
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Table 4.11: R2 values for the ferritin models for men and women 
 Men (N=10,503) Women (N=9,035) 
No Biomarkers R2  R2 Difference R2  R2 Difference 
Saturated Model 8.79% - 7.57% - 
Selected Main Effects & Interactions 5.79% 3% 4.43% 3.14% 
Selected Main Effects Only 5.72% 0.0007 4.29% 0.14% 
Add Biomarkers R2  R2 Difference R2  R2 Difference 
Saturated Model 27.47% - 17.65% - 
Selected Main Effects & Interactions 25.97% 1.5% 16.62% 1.03% 
Selected Main Effects Only 25.32% 0.65% 16.35% 0.27% 
  
4.3.4 Low Haemoglobin Deferrals 
4.3.4.1 Baseline Variable Associations with Number of Low Haemoglobin Deferrals 
Randomisation to shorter inter-donation intervals significantly increased the number of low 
haemoglobin deferrals over 2 years of the trial in both men and women, with a quantitatively larger 
effect in men than women per week shorter inter-donation interval (Table 4.12). Other baseline 
covariates significantly associated with the number of low haemoglobin deferrals after adjusting for 
the randomised inter-donation interval and randomisation minimisation variables (i.e. age, weight, 
centre and new donor status) included, in both men and women, positive associations with black and 
Asian ethnicity compared with white, higher age, non-O blood group, previous diagnosis of anaemia, 
vegetarianism, tea consumption, and the number of previous donations and low haemoglobin 
deferrals. In women only, deferrals were also higher with higher height, mixed ethnicity compared to 
white, those who consumed fruit compared to those who did not, and women who were pre-
menopausal or unsure of their menopausal status compared to post-menopausal. In men only, 
deferrals were higher in ex-smokers compared to non-smokers, and those who used iron supplements 
compared to non-use.  
Significant negative associations with low haemoglobin deferrals were found in both men and women 
for weight, iron multivitamin use, four dietary variables (red meat, poultry, white and oily fish 
consumption), new donor status, and seven iron-related biomarkers (i.e. ferritin, haemoglobin, MCH, 
MCV, red blood cell, white blood cell, and platelet counts). Only in men were deferrals significantly 
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lower among those who consumed vegetables, juice, and smoothies compared to those who did not, 
and in women only were deferrals less with higher levels of MCS. In addition, in women only were 
deferrals lower with current alcohol status compared to never, ex smoking status compared to never, 




Table 4.12: Univariable risk ratios for number of low hb deferrals adjusted for age, weight, centre 
and new donor status 
 Men Women 
Variable Coefficient (SE) P Coefficient (SE) P 
Inter-donation interval (1 week decrease) 1.33 (0.11) <0.001 1.18 (0.090) <0.001 
Demographics     
Height (m)3  0.99 (0.014) 0.71 1.04 (0.013) 0.004 
Weight (kg)3  0.68 (0.11) <0.001 0.80 (0.012) <0.001 
Ethnicity (compared to White)  <0.001  <0.001 
      Mixed  0.97 (0.13) 0.79 1.28 (0.12) 0.009 
      Asian  1.52 (0.12) <0.001 1.53 (0.14) <0.001 
      Black 1.77 (2.2) <0.001 1.70 (0.19) <0.001 
      Chinese 0.87 (0.24) 0.61 0.99 (0.20) 0.95 
      Other 0.91 (0.20) 0.67 1.15 (0.25) 0.51 
Age (years)3 1.34 (0.18) <0.001 0.96 (0.012) <0.001 
PCS (score)3 1.00 (0.013) 0.92 1.00 (0.013) 0.72 
MCS (score)3 0.98 (0.013) 0.14 0.94 (0.011) <0.001 
Non-O Blood Group vs O 1.14 (0.029) <0.001 1.09 (0.026) <0.001 
Contraceptive Pill Use (Y vs N) - - 0.94 (0.030) 0.071 
Menopause – Yes vs No - - 1.66 (0.075) <0.001 
Menopause – Unsure vs No - - 1.17 (0.066) 0.007 
Iron Status     
Anaemia Ever (Y vs N) 2.00 (0.086) <0.001 1.73 (0.044) <0.001 
Iron Prescription Use (Y vs N) 1.52 (0.36) 0.079 0.99 (0.16) 0.93 
Iron Multivitamin Use (Y vs N) 0.71 (0.031) <0.001 0.81 (0.027) <0.001 
Iron Supplement Use (Y vs N) 1.33 (0.14) 0.007 0.99 (0.073) 0.94 
Diet     
Vegetarian (Y vs N) 1.62 (0.093) <0.001 1.40 (0.063) <0.001 
Liver (Portions per Week)3 1.01 (0.013) 0.49 1.01 (0.013) 0.68 
Red Meat (Portions per Week)3 0.91 (0.013) <0.001 0.90 (0.012) <0.001 
Poultry (Portions per Week)3 0.93 (0.014) <0.001 0.93 (0.013) <0.001 
White Fish (Portions per Week)3 0.97 (0.014) 0.045 0.96 (0.013) 0.003 
Oily Fish (Portions per Week)3 0.95 (0.014) <0.001 0.95 (0.013) <0.001 
Vegetable Consumption (Y vs N) 0.82 (0.068) 0.016 0.92 (0.087) 0.37 
Fruit Consumption (Y vs N) 0.99 (0.042) 0.78 1.14 (0.055) 0.005 
Juice Consumption (Y vs N) 0.93 (0.024) 0.003 0.96 (0.023) 0.098 
Smoothie Consumption (Y vs N) 0.89 (0.038) 0.006 1.01 (0.035) 0.85 
Tea Consumption (Y vs N) 1.18 (0.039) <0.001 1.13 (0.032) <0.001 
Lifestyle     
Alcohol Status – Ex vs Never 1.16 (0.077) 0.023 1.06 (0.061) 0.35 
Alcohol Status – Current vs Never 0.92 (0.046) 0.11 0.79 (0.034) <0.001 
Smoking Status – Ex vs Never 0.97 (0.027) 0.33 0.89 (0.024) <0.001 
Smoking Status – Current vs Never 0.76 (0.043) <0.001 0.56 (0.031) <0.001 
Type of Work (compared to sitting)  0.037  <0.001 
      Standing/Walking 1.00 (0.039) 0.99 1.02 (0.031) 0.50 
      Manual Labour 1.13 (0.044) 0.002 1.04 (0.044) 0.41 
      Heavy Manual Labour 1.06 (0.069) 0.36 0.86 (0.095) 0.17 
      Do Not Work 1.03 (0.039) 0.46 0.82 (0.034) <0.001 
Leisure Activity (compared to very inactive)  0.90  0.20 
      Moderately Inactive 1.05 (0.14) 0.72 0.91 (0.11) 0.44 
      Moderately Active 1.03 (0.14) 0.82 0.95 (0.11) 0.68 
      Very Active 1.02 (0.14) 0.89 0.90 (0.11) 0.38 
Occupation – Part Time vs Full Time 1.01 (0.043) 0.90 1.04 (0.031) 0.22 
Occupation – Do Not Work vs Full Time 0.98 (0.033) 0.54 0.88 (0.30) <0.001 
Donation History     
New Donor vs Returning Donor 0.54 (0.037) <0.001 0.84 (0.035) <0.001 
Donations in Past 2 Years (n)3 1.08 (0.016) <0.001 0.91 (0.013) <0.001 
Low Hb Deferrals in Past 2 Years (n)3 1.19 (0.0075) <0.001 1.29 (0.0096) <0.001 
Biomarkers     
Ferritin (µg/L)3 0.50 (0.0060) <0.001 0.53 (0.0061) <0.001 
Haemoglobin (g/dL)3 0.58 (0.0059) <0.001 0.53 (0.0056) <0.001 
Mean Corpuscular Haemoglobin (g/dL)3 0.65 (0.0071) <0.001 0.63 (0.0067) <0.001 
Mean Corpuscular Volume (fL)3 0.71 (0.0091) <0.001 0.69 (0.0081) <0.001 
Red Blood Cell Count (1012/L)3 0.85 (0.012) <0.001 0.85 (0.11) <0.001 
White Blood Cell Count (109/L)3 0.95 (0.013) 0.001 0.95 (0.013) <0.001 
Platelet Count (109/L)3 1.09 (0.014) <0.001 1.07 (0.013) <0.001 
 
3 Per standard deviation increase. SDs reported in Table 3.1 and Table 3.2 
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Variable selection amongst men resulted in five main effects; non-O blood group, baseline 
haemoglobin and ferritin, and the number of donations and low haemoglobin deferrals in the past 
two years, their corresponding interaction effects with inter-donation interval, alongside main effects 
of age, inter-donation interval, weight, donor status, and donor centre and the interaction effect of 
age with inter-donation interval. The significant associations with higher low haemoglobin deferrals 
were (in order of magnitude) higher number of low haemoglobin deferrals in the past two years, the 
inter-donation interval, and age. Conversely, higher baseline ferritin and haemoglobin levels, 
donations in the previous two years, and weight were significantly associated with fewer low 
haemoglobin deferrals (Table 4.13) 
Table 4.13: Relative risks from the final selected model for number of low hb deferrals in the trial for 
men (N=20,945) 
Main Effects 
Variable Coefficient P Value 
Inter-donation interval (1 week decrease) 1.42 (1.38, 1.46) <0.001 
2-Year Low Hb Deferrals (n, 1 SD higher) 1.54 (1.36, 1.72) <0.001 
Age (years, 1 SD higher) 1.37 (1.28, 1.46) <0.001 
2-Year Donations (n, 1 SD higher) 0.79 (0.73, 0.85) <0.001 
Weight (kg, 1 SD higher) 0.83 (0.79, 0.85) <0.001 
Donor Status (New vs Returning) 0.84 (0.69, 1.01) 0.063 
Blood Group (Non-O vs O) 0.93 (0.83, 1.05) 0.242 
Log Ferritin (µg/L, 1 SD higher) 0.53 (0.50, 0.57) <0.001 
Haemoglobin (g/dL, 1 SD higher) 0.54 (0.49, 0.59) <0.001 
Interaction with Inter-donation interval 
Haemoglobin (g/dL, 1 SD higher) 1.09 (1.06, 1.12) <0.001 
2-Year Low Hb Deferrals (n, 1 SD higher) 0.94 (0.91, 0.98) 0.007 
Blood Group (Non-O vs O) 1.04 (1.01, 1.08) 0.023 
2-Year Donations (n, 1 SD higher) 1.03 (1.00, 1.05) 0.020 
Age (years, 1 SD higher) 0.98 (0.96, 0.99) 0.013 
Log Ferritin (µg/L, 1 SD higher) 1.02 (1.00, 1.05) 0.029 
 
Variable selection amongst women resulted in three main and corresponding interaction effects: non-
O blood group, and the number of donations and low haemoglobin deferrals in the previous two years. 
The significant associations with higher frequency of low haemoglobin deferrals were (in order of 
magnitude) higher number of low haemoglobin deferrals in the past two years, age and inter-donation 
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interval. Conversely, significant associations with fewer low haemoglobin deferrals were higher age, 
weight, and number of donations in the previous two years (Table 4.14).  
Table 4.14: Relative risks from the final selected model for number of low hb deferrals in the trial for 
women (N=22,672) 
Main Effects 
Variable Coefficient P Value 
Inter-donation interval (1 week decrease) 1.17 (1.14, 1.20) <0.001 
Age (years, 1 SD higher) 0.97 (0.94, 1.00) 0.04 
Blood Group (Non-O vs O) 0.98 (0.89, 1.08) 0.68 
Weight (kg, 1 SD higher) 0.83 (0.80, 0.86) <0.001 
Donor Status (New vs Returning) 0.90 (0.81, 1.00) 0.051 
2-Year Low Hb Deferrals (n, 1 SD higher) 2.05 (1.93, 2.20) <0.001 
2-Year Donations (n, 1 SD higher) 0.90 (0.85, 0.94) <0.001 
Interaction with Inter-donation interval 
Blood Group (Non-O vs O) 1.04 (0.99, 1.08) 0.015 
2-Year Low Hb Deferrals (n, 1 SD higher)  0.97 (0.95, 0.99) 0.01 
2-Year Donations (n, 1 SD higher) 1.03 (1.01, 1.04) 0.003 
 
4.3.4.2 Effect Modification by Randomised Group 
In men, a higher number of donations in the past two years, and higher baseline haemoglobin and 
ferritin were associated with a greater risk of low haemoglobin deferrals than would have been 
expected on shorter inter-donation intervals. In addition, non-O blood group was associated with a 
lesser risk of low haemoglobin deferrals on shorter inter-donation intervals (Table 4.13). However, at 
the highest levels of baseline ferritin there was little difference in the risk of low haemoglobin deferrals 
(Figure 4.11). 
In women, a higher number of donations in the previous two years was associated with less risk of 
low haemoglobin deferrals on shorter intervals. Conversely, non-O blood group and a higher number 
of low haemoglobin deferrals in the previous two years were associated with less of an increased risk 




Figure 4.11: Marginal effects of age, blood group, baseline haemoglobin and log ferritin, and number 
of donations and low haemoglobin deferrals in the past two years on number of low haemoglobin 
deferrals in the trial for men. Green lines indicate the eight week group, red the 10 week group, and 




Figure 4.12: Marginal effects of blood group, number of donations and low haemoglobin deferrals in 
the past two years on number of low haemoglobin deferrals in the trial for women. Green lines 
indicate the 12 week group, red the 14 week group, and blue the 16 week group. 
 
4.3.4.3 Performance of Models for Number of Low Haemoglobin Deferrals 
Considering the performance of the models, the proportion of variance explained, as measured by the 
pseudo-R2 values, increased marginally (<1%) when interaction effects were added to the model 
containing selected main effects with biomarkers, implying that the addition of interactions does little 
to explain variation in the number of low haemoglobin deferrals experienced by donors over two years. 
Comparing the models with and without biomarkers, in men adding biomarkers contributed an extra 
6% to R2. In women, no biomarkers were selected. The R2 difference between the saturated models 







Table 4.15: Pseudo-R2 values for models of number of low haemoglobin deferrals in the trial for 
women 
 Men (N=16004) Women (N=14605) 
No Biomarkers R2 R2 Difference R2 R2 Difference 
Saturated Model 12.33% - 6.86% - 
Selected Main Effects & Interactions 11.68% 0.65% 5.84% 1.02% 
Selected Main Effects Only 11.5% 0.18% 5.74% 0.1% 
Add Biomarkers R2 R2 Difference R2 R2 Difference 
Saturated Model 18.97% - 18.70% - 
Selected Main Effects & Interactions 17.01% 1.96% 5.84% 12.86% 
Selected Main Effects Only 16.09% 0.93% 5.74% 0.1% 
 
4.4 Discussion 
In this chapter, I have conducted a comprehensive analysis of characteristics associated with four 
donor-health related outcomes, including identifying moderators of the effect of randomised inter-
donation interval. Specifically, the findings suggest characteristics associated with a donor’s ability to 
safely donate over the two year study period, risk of receiving low haemoglobin deferrals, and final 
haemoglobin and ferritin values, and which of these are moderators of the individual’s interval 
assignment. The findings can be used to develop personalised donation intervals in the future. 
4.4.1 Number of Donations 
In both sexes, randomisation to shorter inter-donation intervals did result in an increase in blood 
collected during the trial. Among men, a key finding is that those with higher ferritin were able to 
donate more during the trial on shorter donation intervals, as were men with higher haemoglobin 
levels and more previous blood donations. For women, these associations were present at a smaller 
magnitude. In addition, age was associated with the number of donations given, with older women 
able to donate more than younger women. This is in agreement with previous studies which found 
more donations from older donors [34, 183-185], those of white ethnicity compared to non-white [1, 
4], and a decrease in donations from those with lower ferritin [5]. The main INTERVAL findings also 
concluded that higher ferritin and haemoglobin at baseline were associated with more donations 
during the trial [74]. In addition, a week reduction in time between donations resulted in an increase 
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of 0·23 units in the amount of blood collected per year in men and 0·14 units in women compared 
with the currently-used 12 and 16 week inter-donation intervals [186]. 
Examining variables that were moderators of inter-donation interval in men, the largest differences 
were evident among the most frequent previous donors as well as those with highest baseline ferritin 
levels and use of iron multivitamins. The former can likely be explained by the fact that if a donor has 
already donated frequently in the previous two years, they are likely to be committed to the trial. 
Those using iron multivitamins were able to donate more during the trial than those who did not. This 
could be because those on iron supplementation could represent the more committed donors to the 
trial who were taking an extra precaution to control the risk of iron depletion afforded by more 
frequent blood donation, and this will be further examined in Chapter 5. In addition, those in full time 
employment were able to donate more blood during the trial than those in part time work or out of 
work. This could perhaps be because full time employees are used to managing a schedule and thus 
can schedule donations more easily compared to the additional commitments that may hinder those 
in part time work or not in employment such as childcare. Those out of work may be out of work due 
to mobility issues or family circumstances which may affect their availability to give blood.  
In women, there were similar associations as men with number of previous donations and inter-
donation interval. The difference between the 16 week group and the other groups widened for more 
frequent donors, implying that this group may have been committed enough to take full advantage of 
the extra donation opportunities afforded by more frequent donation intervals. A similar association 
was seen according to baseline PCS score, with the highest scoring women donating relatively more 
in the 12 week group than the 14 week group, likely due to being in better physical health and so able 
to withstand more frequent donation. The most notable association with number of donations in 
women was age, with older women able to donate half an extra donation in two years with a one 
week shorter donation interval. This could be because, as identified in Chapter 2, older women who 
have stopped menstruating are less susceptible to low haemoglobin levels. More biomarkers were 
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moderators of inter-donation interval in men than in women. While there was little difference 
between donations given in the trial at the lowest baseline ferritin levels, the groups separated as 
baseline ferritin increased. 
4.4.2 Two Year Haemoglobin Levels 
For both sexes, the most relevant correlate of a donor’s two year haemoglobin level was their 
haemoglobin level at baseline. For women there was a more pronounced effect of the number of 
previous donations on haemoglobin levels than in men, perhaps because women had a smaller 
maximum number of donations they could have given in the previous two years due to the longer 
minimum inter-donation interval. This effect of previous donation was also found in other studies [113, 
187, 188]. However, a previous study found more associations with haemoglobin levels than these 
results, including associations with smoking status, iron supplementation, and BMI, but concluded 
that dietary variables did not have a significant effect on haemoglobin levels [189]. 
Examining moderators of inter-donation interval, in men baseline haemoglobin levels had the highest-
magnitude of association, with those who had the highest baseline haemoglobin having the highest 
two-year haemoglobin, and those on the 12 week group having higher haemoglobin compared to 
other groups. Considering the aim to safely maximise the blood supply, men with higher baseline 
haemoglobin levels could be allocated shorter inter-donation intervals, however there is currently a 
lack of routine haemoglobin measurement in practice. 
For women, the association between haemoglobin at the start and end of the trial was such that those 
women on the 12 week group had a lower two year haemoglobin than those on the 14 and 16 week 
groups at the highest levels. Women with fewer than four donations in the previous two years had 
similar haemoglobin levels regardless of inter-donation interval while larger differences were 
observed between randomised inter-donation intervals with more previous donations. This could 
perhaps be explained by the fact that women with fewer donations in the past have had more time to 
recover haemoglobin between donations. 
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4.4.3 Ferritin Levels 
For both sexes, the associations with baseline variables and two-year ferritin levels were similar. 
Baseline ferritin had the largest association with two-year ferritin. Those with higher donations in the 
past had a lower two-year ferritin, particularly in the shortest inter-donation interval. For men only, 
returning donors had lower two-year ferritin than those who were first time donors at the 
commencement of the trial. This could be due to the removal of iron from the body as a consequence 
of blood donation, and is in agreement with previous studies [113, 188]. Other studies also found 
associations between ferritin levels and donation history [76, 113, 190-192], and also found a lack of 
major association with dietary variables [190]. 
The effect of inter-donation interval on ferritin levels was moderated by red blood cell count, MCH 
and baseline ferritin in men. Baseline ferritin had the largest association with two year ferritin. As 
baseline ferritin levels rose, those on the 8 week group had lower two year ferritin than the 10 and 12 
week group members, and at the highest level the 12 week group had higher ferritin than those in the 
10 week group as well as the 8 week group. There was also a greater separation between randomised 
groups at the higher levels of baseline red blood cell count and MCH. If assessment of ferritin levels is 
to be considered in the future, biomarker analysis which is not routine would be required. 
As for men, baseline ferritin had the largest association with two-year ferritin levels, and had 
significant interaction with randomised inter-donation interval in women. Differences in two-year 
ferritin levels diverged between inter-donation intervals as baseline ferritin increased. The association 
between red blood cell count and two year ferritin in women was similar to men. There was also an 
association between two-year ferritin and the number of previous donations, showing women who 
had donated more in the past had lower ferritin, likely due to the above relationship between previous 
donations and donation during the trial, and so they would lose more ferritin during the trial by 
donating more. In addition to the biomarkers, the interaction between use of iron supplements and 
inter-donation interval was significant, with women who did not take iron supplements having lower 
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two-year ferritin levels. This may be because women who take iron supplements have better overall 
management of their iron stores, which would be reflected in their ferritin levels. 
4.4.4 Low Haemoglobin Deferrals 
There were more variables found to be moderators of the effect of inter-donation interval on low 
haemoglobin deferrals in men than in women. The strongest associations were with baseline ferritin 
and previous low haemoglobin deferrals. At the lowest baseline ferritin levels, there were larger 
differences in deferral rates, with the 8 week group having the highest and 12 week the lowest, 
compared with the highest levels where deferral rates were similar across the inter-donation groups. 
This is perhaps unsurprising as ferritin is a measure of iron stores in the body, and so those with low 
ferritin levels are likely to have lower haemoglobin levels.  
Men with more low haemoglobin deferrals in the past received more haemoglobin deferrals during 
the trial, perhaps because they are more susceptible to having lower haemoglobin and thus also 
deferrals. In concordance with Chapter 2, older men experienced more low haemoglobin deferrals 
than their younger counterparts. There was also a difference by blood group, with non-O blood group 
associated with slightly higher low haemoglobin deferrals on shorter inter-donation intervals. Baseline 
haemoglobin levels were also associated with low haemoglobin deferrals. Men with the highest 
baseline haemoglobin levels had fewer low haemoglobin deferrals, likely because these donors were 
more likely to be able to recover their haemoglobin levels as they started at a higher level. Repeat 
donors experienced more of an increase in low haemoglobin deferrals in the 8 week group than the 
10 and 12 week groups. 
In women two moderators of inter-donation interval on low haemoglobin deferrals were found – 
number of previous donations and low haemoglobin deferrals. More committed donors received 
fewer low haemoglobin deferrals during the trial. This may be because donors who have donated 
more in the past are more used to managing their iron levels so that they are more likely to come back 
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to donate only when their haemoglobin levels are sufficient. Women with more low haemoglobin 
deferrals in the past also experienced more such deferrals during the trial. 
4.4.5 Implications 
The INTERVAL trial’s primary aim was to assess the efficacy and safety of shorter inter-donation 
intervals as one way to maximise the number of donations that can be given by the blood donor 
population in England. However, avoidance of low haemoglobin deferrals is a key issue, and this can 
be aided by knowing donors’ haemoglobin and ferritin levels pre-donation. The variables found to 
have the strongest associations with donations in the trial were also moderators of the effect of inter-
donation interval and could be conveniently collected from donors using existing records or 
questionnaires, such as number of previous donations, occupation status, iron multivitamin use, age, 
and PCS and MCS scores. The same was true of low haemoglobin deferrals, with a donor’s donation 
and deferral history being key moderators of inter-donation interval for both sexes, as well as age and 
blood group for men. 
However, haemoglobin levels, and particularly ferritin levels, often had a higher magnitude of 
association than these more easily available variables. While haemoglobin levels per visit can 
sometimes be recorded when haemoglobin is measured before donation, this is not current practice 
in the UK. In addition, ferritin levels are not routinely measured, and neither are other blood based 
biomarkers, some of which could also be useful in assigning personalised donation intervals alongside 
history of donations and deferrals. In addition, the cost of measuring ferritin is greater than if a 
haemotology analyser (e.g. Sysmex XN in the INTERVAL trial) were routinely used, the haemoglobin 
and other biomarker information could be readily available, although this comes at an additional cost. 
These results could also be used to predict donors’ ferritin levels, which requires different assay for 
measurement. This information could be a useful counterpart to low haemoglobin deferral 
considerations when assigning donation intervals. 
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4.4.6 Strengths and Limitations 
The primary strengths of INTERVAL were its trial design and scale. Due to the large sample size of 
45,000 participants and high completeness of follow-up including 99.5% completeness for the primary 
outcome could be achieved due to the blood service’s database [74], statistical power to compare 
outcomes across three donation intervals for each sex was achieved. Analysing the inter-donation 
interval as a continuous variable also allowed for greater statistical power. The design of the trial 
helped reduce confounding compared with observational studies and represented all areas of England 
as it was facilitated by the regular blood service [74]. It is possible that the true effect of the inter-
donation interval may not have been accurately captured in the continuous modelling, as the assigned 
inter-donation interval may not reflect the participant’s actual time to return to donate. However, this 
does not prevent interpretation on the basis of the intention-to-treat analysis, and while the true 
inter-donation interval may have varied around the randomly assigned interval, approximately 75% of 
trial participants attended within one week of their assigned inter-donation interval (Figure 4.13) [74]. 
Conversely, the trial context may have encouraged greater adherence to the assigned inter-donation 
interval, potentially reducing external validity in the usual blood donation context. While there may 
be concerns that non-random attrition may bias estimation of the true effect of the randomised inter-
donation interval on outcomes, such bias seems unlikely as the dropout rates during the trial were not 
differential between the randomised inter-donation interval groups [74]. Furthermore, completeness 
of data for all primary and secondary outcomes was comparable across all three sex-specific inter-




Figure 4.13: Adherence to assigned randomised inter-donation interval, either through making a 
donation or receiving a deferral. Approximately 75% of participants returned to donate within one 
week of their assigned interval, and adherence was not differential by trial arm [74]. 
Limitations of the study included the trial setting, which may overestimate the impact of the trial’s 
primary outcome in particular if applied to the general UK blood donor population [73]. In addition, 
only around 45% of invited donors consented to participate in the trial. The trial also excluded donors 
without internet access, and so the results may not be generalisable to these donors [74]. Moreover, 
while few self-reported variables made it into the final models, several variables, particularly dietary 
variables, were self-reported, and so the true impact of these could be different than that which was 
observed. In addition, while variance inflation factors were low in the models, it is possible that there 
exists collinearity between biomarker variables such as MCV, MCH, and baseline haemoglobin, which 
could affect results. There are possible limitations in the statistical modelling used in these analyses. 
While the Poisson model assumptions may not have been strictly met by the deferral data, the 
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assumption of equality of mean and variance could be relaxed by using robust standard errors. In 
addition, there was a potential limitation in assuming that age adjustment also captured differences 
due to menopausal status in women. Menopausal status was self-reported at baseline (as Yes, No, or 
Unsure) but the exact age at menopause was not specifically ascertained. The mean age at baseline 
was 59.11 years for post-menopausal women and was 39.14 years for premenopausal women, a large 
20 years difference that would partly explain the result that the menopausal status variable was not 
found to be an independent predictor in multivariable regression models adjusted for baseline age 
and other variables associated with menopausal status.  
4.4.7 Conclusions 
This chapter has identified key correlates and moderators of the effect of inter-donation interval on 
four key outcomes – the number of donations, low haemoglobin, and haemoglobin and ferritin levels. 
With the exception of ferritin, many of the variables that were key moderators of the effect of inter-
donation interval on these outcomes are routinely collected by the blood service, or else can be 
collected easily using questionnaires. In general, maximising donations while minimising deferrals 
does not result in practical difficulties as these were often related to similar variables. When the same 
variable affected both, donations are maximised and deferrals minimised at the same levels of the 
variable. Consequently, personalising donation intervals is likely to be achievable in practice by the 
blood service. There are other considerations when assigning donors to shorter inter-donation 
intervals such as post-donation symptoms and well-being, which will be addressed in Chapter 5 and 
Chapter 6 respectively. 
The primary question raised is whether ferritin testing should be used if the blood service intends to 
introduce personalised donation intervals. It was a moderator of the effect of inter-donation interval 
on most outcomes and had a high magnitude of association with number of donations for both sexes, 
and number of low haemoglobin deferrals for men. However, implementing ferritin testing would 
come at a cost to the blood service.  
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Chapter 5 – Reported Occurrence of Symptoms in INTERVAL and the 
Role of Iron Supplementation as a Mediator of Symptoms 
Summary 
Iron deficiency is a frequently reported adverse consequence of blood donation that can be 
exacerbated by more frequent donation as found in the INTERVAL trial. Iron supplementation has 
been suggested to relieve symptoms associated with iron deficiency. Mitigation of post-donation 
symptoms is important in donor management, as donors who experience symptoms are less likely to 
return to donate. 
In the INTERVAL trial, participants were asked to self-report a range of symptoms every six months, 
including tiredness, breathlessness, fainting, and restless legs syndrome, as well as whether they were 
using iron supplementation. These data facilitate prospective analysis of risk factors for reported 
symptoms, and assessment of potential mediators of the effect of randomised inter-donation interval 
on symptoms, specifically iron supplementation. 
In both sexes, randomised shorter inter-donation intervals significantly increased reported occurrence 
of symptoms, including tiredness, breathlessness, dizziness, fainting or feeling faint, restless legs 
syndrome and doctor diagnosed low iron. Additionally, in men only, reported occurrences of 
palpitations and chest pain were higher in shorter randomised inter-donation intervals. The reported 
use of doctor prescribed iron supplements gradually increased in the course of the trial from 2.2% at 
baseline to 4.4% at 2 years. While use of iron supplementation, whether through a supplement or 
prescribed by a doctor, was associated with symptoms in both sexes, it did not mediate the effect of 
inter-donation interval assignment on symptoms. 
While there are other reasons why iron supplementation may be offered to blood donors, such as a 
desire to reduce low haemoglobin deferrals, the analyses herein suggest such strategy may not be 




Iron deficiency affects 25-35% of blood donors and is a widely reported adverse consequence of blood 
donation [76, 84, 193]. A  standard blood donation (about 470 ml of blood) removes around 240-
260mg of iron [137, 194]. This can often be between one and two thirds of a woman’s iron stores [195] 
and as much as 81% of iron stores in a menstruating woman (Figure 5.1). Post-menopausal women, 
while also at greater risk of iron deficiency than men, have much greater iron levels than pre-
menopausal women, with average ferritin values increasing with age to an average of 86 ug/L post-
menopause, compared to 32-53 ug/L in pre-menopausal women [193]. Physiological iron absorption 
is between 3 and 4 mg per day maximum [196, 197], and may not give sufficient time for a donor to 
recover iron levels if donating at short intervals. 
 
Figure 5.1: Iron stores in blood donors compared with iron lost in one donation [193]. 
Studies have shown that there is a higher prevalence of iron deficiency among younger women, and 
those who donate at higher intensity, whether through more donations or less time between 
donations [76, 84]. In the REDS -II study that assessed iron status in blood donors in the USA, donation 
intensity stood out as the most predictive factor of iron depletion [84]. It is possible that donors who 
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give blood will be subject to post-donation symptoms, such as vasovagal reactions (VVRs), due to iron 
deficiency following blood donation [198]. Subjective experience of mild VVRs was found to reduce 
donor return rates by 20% in first time donors and 33% for repeat donors, and male donors were 
found to be less likely to return following a VVR than females [199]. The statistic of repeat donors 
returning less after a VVR is of concern, as donations from repeat donors make up a large proportion 
of the blood supply, and so efforts to minimise symptoms from donation are crucial to maintaining a 
sufficient blood supply.  
5.1.1 Possible Consequences of Iron Deficiency and Use of Iron Supplementation to Relieve 
Symptoms 
5.1.1.1 Restless Legs Syndrome 
Previous studies have investigated the link between iron stores, iron supplementation and restless 
legs syndrome. Restless legs syndrome is characterised by paraesthesia in the legs, occurring at rest, 
which is relieved by movement. It frequently causes sleep disturbance, and has been linked to iron 
deficiency [200].  
There have been inconclusive results from studies examining a relationship between restless legs 
syndrome and iron stores in blood donors. While two studies found that restless legs syndrome 
symptoms were improved when donors used iron supplementation [201, 202]. In a systematic review 
of studies with blood donor populations, six out of nine studies did not report an association between 
iron deficiency and restless legs syndrome [203].This may be because iron balance does not affect all 
causes of restless legs syndrome. Other conditions associated with restless legs syndrome include 
renal failure, pregnancy, and neuropathy [200, 204]. As such, restless legs syndrome may be 
inconsistently reversible with iron supplementation when associated with iron deficiency [193, 201, 
202, 205]. Blood donors who develop such symptoms may not necessarily do so due to iron deficiency, 




Pica is another documented side effect of iron deficiency and blood donation. The most common form 
of pica, the desire to eat non-nutritious substances, associated with iron deficiency is eating ice [201]. 
A study in a blood donor population in the USA found that pica and iron status were associated in 
female donors but not male donors, however incidence of pica was low [205]. 
Another study investigated the relationship between pica and haemoglobin levels and found that 
lower haemoglobin levels corresponded to a higher prevalence of pica. This suggests that, as with 
restless legs syndrome, there could be other mechanisms which cause pica in donors than simply iron 
deficiency [206]. 
5.1.1.3 Fatigue 
Fatigue is a widely reported symptom of iron deficiency [207, 208]. However, iron repletion has 
benefited patients complaining of chronic fatigue [193]. It is possible then that iron supplementation 
could help relieve fatigue if donors develop it as a consequence of more frequent donation.  
A previous study found that the ability of iron supplementation to relieve fatigue was dependent on 
iron stores, with only those with ferritin values below 50 ug/L reporting a decrease in fatigue after one 
month of iron supplementation, and found an effect of iron supplementation in relieving fatigue in 
adolescent girls [209]. Another study found that the number of donors reporting fatigue more than 
halved following iron supplementation [210]. One meta-analysis of six randomised controlled trials 
and six cross-sectional studies in non-anaemic individuals and found that iron supplementation 
reduced fatigue. The meta-analysis was also robust to sensitivity analysis without evidence of 
publication bias [208].  
5.1.1.4 Physical Symptoms 
Some studies have investigated the relationship between physical symptoms such as exercise capacity 
and iron supplementation in blood donors, as well as an effect on general quality of life.  
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A meta-analysis found that exercise capacity was reduced in donors two days following a blood 
donation [211]. While this could be due to decreased blood volume, it is possible that reduced iron 
levels could also play a role. Randomised double-blind controlled trials have found that iron 
supplementation can be associated with an increase in aerobic capacity [212-215] and a decrease in 
muscle fatigue [216]. 
The INTERVAL trial assessed several physical symptoms which have not been studied in the literature, 
including fainting, breathlessness and chest pain, and found that these were more prevalent in the 
shorter donation groups [74]. It is possible that, with such donors losing more iron during the trial, 
that this could be driven in part by iron stores. 
5.1.1.5 Cognitive Symptoms 
Iron has an impact on the brain’s development, and some have particularly pointed to risks associated 
with blood donation and the associated loss of iron in the development of adolescents.  
Verbal learning and memory in adolescent girls has been shown to be improved with iron 
supplementation [217], and a systematic review of 14 studies on women and children’s cognition 
found that iron supplementation improved attention, concentration and intelligence. There was no 
effect on non-anaemic participants [218]. It is possible therefore that iron supplementation could help 
reduce the risks of cognitive symptoms in blood donors due to iron deficiency. 
5.1.1.6 Side Effects of Iron Supplementation 
Other symptoms have been studied in relation to iron supplementation, often by being reported as 
side effects by participants. These side effects include gastrointestinal symptoms, such as gastric 
discomfort, diarrhoea, and constipation [195, 210, 219].  
There is also the question of whether donors who take iron supplementation are more susceptible to 
VVRs than those who do not. One study which randomised donors to take iron supplementation or 
not before donation found no significant difference between symptoms in the iron and placebo groups, 
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with the majority of adverse events reported by blood donors were related to venepuncture [220]. A 
meta-analysis of four studies found that the risk of adverse events was not different between the 
group of donors taking iron supplements and placebo group [221]. On the other hand, in another 
study, the iron group had significantly more people report any symptom (P=0.002) [195], and a meta-
analysis of four studies (1748 participants) showed a significant increase in adverse events was 
associated with iron supplementation (Risk ratio 16 (1.23-2.07)) [155]. It is therefore unclear if iron 
supplementation affects adverse events. 
5.1.2 Conclusions From Current Literature 
Short-term iron supplementation in donors may help to reduce the risk of post-donation 
adverse symptoms, including restless legs syndrome, pica, and fatigue.  
One limitation of the studies that have been carried out on iron supplementation and symptoms is 
that they often suffer from low sample sizes. It is possible that, due to its much larger sample size, 
INTERVAL data could address this limitation. Moreover, characteristics of study populations are 
variable and so conclusions from previous literature may not be generalisable to a healthy blood donor 
population. In addition, many symptoms recorded in INTERVAL such as feeling faint, breathlessness, 
and chest pain, had not been widely studied, or studied at all. However, iron supplementation was 
not included in INTERVAL’s trial design, and symptoms was a secondary outcome of the trial. 
5.1.3 Post-Donation Symptoms and Iron Supplementation in INTERVAL 
Variation of the inter-donation interval as conducted in INTERVAL could present an increased 
challenge to the UK blood service from iron deficiency as donors lose iron more regularly due to more 
regular blood donation. 
INTERVAL studied not just serious adverse events and VVRs such as heart attacks, but also less serious 
post-donation symptoms which a donor may attribute to frequent blood donation and may affect 
their willingness to return.  
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The symptoms studied in INTERVAL were tiredness, breathlessness, dizziness, chest pain, palpitations, 
fainting or feeling faint, and restless legs syndrome. Previous findings from the INTERVAL study have 
found that increasing the inter-donation interval did not cause an increase in fainting events, or harm 
cognitive function or physical ability of donors. However, there was a moderate increase in other 
symptoms, particularly amongst men [74]. In an extension study, there were no clear differences 
between frequency of reporting symptoms by randomised group [186]. This may be because those 
who experienced increased symptoms during the INTERVAL’s two-year period may have been less 
likely to participate in the extension study. 
5.1.4 Statistical Mediation 
In clinical trials, it is possible that there is an event or change in other characteristics influenced by  
the treatment, which may explain the effect of the intervention observed on outcomes [222]. In 
INTERVAL, the randomised inter-donation interval may affect symptoms directly or via iron-related 
pathways, which would also be influenced by iron supplementation. In this case, iron supplementation 
would be a mediator of the effect of inter-donation interval. If this is not considered when performing 
analysis, it is possible that models will over or underestimate the effects of predictors, and some which 
appear significant may not be due to confounders which are not present in the model.  
Figure 5.2 gives a graphical interpretation of a mediator. Without the mediator (iron supplementation), 
it is assumed that the effect of the independent variable (randomised inter-donation interval) on the 
outcome variable (symptom) is from the direct effect (path c). It is possible instead that there could 
be the mediator variable the indirect effect of the independent variable on outcome (via path a and 
path b) may be not be ignorable. 
A mediator meets the following conditions: that variations in the independent variable significantly 
account for variations in the mediator, and vice-versa, and that there is a significant change in the 
direct effect of the independent variable on the outcome (path c vs path cadjusted) when the mediator 
is added to the model [223]. An extension to these criteria is the MacArthur method, which extends 
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this framework by requiring the inclusion of an interaction between the independent variable (i.e. 
inter-donation interval) and the proposed mediator [224]. The MacArthur method essentially 
accounts for the possibility that a statistically significant interaction may reflect statistical mediation 
[225], thereby decreasing the probabilities of both a type I error (rejecting the null hypothesis when 






Figure 5.2: Diagram of the effect paths when a mediator is present. When no mediator is present, 
only effect c is recorded by the model. When the mediator is added, c becomes cadjusted. 
 
5.1.5 Chapter Aims 
To enhance the evidence base and overcome the limitations of previous studies on the occurrence of 
donor symptoms including fatigue, fainting, and restless legs syndrome, in this chapter I investigated 
the relationship between randomised inter-donation interval and symptoms thought to be related to 
iron deficiency. I also investigated iron supplementation as potential mediator of the effect of 
randomised inter-donation interval on symptoms. 
5.2 Methods  
5.2.1 Measurement of Symptoms in INTERVAL 
All symptoms were assessed in the six-monthly questionnaires that asked participants if they had 
experienced a list of symptoms in the past six months. Clinical Restless legs syndrome was also 
assessed via the Cambridge-Hopkins questionnaire at the 18th and 24th months of follow [7, 169]. Pica 
was assessed by questions which asked participants if they had craved and regularly eaten or chewed 











5.2.2 Iron Supplementation in the INTERVAL trial 
Iron supplementation was not randomised in the INTERVAL trial, however its usage was enquired in 
the questionnaires completed by participants. At baseline and after two years participants were asked 
if they took iron supplements prescribed by a doctor, or contained within a multivitamin, or iron only 
supplements. Every six months, participants were asked if they had seen a doctor who had diagnosed 
them with low iron or prescribed them iron supplements. 
5.2.3 Statistical Analysis 
Logistic regression models fitted using the generalised estimating equation (GEE) modelling 
framework [226, 227] were used to assess the effect of inter-donation interval on symptoms and 
assess role of iron supplementation use as a potential mediator. The GEE modelling framework is 
primarily designed to assess predictors of the mean of a transformed response (e.g. log odds) while 
accounting for relatedness of observations within clusters based on an assumed working correlation 
matrix. This framework  was used in order to  take into account to account correlation of repeated 
observations on the same individual [228, 229].  Each symptom was assessed up to four times during 
the study [7] and so data rows were not independent and identically distributed [230, 231]. An 
exchangeable correlation structure was assumed for the repeated measures within individuals, 
meaning equally correlated  across time points [232], with individuals considered independent. 
However, for unbiased inferences, the GEE model requires that data be missing completely at random 
(MCAR), i.e. that the probability distribution of missing measurements is independent of both the 
unobserved and observed measurements. Because this may be a rather strong assumption, sensitivity 
analyses were conducted based on mixed effects logistic regression (MELOGIT) which provides 
unbiased inferences under the less strict, but more plausible, missing at random (MAR) assumption, 
i.e. that the probability distribution of missing measurements is independent of the unobserved 
measurements given the observed measurements. 
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Analyses were sex-specific and the effect of randomised inter-donation interval was modelled as a 
linear trend. Covariate adjustments were introduced in three progressive models to assess changes in 
the effect of randomised inter-donation interval with adjustments. Model 1 adjusted for age, weight, 
new donor status, and donation centre. Model 2 further adjusted for the participant’s use of iron 
supplementation at baseline. Model 3 further adjusted for the participant’s use of iron 
supplementation during the trial as assessed by the six-month questionnaires. All associations were 
presented with a 95% confidence interval. Statistical significance was based on p < 0.05 throughout. 
5.3 Results 
5.3.1 Frequency of Symptoms 
The three most frequently reported symptoms were tiredness, restless legs, and dizziness. Comparing 
the results of the 12-week group, the frequency of symptoms reporting was generally higher in women 
than men (Table 5.1).  
5.3.2 Completion of Questionnaire 
For all symptoms in all randomised groups, the proportion of INTERVAL participants completing the 
questionnaire reduced over the 2-year trial period. (Table 5.2). However, dropout during follow up 
was not differential across the randomised inter-donation intervals, and therefore inferences should 
remain unbiased. Furthermore, the GEE modelling framework used for analyses allowed the inclusion 
of information from all available questionnaires completed during follow up, as opposed to requiring 
restriction to participants with all questionnaires completed.   
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Table 5.1: Number of donors (%) who reported symptoms or iron prescription at any point during 
the trial by randomised group 
 Men Women 
 8 weeks   
(N = 7456) 
10 weeks 
(N = 7446) 
12 weeks 
(N = 7452) 
12 weeks 
(N = 7567) 
14 weeks 
(N = 7565) 
16 weeks 
(N = 7548) 
Any Symptom       
Yes 3458 (46.4) 3244 (43.6) 3090 (41.5) 4210 (55.6) 4060 (53.7) 3967 (52.6) 
Tiredness       
Yes 2034 (27.3) 1774 (23.8) 1720 (23.1) 2561 (33.8) 2343 (31.0) 2277 (30.2) 
Breathlessness       
Yes 942 (12.6) 783 (10.5) 710 (9.5) 1083 (14.3) 963 (12.7) 967 (12.8) 
Palpitations       
Yes 698 (9.4) 633 (8.5) 585 (7.9) 1234 (16.3) 1116 (14.8) 1150 (15.2) 
Dizziness       
Yes 1039 (13.9) 947 (12.7) 886 (11.9) 1706 (22.5) 1618 (21.4) 1525 (20.2) 
Feeling Faint       
Yes 774 (10.4) 660 (8.9) 598 (8.0) 1257 (16.6) 1162 (15.4) 1119 (14.8) 
Fainting       
Yes 125 (1.7) 96 (1.3) 82 (1.1) 249 (3.3) 225 (3.0) 211 (2.8) 
Chest Pain       
Yes 455 (6.1) 405 (5.4) 384 (5.2) 415 (5.5) 367 (4.9) 409 (5.4) 
RLS       
Yes 1442 (19.3) 1334 (17.9) 1245 (16.7) 1841 (24.3) 1764 (23.3) 1741 (23.1) 
Iron Prescription       





Table 5.2: Number (%) of INTERVAL participants who completed the questions for reporting 
symptoms at each time point in the trial by randomised group 
 Men Women 
Symptom 8 weeks  
(N = 7456) 
10 weeks 
(N = 7446) 
12 weeks 
(N = 7452) 
12 weeks 
(N = 7567) 
14 weeks 
(N = 7565) 
16 weeks 
(N = 7548) 
Tiredness       
6 months 5927 (79%) 5869 (79%) 5733 (77%) 5889 (78%) 5953 (79%) 5875 (78%) 
12 months 5396 (72%) 5395 (72%) 5369 (72%) 5330 (70%) 5479 (72%) 5301 (70%) 
18 months 4789 (64%) 4814 (65%) 4831 (65%) 4679 (62%) 4737 (63%) 4694 (62%) 
24 months 4908 (66%) 4922 (66%) 4937 (66%) 4715 (62%) 4714 (62%) 4651 (62%) 
Breathlessness       
6 months 5921 (79%) 5862 (79%) 5725 (77%) 5875 (78%) 5943 (79%) 5866 (78%) 
12 months 5387 (72%) 5385 (72%) 5364 (72%) 5322 (70%) 5372 (71%) 5298 (70%) 
18 months 4787 (64%) 4812 (65%) 4827 (65%) 4675 (62%) 4730 (63%) 4690 (62%) 
24 months 4886 (66%) 4896 (66%) 4926 (66%) 4695 (62%) 4701 (62%) 4633 (61%) 
Palpitations       
6 months 5913 (79%) 5855 79%) 5721 (77%) 5869 (78%) 5946 (79%) 5869 (78%) 
12 months 5385 (72%) 5379 (72%) 5362 (72%) 5311 (70%) 5371 (71%) 5282 (70%) 
18 months 4780 (64%) 4816 (65%) 4815 (65%) 4665 (62%) 4762 (63%) 4683 (62%) 
24 months 4895 (66%) 4914 (66%) 4926 (66%) 4702 (62%) 4707 (62%) 4641 (61%) 
Dizziness       
6 months 5917 (79%) 5853 (79%) 5723 (77%) 5868 (78%) 5938 (78%) 5867 (78%) 
12 months 5387 (72%) 5380 (72%) 5360 (72%) 5312 (70%) 5365 71%) 5291 (70%) 
18 months 4777 (64%) 4810 (65%) 4820 (65%) 4671 (62%) 4731 (63%) 4680 (62%) 
24 months 4908 (66%) 4916 (66%) 4938 (66%) 4715 (62%) 4714 (62%) 4651 (62%) 
Feeling Faint       
6 months 5912 (79%) 5846 (79%) 5715 (77%) 5866 (78%) 5933 (78%) 5865 (78%) 
12 months 5377 (72%) 5381 (72%) 5353 (72%) 5312 (70%) 5366 (71%) 5292 (70%) 
18 months 4784 (64%) 4804 (65%) 4823 (65%) 4666 (62%) 4716 (62%) 4681 (62%) 
24 months 4908 (66%) 4914 (66%) 4938 (66%) 4715 (62%) 4714 (62%) 4651 (62%) 
Fainting       
6 months 5904 (79%) 5844 (79%) 5707 (77%) 5849 (77%) 5925 (78%) 5837 (77%) 
12 months 5367 (72%) 5376 (72%) 5345 (72%) 5300 (70%) 5352 (71%) 5270 (70%) 
18 months 4763 (64%) 4794 (64%) 4817 (65%) 4653 (61%) 4704 (62%) 4661 (62%) 
24 months 4907 (66%) 4917 (66%) 4935 (66%) 4709 (62%) 4711 (62%) 4647 (62%) 
Chest Pain       
6 months 5905 (79%) 5842 (79%) 5718 (77%) 5857 (77%) 5919 (78%) 5838 (77%) 
12 months 5362 (72%) 5377 (72%) 5339 (72%) 5299 (70%) 5341 (71%) 5267 (70%) 
18 months 4767 (64%) 4799 (64%) 4814 (65%) 4663 (62%) 4712 (62%) 4669 (72%) 
24 months 4886 (66%) 4905 (66%) 4909 (66%) 4689 (62%) 4692 (62%) 4624 (61%) 
RLS       
6 months 5896 (79%) 5835 (79%) 5700 (77%) 5853 (77%) 5918 (78%) 5839 (77%) 
12 months 5387 (72%) 5387 (72%) 5362 (72%) 5318 (70%) 5370 (71%) 5283 (70%) 
18 months 4795 (64%) 4814 (65%) 4834 (65%) 4686 (62%) 4747 (63%) 4704 (62%) 
24 months 4851 (65%) 4863 (65%) 4894 (66%) 4664 (62%) 4668 (62%) 4601 (61%) 
Iron Prescription       
6 months 5900 (79%) 5835 (78%) 5694 (76%) 5871 (78%) 5935 (78%) 5856 (78%) 
12 months 5370 (72%) 5364 (72%) 5267 (71%) 5308 (70%) 5369 (71%) 5268 (70%) 
18 months 4687 (63%) 4733 (64%) 4656 (62%) 4594 (61%) 4662 (62%) 4620 (61%) 




5.3.3 Associations with Baseline Variables and Symptoms 
Multivariable adjusted associations of randomised inter-donation interval and other baseline variables 
and reported symptoms are summarised in Table 5.3. In both men and women, shorter randomised 
inter-donation interval significantly increased the odds of all symptoms assessed, other than pica (in 
both sexes) and chest pain (in women).  
As regards other baseline variables, for men, older age was associated with lower odds of reporting 
fainting or feeling faint, palpitations, chest pain and pica. Higher weight was associated with lower 
odds of reporting fainting or feeling faint and doctor diagnosed low iron. Higher baseline haemoglobin 
and baseline ferritin were associated with lower odds of reporting all symptoms, and a higher number 
of donations in the past two years was associated with lower odds of reporting all symptoms except 
pica. A higher number of low haemoglobin deferrals in the past was associated with lower odds of 
reporting fainting or feeling faint. On the other hand, older age was associated with higher odds of 
reporting breathlessness, restless legs syndrome, and doctor diagnosed low iron, and higher weight 
was associated with higher odds of reporting breathlessness and pica (Table 5.3). 
For women, older age was associated with lower odds of reporting fainting or feeling faint, tiredness, 
dizziness, chest pain, and pica. Higher weight was associated with lower odds of reporting fainting or 
feeling faint. First time donor status was associated with lower odds of reporting dizziness. A higher 
number of low haemoglobin deferrals was associated with lower odds of reporting tiredness and 
breathlessness. Higher baseline ferritin was associated with lower odds of reporting all symptoms 
except for chest pain and pica. As in men, higher haemoglobin levels were associated with lower odds 
of reporting all symptoms, a higher number of donations in the past two years was associated with 
lower odds of reporting all symptoms except pica. On the other hand, older age was associated with 
higher odds of reporting restless legs syndrome; higher weight was associated with higher odds of 
reporting tiredness and breathlessness, and higher low haemoglobin deferrals in the previous two 
years was associated with higher odds of reporting doctor diagnosed low iron (Table 5.3). 
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Table 5.3: Odds ratios of associations between baseline variables and reported symptoms over the two year trial period 
Variable Fainting or 
Feeling Faint 





Inter-Donation Interval4 1.07 (1.04, 1.11) 1.06 (1.04, 1.08) 1.09 (1.06, 1.12) 1.05 (1.02, 1.08) 1.06 (1.04, 1.09) 1.05 (1.01, 1.10) 1.03 (1.01, 1.05) 1.20 (1.16, 1.24) 1.05 (0.93, 1.19) 
Age (years)5 0.83 (0.79, 0.88) 0.96 (0.93, 1.00) 1.11 (1.06, 1.17) 0.85 (0.80, 0.90) 0.98 (0.94, 1.03) 0.86 (0.80, 0.93) 1.20 (1.16, 1.24) 1.46 (1.37, 1.55) 0.42 (0.33, 0.54) 
Weight (kg)5 0.87 (0.82, 0.92) 1.02 (0.98, 1.05) 1.17 (1.11, 1.23) 1.03 (0.97, 1.09) 0.96 (0.92, 1.01) 1.04 (0.97, 1.12) 1.03 (0.99, 1.07) 0.83 (0.78, 0.89) 1.48 (1.24, 1.77) 
New Donor (Y/N) 0.92 (0.75, 1.13) 0.96 (0.84, 1.09) 0.87 (0.71, 1.08) 0.84 (0.67, 1.06) 0.97 (0.80, 1.17) 0.83 (0.62, 1.11) 1.06 (0.92, 1.22) 0.87 (0.66, 1.18) 0.84 (0.38, 1.84) 
Haemoglobin (g/dL)5 0.81 (0.77, 0.86) 0.92 (0.89, 0.95) 0.99 (0.94, 1.04) 0.92 (0.87, 0.98) 0.84 (0.80, 0.89) 0.93 (0.85, 1.00) 0.92 (0.89, 0.96) 0.71 (0.66, 0.75) 0.48 (0.38, 0.61) 
Ferritin (µg/L)5 0.88 (0.84, 0.93) 0.92 (0.89, 0.95) 0.84 (0.80, 0.89) 0.92 (0.87, 0.97) 0.86 (0.82, 0.90) 0.89 (0.83, 0.96) 0.85 (0.82, 0.88) 0.64 (0.61, 0.75) 0.70 (0.56, 0.86) 
2-Year Donations (n)5 0.84 (0.80, 0.89) 0.88 (0.85, 0.91) 0.84 (0.80, 0.89) 0.84 (0.79, 0.90) 0.87 (0.83, 0.91) 0.90 (0.83, 0.97) 0.88 (0.85, 0.92) 0.86 (0.81, 0.92) 0.82 (0.64, 1.04) 
2-Year Low Hb Deferrals (n)5 0.91 (0.84, 0.98) 0.99 (0.96, 1.03) 1.02 (0.96, 1.08) 0.96 (0.89, 1.04) 0.96 (0.90, 1.01) 1.00 (0.92, 1.09) 0.96 (0.92, 1.00) 1.10 (1.05, 1.16) 0.85 (0.60, 1.03) 
Women 
Inter-Donation Interval4 1.04 (1.01, 1.06) 1.04 (1.02, 1.06) 1.04 (1.01, 1.06) 1.03 (1.00, 1.05) 1.04 (1.02, 1.06) 1.00 (0.96, 1.04) 1.01 (0.99, 1.03) 1.09 (1.06, 1.12) 1.00 (0.92, 1.09) 
Age (years)5 0.62 (0.60, 0.65) 0.84 (0.81, 0.86) 0.97 (0.92, 1.02) 0.99 (0.94, 1.03) 0.83 (0.80, 0.86) 0.72 (0.67, 0.78) 1.30 (1.26, 1.34) 0.95 (0.91, 1.00) 0.94 (0.93, 0.96) 
Weight (kg)5 0.90 (0.86, 0.94) 1.07 (1.04, 1.10) 1.13 (1.08, 1.18) 0.97 (0.93, 1.02) 1.01 (0.98, 1.05) 1.03 (0.96, 1.11) 1.03 (1.00, 1.07) 0.93 (0.88, 0.98) 1.01 (1.00, 1.02) 
New Donor (Y/N) 0.98 (0.86, 1.12) 0.92 (0.83, 1.01) 0.89 (0.76, 1.04) 0.86 (0.74, 1.00) 0.87 (0.77, 0.99) 0.86 (0.67, 1.09) 0.93 (0.83, 1.03) 0.92 (0.78, 1.09) 0.80 (0.48, 1.36) 
Haemoglobin (g/dL)5 0.87 (0.83, 0.92) 0.91 (0.88, 0.94) 0.91 (0.86, 0.96) 0.95 (0.90, 0.99) 0.87 (0.83, 0.91) 0.92 (0.84, 1.00) 0.94 (0.91, 0.97) 0.69 (0.65, 0.73) 0.49 (0.43, 0.56) 
Ferritin (µg/L)5 0.91 (0.88, 0.95) 0.96 (0.94, 0.99) 0.88 (0.84, 0.92) 0.95 (0.91, 0.99) 0.92 (0.89, 0.95) 0.95 (0.89, 1.02) 0.91 (0.89, 0.94) 0.67 (0.64, 0.70) 0.99 (0.98, 1.00) 
2-Year Donations (n)5 0.82 (0.78, 0.87) 0.81 (0.78, 0.84) 0.77 (0.73, 0.82) 0.83 (0.79, 0.88) 0.81 (0.77, 0.84) 0.83 (0.76, 0.91) 0.86 (0.83, 0.89) 0.74 (0.69, 0.78) 0.94 (0.85, 1.04) 
2-Year Low Hb Deferrals (n)5 0.98 (0.95, 1.01) 0.96 (0.94, 0.99) 0.95 (0.92, 0.98) 0.99 (0.95, 1.02) 0.98 (0.96, 1.01) 0.98 (0.92, 1.03) 0.98 (0.96, 1.01) 1.07 (1.04, 1.10) 0.92 (0.67, 1.28) 
 
4 Per one week decrease 
5 Per standard deviation increase. SDs reported in Table 3.1 and Table 3.2 
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5.3.4 Trends of Symptoms over Trial Period 
The proportion of donors reporting symptoms generally increased over the 2-year trial period and was 
generally higher in women than men (Figure 5.3). Approximately 15-20% of men and 20-28% of 
women reported feeling tired during at least one six month period of the trial and between 5-10% of 
men and women reported feeling breathless. The proportion of donors reporting palpitations steadily 
increased from ~4% to ~6% for male donors and from ~7% to ~13% for women. The proportion of 
donors experiencing dizziness rose from ~4-6% in men and ~9-11% in women after six months on the 
trial to ~5-7% in men and ~11-13% in women after 12 months. This further rose to ~9-11% in men and 
~15-17% in women, with the shortest donation group reporting most symptoms. The proportion of 
donors who reported fainting or feeling faint steadily rose from ~4% to ~6-8% for men during the 
study period, and ~7-8% to ~10-11% in women. The proportion of participants reporting chest pain 
did not vary by sex or randomised group, rising from ~2% to ~4% during the trial. Restless legs 
syndrome also steadily rose during the trial, with men on the eight week group experiencing it more 
often. RLS levels rose from ~9-10% to ~14-16% by the end of the trial. There was less of a difference 
by randomised group for women, with RLS prevalence rising from ~14-15% at the start of the trial to 
~22% irrespective of randomised group by the end. Prevalence of pica, which was only measured at 
the end of the trial, was low for both sexes and did not vary significantly by randomised group. 




Figure 5.3: Frequency of tiredness, breathlessness, palpitations, dizziness, fainting or feeling faint, 
chest pain, restless legs syndrome, and pica over the two-year trial period by sex and randomised 
group, denoted by the percentage who indicated each symptom on the questionnaire.  
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5.3.5 Trends of Symptoms over Donation Period by Iron Supplementation 
The proportion of donors using doctor prescribed iron supplements rose during the trial in both sexes. 
In men, the eight week group had the highest usage of iron supplements, and differences between 
the randomised groups significantly diverged as the trial progressed. More women than men used 
iron supplements at all time points during the trial. The 12 week group usually had the highest 
proportion of iron supplement users in women, but there was less clear divergence over time in 
women as compared to men (Figure 5.4) 
 
Figure 5.4: Proportion of donors using doctor prescribed iron supplements during INTERVAL, 
denoted by the percentage who indicated yes on the questionnaire. Higher numbers of women than 
men used iron supplementation. 
The proportion of donors reporting symptoms was higher among donors who also reported iron-
supplementation use over the 2-year trial period than those who did not (Figure 5.5). Moreover, the 
proportion of iron-supplementation users reporting symptoms appeared stable over the 2-year 
donation period, in contrast to an apparent rise in reporting of symptoms for donors not using iron-
supplementation. The only exceptions were palpitations in men and chest pain in both sexes, which 
consistently had a similar proportion of donors reporting these symptoms regardless of whether they 




Figure 5.5: Frequency of tiredness, breathlessness, palpitations, dizziness, fainting or feeling faint, 
chest pain, restless legs syndrome, and pica over time by randomised group and iron supplement 
use. Panels indicate each inter-donation interval group, blue lines those who did not use iron 
supplementation, and red lines those who did. 
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5.3.6 Assessing mediation with Iron Supplementation 
The proportion of donors reporting symptoms was generally higher in the shorter inter-donation 
intervals. The odds of reporting feeling faint or breathless, increased by approximately 10%, whereas 
the odds of reporting feeling tired, experiencing papulations, dizziness, and chest pain increased by 
approximately 4-5% per week shorter inter-donation interval. Odds of RLS increased by 3%. There was 
no significant increase in the odds of reporting pica (Table 5.4). For women, the odds of reporting 
fainting or feeling faint, tiredness, breathlessness and dizziness increased by 3-4% for each week 
shorter donation interval. The odds of reporting palpitations rose by 2%. There was no significant 
difference in the odds of reporting chest pain, restless legs syndrome, or pica (Table 5.5). 
Use of iron supplementation, whether through a supplement or prescribed by a doctor, was 
significantly associated with symptoms in both men (Table 5.4) and women (Table 5.5). However, the 
effect of randomised inter-donation interval on symptoms did not change with the progressive 
addition of iron supplementation variables in the models, suggesting it did not mediate the effect of 
inter-donation interval assignment on symptoms. 
As regards the prospective observational associations of iron supplementation and symptoms, in men 
baseline iron supplementation was most strongly associated with reported palpitations, dizziness, 
tiredness, and fainting or feeling faint, with 15-30% increase in odds found (Table 5.4). In women, 
baseline iron supplementation was most strongly associated with reported tiredness, breathlessness, 
palpitations, and fainting or feeling faint, with 14-21% increase in odds found (Table 5.5). 
Iron supplementation during the trial was a notably stronger correlate of symptoms than baseline iron 
supplement use, and was statistically significantly associated with all symptoms studied in both men 
(Table 5.4) and women (Table 5.4). However, the further adjustment for iron supplementation during 
the trial did not importantly change the magnitude of association between baseline iron 
supplementation and symptoms nor the effect of randomised inter-donation interval on the 
symptoms. Application of the MacArthur method did not significantly alter the effect of randomised 
inter-donation interval on symptoms; there was no statistically significant interaction between 
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randomised inter-donation interval and iron supplementation for any symptom in men or women (all 
p>0.05, range 0.13 – 0.91). 
Table 5.4: Odds ratios (95% CI) of the effect of inter-donation interval on symptoms from the models 
assessing symptoms by randomised group and iron supplementation in men 
Symptom/Variable Model 1 Model 2 Model 3 
Tiredness (N=61979)    
Randomised Group 1.06 (1.04, 1.08) 1.06 (1.04, 1.08) 1.06 (1.04, 1.07) 
Baseline Iron Supplementation  1.15 (1.06, 1.25) 1.15 (1.06, 1.25) 
Iron Supplementation during Trial   3.84 (3.42, 4.32) 
Breathlessness (N=61875)    
Randomised Group 1.09 (1.06, 1.12) 1.09 (1.06, 1.12) 1.08 (1.05, 1.11) 
Baseline Iron Supplementation  1.11 (0.97, 1.27) 1.11 (0.97, 1.26) 
Iron Supplementation during Trial   3.66 (3.13, 4.28) 
Palpitations (N=61861)    
Randomised Group 1.05 (1.02, 1.08) 1.05 (1.02, 1.08) 1.05 (1.01, 1.08) 
Baseline Iron Supplementation  1.32 (1.14, 1.52) 1.32 (1.14, 1.52) 
Iron Supplementation during Trial   2.28 (1.87, 2.77) 
Dizziness (N=61892)    
Randomised Group 1.06 (1.04, 1.09) 1.06 (1.04, 1.09) 1.06 (1.03, 1.09) 
Baseline Iron Supplementation  1.28 (1.14, 1.44) 1.28 (1.14, 1.44) 
Iron Supplementation during Trial   2.65 (2.26, 3.10) 
Fainting or Feeling Faint (N=61931)    
Randomised Group 1.07 (1.04, 1.11) 1.07 (1.04, 1.11) 1.07 (1.04, 1.10) 
Baseline Iron Supplementation  1.20 (1.05, 1.38) 1.20 (1.05, 1.38) 
Iron Supplementation during Trial   3.12 (2.61, 3.74) 
Chest Pain (N=61724)    
Randomised Group 1.05 (1.01, 1.10) 1.05 (1.01, 1.10) 1.05 (1.01, 1.09) 
Baseline Iron Supplementation  1.13 (0.95, 1.36) 1.13 (0.95, 1.36) 
Iron Supplementation during Trial   2.28 (1.75, 2.97) 
RLS (N=83115)    
Randomised Group 1.03 (1.01, 1.05) 1.03 (1.01, 1.05) 1.03 (1.01, 1.05) 
Baseline Iron Supplementation  1.10 (0.99, 1.21) 1.10 (1.00, 1.21) 
Iron Supplementation during Trial   1.40 (1.23, 1.59) 
Pica (N=80425)    
Randomised Group 1.05 (0.93, 1.19) 1.05 (0.93, 1.19) 1.05 (0.93, 1.19) 
Baseline Iron Supplementation  1.56 (0.92, 2.65) 1.55 (0.92, 2.64) 
Iron Supplementation during Trial   2.79 (1.07, 7.28) 
Doctor Diagnosed Low Iron (N=62092)    
Randomised Group 1.20 (1.16, 1.24) 1.20 (1.16, 1.24) 1.23 (1.17, 1.28) 
Baseline Iron Supplementation  0.94 (0.80, 1.10) 0.78 (0.63, 0.97) 





Table 5.5: Coefficients (95% CI) of the effect of inter-donation interval on symptoms from the 
models assessing symptoms by randomised group and iron supplementation in women 
Symptom/Variable Model 1 Model 2 Model 3 
Tiredness (N=61025)    
Randomised Group 1.04 (1.02, 1.06) 1.04 (1.02, 1.06) 1.04 (1.02, 1.05) 
Baseline Iron Supplementation  1.22 (1.15, 1.30) 1.23 (1.15, 1.31) 
Iron Supplementation during Trial   5.45 (4.97, 5.98) 
Breathlessness (N=60913)    
Randomised Group 1.04 (1.01, 1.06) 1.04 (1.01, 1.06) 1.03 (1.00, 1.05) 
Baseline Iron Supplementation  1.20 (1.09, 1.32) 1.20 (1.08, 1.32) 
Iron Supplementation during Trial   4.54 (4.06, 5.09) 
Palpitations(N=60886)    
Randomised Group 1.03 (1.00, 1.05) 1.02 (1.00, 1.05) 1.02 (1.00, 1.05) 
Baseline Iron Supplementation  1.17 (1.06, 1.28) 1.16 (1.06, 1.28) 
Iron Supplementation during Trial   2.45 (2.19, 2.74) 
Dizziness (N=60910)    
Randomised Group 1.04 (1.02, 1.06) 1.04 (1.02, 1.06) 1.03 (1.01, 1.05) 
Baseline Iron Supplementation  1.08 (0.99, 1.17) 1.07 (0.99, 1.17) 
Iron Supplementation during Trial   3.14 (2.85, 3.47) 
Fainting or Feeling Faint (N=60960)    
Randomised Group 1.04 (1.01, 1.06) 1.04 (1.01, 1.06) 1.03 (1.01, 1.05) 
Baseline Iron Supplementation  1.14 (1.05, 1.25) 1.14 (1.04, 1.24) 
Iron Supplementation during Trial   3.64 (3.26, 4.07) 
Chest Pain (N=60690)    
Randomised Group 1.00 (0.96, 1.04) 1.00 (0.96, 1.04) 0.99 (0.95, 1.03) 
Baseline Iron Supplementation  0.99 (0.84, 1.17) 0.99 (0.84, 1.17) 
Iron Supplementation during Trial   2.84 (2.35, 3.43) 
RLS (N=82131)    
Randomised Group 1.01 (0.99, 1.03) 1.01 (0.99, 1.03) 1.01 (0.99, 1.03) 
Baseline Iron Supplementation  1.08 (1.01, 1.16) 1.08 (1.01, 1.16) 
Iron Supplementation during Trial   1.23 (1.13, 1.34) 
Pica (N=83085)    
Randomised Group 1.01 (0.92, 1.10) 1.01 (0.92, 1.10) 1.00 (0.92, 1.09) 
Baseline Iron Supplementation  0.96 (0.67, 1.37) 0.95 (0.66, 1.36) 
Iron Supplementation during Trial   2.82 (1.79, 4.43) 
Doctor Diagnosed Low Iron (N=61194)    
Randomised Group 1.09 (1.06, 1.12) 1.09 (1.06, 1.12) 1.09 (1.05, 1.13) 
Baseline Iron Supplementation  0.99 (0.89, 1.11) 0.88 (0.75, 1.04) 
Iron Supplementation during Trial   NA 
 
5.3.7 Sensitivity analyses 
Results of sensitivity analyses comparing the effect of inter-donation interval on symptoms estimated 
from logistic regression models fitted under the generalised estimating equations framework (GEE-
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LOGIT) versus mixed effects framework (ME-LOGIT) were similar (Figure 5.5), suggesting results were 
fairly robust to assumptions of missing data mechanisms. 
 
Figure 5.6: Comparison of effect of randomised inter-donation interval on symptoms estimated from 
logistic regression models fitted under the generalised estimating equations framework (GEE-LOGIT) 
versus mixed effects framework (ME-LOGIT). 
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In this chapter, I have investigated the symptoms that donors reported during the INTERVAL trial. Eight 
symptoms were recorded during the trial: tiredness, breathlessness, palpitations, dizziness, fainting 
or feeling faint, chest pain, restless legs syndrome, and pica. These symptoms were reported every six 
months during the trial by self-reported questionnaires. Minimising post-donation symptoms is a key 
consideration for donor retention [199]. The three most commonly reported symptoms were 
tiredness, dizziness, and restless legs syndrome. Participants who took iron supplements, whether 
before or during the trial period, reported symptoms more often than those who did not.  
5.4.1 Symptom Levels in INTERVAL 
In both men and women, the most frequently reported symptom during the trial was feeling more 
tired than usual. This was reported by up to 25% of men and 28% of women, with a higher percentage 
of women than men reporting this symptom at all time points during the trial. This is likely because 
tiredness is a known symptom of iron deficiency, and women, particularly premenopausal women, 
lose a higher percentage of their body’s iron stores in a blood donation than men. 
Restless legs syndrome was the next most commonly reported. Other symptoms had lower frequency 
of reporting, with pica in particular reported by a very low proportion of the trial participants despite 
being a documented side effect of blood donation and iron deficiency [198]. It is possible, however, 
that some of those who experienced symptoms dropped out of the trial as a consequence, and so the 
true levels of symptoms in INTERVAL could have been higher. 
 
5.4.2 Mediation of Effect of Randomised Inter-donation interval by Iron Supplementation 
Examining the effect of randomised group on the odds of developing symptom quantitatively, I found 
that in men, the only symptoms that did not significantly increase with shorter inter-donation intervals 
were chest pain and pica. This may partly be due to low statistical power as few men experienced 
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these symptoms during the trial, especially pica. In women, fewer symptoms were increased by more 
frequent donation. In addition to chest pain and pica, prevalence of palpitations and restless legs 
syndrome did not significantly increase with shorter inter-donation intervals. 
It was hypothesised that iron supplementation may mediate the effect of randomised group. This 
would mean that some of the changes in symptoms observed were actually attributable to iron 
supplementation during the trial rather than more frequent donation. However for both sexes, and 
all symptoms, the effect of randomised group was not significantly different when iron 
supplementation at baseline, and during the trial, were accounted for.  
5.4.3 Implications 
One proposed method of reducing post-donation symptoms in blood donors is by recommending iron 
supplementation [193]. However, the INTERVAL trial results presented in this chapter suggested that 
iron supplementation did not mediate the effect of randomised group on development of symptoms. 
This means that iron supplementation in the INTERVAL trial setting did not offset the risk of donors 
reporting symptoms due to donating blood more frequently than usual. While there are other reasons 
why iron supplementation would be offered to blood donors such as a desire to reduce low 
haemoglobin deferrals, it may not be sufficient to combat the effect of shorter inter-donation intervals 
on occurrence of symptoms. 
5.4.4 Strengths and Limitations 
The primary strength in this analysis is the use of the longitudinal data from INTERVAL trial, which 
were collected routinely every six months from a very large sample. In addition, the modelling 
framework adopted allowed the use of all information from all available time points to minimise 
selection biases and increase statistical power.  
The primary limitation of this analysis is the method of reporting symptoms. This was performed using 
self-reported questionnaires. These contained questions asking donors if they had been more tired, 
experienced chest pain, fainted etc during the past six months. While some of these events, such as 
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fainting, are unlikely to be forgotten and are objective, other questions, such as “whether you have 
been more tired than usual” have a subjective interpretation. This could affect results: one donor’s 
perception of becoming sufficiently more tired, dizzy, or breathless to report that they had 
experienced this symptom on the questionnaire could be quite different from that of another donor. 
In addition, it is possible that, due to the non-blinded nature of the trial, those on shorter randomised 
inter-donation intervals were more aware of symptoms, thus more likely to attribute these to their 
increased donation frequency and report these on their questionnaires. 
A specific limitation to the mediation analysis of the models investigating doctor prescribed low iron 
levels during the trial is illustrated in Figure 5.6. It is perhaps unsurprising that almost all those who 
had doctor prescribed iron supplements in a six month period also took iron supplements in the same 
period, as this would likely be what has been prescribed to them. This interpretation would present 
iron supplementation as a predictor of doctor diagnosed iron levels, rather than a consequence of it. 
It is possible that this relationship may apply to other symptoms.  
Dropout levels in the trials could also influence the results from these analyses. It is possible that 
donors who experienced more severe or more frequent symptoms dropped out of the trial as a 
consequence. The true symptom levels of donors in the trial are therefore unknown, and it is possible 
that only healthier donors completed the trial, which would bias these results. However, as dropout 
was not differential by randomised inter-donation interval, the assessment of the effect of 





Figure 5.7: Comparison of doctor diagnosed low iron levels by randomised group and iron 
supplement use, denoted by the percentage who indicated yes on the questionnaire. Almost all 
those who indicated they were using iron supplementation on the questionnaire had these 
prescribed by a doctor in the prior six months. 
 
5.4.5 Conclusions 
Development of post-donation symptoms is a risk of blood donation. These range in severity from 
feeling more tired, to fainting, or developing complications such as RLS and pica. Decreasing the inter-
donation interval will slightly increase the risk of experiencing any such symptom, although for some 
of these such as pica and chest pain, the risk is low.  
Iron supplementation, while often proposed as a solution to this problem, does not offset the 
increased risk of developing symptoms with more frequent donation, and so alternative strategies for 
minimising the risk of post-donation symptoms should be studied. It is possible that there are 
dynamics unaccounted for in these results, as donors who were experiencing symptoms post-
donation may have subsequently taken iron supplements. In addition, they may have stopped doing 
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without taking iron supplementation started doing so upon developing symptoms. So, it is possible 







Chapter 6 – Effect of Shorter Inter-donation Interval on Blood Donor 
Well-being. 
Summary 
Shortening the length of time between donations could lead to consequences such as more low 
haemoglobin deferrals, lower haemoglobin and ferritin levels, and some post-donation symptoms for 
some donors. These could have a detrimental effect on well-being and overall quality of life. 
In INTERVAL, donor well-being was assessed using the Sf-36 questionnaire at baseline and after two 
years, and the shorter Sf-12 questionnaire every six months. These questionnaires allow calculation 
of well-being scores in eight domains, which are then used to form two summary scores, the Physical 
Component Score (PCS) and Mental Component Score (MCS), assessing physical and mental wellbeing  
respectively. These well-being measures have seldom been studied in blood donor populations.  
In both sexes, shorter randomised inter-donation interval did not have a significant effect on the PCS, 
MCS, and their associated sub-components, with the exception of physical role functioning in men 
which decreased with shorter inter-donation interval (coefficient: -0.026 95%CI (-0.052, -0.005), 
p=0.016). PCS and MCS scores during the trial were modestly associated with other baseline 
characteristics, including age, weight, and iron supplementation use. 
While some changes in PCS, MCS and their sub-components over time were observed, they were not 
of clinical significance. The same was found of associations with baseline variables. Consequently, it is 
unlikely that there are major risks of increased frequency of blood donation to donors’ physical and 
mental wellbeing. 
6.1 Introduction 
It is possible that shortening inter-donation intervals could lead to additional safety concerns as 
donors attempt to donate more frequently than they should. Some donors may find that more 
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frequent donation and its effects such as losing more iron more regularly affects their capacity to carry 
out physical activities. It is not clear how changes to the inter-donation interval, such as those trialled 
in INTERVAL, may affect physical and mental wellbeing. This is a largely unaddressed question in the 
literature on blood donors and trials containing blood donor participants. Just one previous study, the 
Danish Blood Donor Study, has considered quality of life scores as an outcome in a blood donor 
population, and it found no relationship between donation frequency and quality of life [233].  
6.1.1 Well-being Assessment using the Sf-36 Questionnaire 
The Sf-36 questionnaire is a widely used questionnaire that captures quality of life in populations. It is 
commonly used in the UK in order to help with planning of services, and to measure the effect of 
clinical and social interventions [234-237]. It has been effective at comparing general populations and 
specific subgroups within these populations, such as populations stratified by sex or socio-economic 
status [238-241]. While it has proven suitable for use on populations, its effectiveness at the individual 
level is uncertain [242]. 
6.1.2 Construction of the PCS and MCS Summary Scores 
The Sf-36 questionnaire comprises 36 questions that are grouped into eight domains (Figure 6.1): 
limitations to all physical activities (Physical Functioning); problems with work and daily activities due 
to physical health (Role limitation due to Physical health problems); pain and limitations due to pain 
(Bodily Pain); problems with work and daily activities due to emotional problems (Role Limitations due 
to Emotional problems); assessment of health and how it may improve (General Health Perception); 
interference with social activities due to physical or emotional problems (Social  Functioning); 
tiredness and energy levels (Vitality);  and feelings of nervousness, depression, happiness and calm 
(Mental Health) [243-245]. These domains are then used to form two overall summary scores, the 
Physical Component Score (PCS) and the Mental Component Score (MCS), measuring a physical and 
mental health well-being respectively. All eight domains contribute to calculation of PCS and MCS with 
different weights [176, 246-248]. The exact weights of the sub-components vary by country. In most 
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countries, a sub-component that contributes positively to one score will contribute negatively to the 
other aside from vitality, which contributes positively to both. This causes the scores to be orthogonal 
and so uncorrelated [249]. In the UK, general health contributed positively to both scores [176] (Table 
6.1). 
Table 6.1: Coefficients (weights) used to derive the PCS and MCS for the Sf-36v2 in the UK [176] 
Sub-component PCS coefficient MCS coefficient 
Physical functioning 0.456 -0.227 
Role physical 0.362 -0.102 
Bodily pain 0.367 -0.130 
General health 0.199 0.036 
Vitality -0.050 0.278 
Social functioning -0.028 0.272 
Role emotional -0.110 0.329 
Mental Health -0.256 0.460 
 
The PCS and MCS scores can be standardised using population norms, transforming them to have a 
mean of 50 and standard deviation of 10 [250]. This allows scores to have a recognisable interpretation, 
with a value of above 50 indicating above-average health and below 50 indicating below-average 
health. In addition, norm-based scoring has an advantage for the clinicians and researchers 
administering the questionnaire as they do not need to remember or refer to norms for the summary 
scores and their subscales [251]. It also allows comparison across populations and sub-populations 
[246]. The population norms used in the UK are taken from the ONS survey of Britain in 1992, the 
Health Survey for England, the Oxford Healthy Life Survey General Household Survey conducted in 





Figure 6.1: Diagram showing which questions in the Sf-36 survey correspond to which components 
of the PCS and MCS [254]. Highlighted questions comprise the Sf-12 survey. 
6.1.3 Performance and Validity of the Sf-36 
In a UK based population, the mean PCS was calculated as 50.8 and the mean MCS was 52.2 [255]. 
However, there have been recorded gender differences in scores. Women reported lower scores for 
all sub-sections of the Sf-36 than men except general health [242]. The Sf-36 was also found to have 
good internal validity [242] and was able to detect health differences expected from those in manual 
and non-manual jobs, and those who live with a chronic illness [176]. One UK based longitudinal study 
found that unadjusted mean scores were lower than baseline after three years, and that men and 
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women reported declines in different subscales by age  [256]. Younger men had a greater decline in 
mental health, emotional role limitation, vitality and social role functioning than older men. In women, 
this relationship was seen in the vitality and general health sub-components [256]. 
6.1.4 The Sf-12 Questionnaire 
The Sf-12 questionnaire is a shorter version of the Sf-36 containing the 12 questions that contribute 
the most to the Sf-36 components [257]. The questions selected for the Sf-12 questionnaire are two 
from the physical functioning and mental health scales, as these best predict physical and mental 
health overall, two items from the physical and emotional role domains, and one item from the 
remaining four domains [255]. This has the advantage of lessening the burden on those taking the 
questionnaire by reducing the length of time taken to complete the questionnaire to five minutes.  
The initial validation study of the Sf-12 questionnaire found that correlations between the Sf-36 and 
Sf-12 PCS was 0.95, and for MCS this was 0.97 [257]. Other studies have similarly found that scores 
from the Sf-36 and Sf-12 are highly correlated [255, 257, 258]. 
6.1.5 Chapter Aims 
The key secondary outcome in the INTERVAL trial was self-reported well-being [7] as measured by the 
Sf-36 questionnaire [245, 259, 260] at baseline and after two years of follow-up, and the Sf-12 every 
six months [257]. Findings from INTERVAL showed no significant effect of shorter inter-donation 
interval on physical and mental health well-being scores [74]. However, there was no analysis of the 
sub-components. It is possible that increased donation frequency could affect some of these 
subcomponents more than others, and this variation may not be captured by the PCS and MCS 
summary scores. The aim of this chapter was to assess the effect randomised inter-donation intervals 




6.2.1 Sf-36 and Sf-12 Data Collection in INTERVAL 
At baseline and after two years of follow-up, participants completed the full Sf-36 questionnaire, and 
every six months, the Sf-12 questionnaire was asked [7]. No question was compulsory and it was 
possible for participants not to answer all questions. The exact questions and their ordering are 
provided in Appendix C. 
6.2.2 Statistical Analysis 
To assess characteristics associated with well-being scores irrespective of inter-donation interval 
assignment, cross-sectional correlates of baseline PCS and MCS were assessed using a linear model 
adjusted for age, sex, and centre (Chapter 4). The difference in R2 when each cross-sectional correlate 
was added to the model was examined to assess its added value. 
Longitudinal analyses were conducted using the GEE modelling framework (see Chapter 5). This was 
chosen as the GEE model can take into account correlation of repeated observations on the same 
individual, and its estimation of fixed effect coefficients is generally more robust to assumed structure 
of working correlation matrix [228, 229]. There was a maximum of five observations per individual for 
each of PCS, MCS and their sub-components during the study [7] and so data rows were not 
independent and identically distributed [230, 231]. An exchangeable correlation structure was 
assumed for the repeated measures within individuals, meaning equally correlated  across time points 
[232], with individuals considered independent.  
Three models were constructed to assess the longitudinal associations with PCS and MCS scores and 
their sub-components. The first model contained inter-donation interval, the second added donor 
centre, age, weight, and new donor status, and the third model added iron supplementation and 
donation history data, specifically: whether a participant had been previously diagnosed with anaemia 
or was using iron prescriptions, the number of donations in the previous two years, and the number 
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of low haemoglobin deferrals the participant had experienced in the previous two years. Statistical 
significance was based on p < 0.05 throughout. 
6.3 Results 
6.3.1 Response Rates of the Sf-36 and Sf-12 Questionnaires 
For both the PCS and MCS in all randomised groups, the proportion of INTERVAL participants 
completing the questionnaire generally reduced over the trial period and this was similar across 
randomised group. Slightly more participants completed the two-year follow-up questionnaire than 
the 18 month questionnaire. At two-year follow-up, slightly lower proportions of women than men 
completed the Sf-36 questionnaire (Table 6.2). However, dropout during follow up was not differential 
across the randomised inter-donation intervals, and therefore inferences should remain unbiased. 
Furthermore, the GEE modelling framework used for analyses allowed the inclusion of information 
from all available questionnaires completed during follow up, as opposed to requiring restriction to 
participants with all questionnaires completed.   
Table 6.2: Number (%) of INTERVAL participants completing the Sf-36 and Sf-12 questionnaire at 
each time point in the trial by randomised group 
 Men Women 
Score 8 weeks  
(N = 7456) 
10 weeks 
(N = 7446) 
12 weeks 
(N = 7452) 
12 weeks 
(N = 7567) 
14 weeks 
(N = 7565) 
16 weeks 
(N = 7548) 
PCS       
Baseline 7398 (99%) 7395 (99%) 7412 (99%) 7507 (99%) 7515 (99%) 7495 (99%) 
6 months 5910 (79%) 5852 (79%) 5724 (77%) 5893 (78%) 5950 (79%) 5879 (79%) 
12 months 5386 (72%) 5377 (72%) 5362 (72%) 5329 (70%) 5380 (71%) 5308 (70%) 
18 months 4785 (64%) 4810 (65%) 4823 (65%) 4671 (62%) 4747 (63%) 4691 (62%) 
24 months 4924 (66%) 4942 (66%) 4968 (67%) 4745 (63%) 4739 (63%) 4683 (62%) 
MCS       
Baseline 7398 (99%) 7396 (99%) 7415 (99%) 7509 (99%) 7516 (99%) 7498 (99%) 
6 months 5912 (79%) 5853 (79%) 5727 (77%) 5894 (78%) 5957 (79%) 5880 (78%) 
12 months 5393 (72%) 5376 (72%) 5372 (72%) 5335 (71%) 5381 (71%) 5309 (70%) 
18 months 4789 (64%) 4812 (65%) 4827 (65%) 4676 (62%) 4750 (63%) 4695 (62%) 




6.3.3 Characteristics of Respondents at Baseline and after Two Years 
Characteristics of the INTERVAL participants who completed the baseline and two year Sf-36 
questionnaires were broadly similar (Table 6.3). Comparing men and women, it was found that 
women had a lower height and weight than men on average and were younger. Women had 
substantially lower ferritin than men, and more low haemoglobin deferrals in the previous two years. 
In addition, a higher proportion of women had a previous diagnosis of anaemia than men (~20% 
difference) and more women than men were taking iron multivitamins and iron supplements on a 
regular basis. Comparing those who completed the survey after two years with participants at baseline, 
in men, those who completed the two-year questionnaire were slightly older (mean age 45.2 vs 47.7), 
and other characteristics were similar. Similarly, women who completed the two-year survey were 
slightly older (mean age 41.3 vs 44.4) and other characteristics were broadly similar (Table 6.3). 
Table 6.3: Baseline characteristics of INTERVAL participants who completed the Sf-36 questionnaire 
at baseline and after two-years of follow-up 









Height (m) 1.79 (0.08) 1.79 (0.08) 1.65 (0.07) 1.65 (0.07) 
Weight (kg) 85.1 (14.5) 84.9 (14.1) 71.6 (14.8) 71.2 (14.3) 
Age (years) 45.2 (14.2) 47.7 (13.4) 41.3 (14.0) 44.4 (13.6) 
Ethnicity     
  White 18576 (95%) 12602 (96%) 19417 (96%) 12458 (96%) 
  Mixed 245 (1%) 141 (1%) 308 (2%) 167 (1%) 
  Asian 507 (3%) 265 (2%) 268 (1%) 121 (1%) 
  Black 169 (1%) 99% (1%) 173 (1%) 112 (1%) 
  Chinese 61 (<1%) 36 (<1%) 71 (<1%) 44 (<1%) 
  Other 83 (<1%) 54 (<1%) 58 (<1%) 29 (<1%) 
PCS (score) 56.8 (4.56) 56.9 (4.29) 57.0 (4.67) 57.0 (4.58) 
MCS (score) 54.5 (6.12) 54.9 (5.70) 53.5 (6.61) 53.9 (6.27) 
Blood Group – O 10574 (47%) 7082 (48%) 10869 (48%) 6790 (48%) 
Previous Anaemia – Yes 971 (4%) 675 (5%) 5411 (25%) 3536 (26%) 
Iron Prescription Use - Yes 48 (<1%) 32 (<1%) 132 (1%) 84 (1%) 
Iron Multivitamin Use - Yes 2809 (13%) 1870 (13%) 4050 (18%) 2680 (19%) 
Iron Supplement Use - Yes 202 (1%) 146 (1%) 603 (3%) 410 (3%) 
2-Year Donations (n) 3.58 (1.86) 3.86 (1.80) 2.87 (1.66) 3.15 (1.64) 
2-Year Low Hb Deferrals (n) 0.04 (0.23) 0.05 (0.25) 0.12 (0.39) 0.13 (0.39) 
Haemoglobin (g/dL) 15.0 (1.00) 14.9 (0.98) 13.4 (0.92) 13.4 (0.88) 




6.3.4 Cross-Sectional Correlates of PCS and MCS 
Baseline PCS and MCS were minimally correlated with other baseline variables as evidenced by the R2 
change when correlates were added to models adjusted for age, and sex (Figures 6.2-6.5). The 
majority of characteristics explained less than 1% of variation in baseline PCS and MCS. Higher weight 
was associated with slightly lower PCS (Figure 6.2), and more active leisure activity was associated 
with a slightly higher PCS and MCS (Figure 6.3). The baseline PCS and MCS explained the most variation 





Figure 6.2: Cross-sectional correlates of baseline PCS and continuous variables (R2 difference in 
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Figure 6.3: Cross-sectional correlates of baseline PCS and categorical variables (R2 difference in 




Figure 6.4: Cross-sectional correlates of baseline MCS and continuous variables (R2 difference in 
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Figure 6.5: Cross-sectional correlates of baseline MCS and categorical variables (R2 difference in 
brackets) Variables are plotted against MCS for men (blue) and women (red). 
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6.3.5 Trends of PCS, MCS, and their Sub-Components over Time 
There was a similar trend in the PCS, MCS, and their sub-component scores over time for both sexes 
in all randomised groups. The PCS, Physical Functioning, Bodily Pain, General Health Perceptions, 
Physical Functioning, Emotional Role Functioning, and Mental Health scores in both sexes, and the 
MCS in women, followed a similar pattern. The six-monthly scores from the Sf-12 were ~1-2 points 
lower than the baseline score measured by the Sf-36, and the two-year score was comparable to the 
baseline score. In most scores aside from general health perceptions, women scored slightly lower 
than men. The Physical Role Functioning score varied little throughout the two years of follow up, and 
there was no difference by sex. The Vitality score followed a different trend, and fell slightly every six 
months in both sexes, including after two years of follow-up. Social Role Functioning and MCS in men 
fell between baseline and six months, but varied little from six months to two years. There was little 
observed difference in any score by inter-donation interval in both sexes (Figures 6.6 – 6.7). 
 
 
Figure 6.6: Mean PCS and MCS at each six month interval of the trial, recorded using the Sf-36 or Sf-




Figure 6.7: Mean scores of Physical Functioning, Physical Role Functioning, Bodily Pain, General Health 
Perceptions, Vitality, Social Role Functioning, Emotional Role Functioning, and Mental Health, 
recorded using the Sf-36 or Sf-12 questionnaire, stratified by randomised group 
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6.3.6 Associations between baseline variables and PCS, MCS, and their sub-components 
The only sub-component for which inter-donation interval was associated with a significant change 
was Physical Role Functioning in men (Table 6.4 Model 3 coefficient -0.026 95%CI [-0.052, -0.005], 
p=0.016). For all other sub-components in both sexes, as well as the PCS and MCS summary scores, 
the effect of inter-donation interval was non-significant and unchanged by addition of covariates to 
the model (Table 6.4). Modelling of sub-components adjusted for baseline characteristics, iron 
supplementation and donation history found in men that higher age and weight were significantly 
associated with lower Physical Functioning, Physical Role Functioning, Bodily Pain, General Health, and 
Social Role Functioning. Additionally, use of iron supplements and a previous diagnosis of anaemia 
were significantly associated with lower scores in all sub-components. A higher number of low 
haemoglobin deferrals was associated with lower score for Physical Role Functioning and Bodily Pain. 
In contrast, a higher number of donations in the previous two years was significantly associated with 
higher scores in all sub-components. Higher age was significantly associated with higher Social Role 
Functioning, Emotional Role Functioning, and Mental Health (Table 6.5).  
In women, higher age was significantly associated with lower Physical Functioning, Physical Role 
Functioning, and Bodily Pain, and higher scores in all other sub-components. Higher weight was 
significantly associated with lower scores in all sub-components except for Social Role Functioning 
which was not significantly different by weight. Use of iron prescriptions was significantly associated 
with lower Physical Functioning, Physical Role Functioning, Bodily Pain, General Health and Social Role 
Functioning, and a previous diagnosis of anaemia was significantly associated with lower scores in all 
sub-components except for Physical Functioning. On the other hand, a higher number of donations in 
the previous two years was associated with higher scores in all sub-components. In contrast to men, 
the number of low haemoglobin deferrals in the previous two years did not significantly affect any 
sub-component scores (Table 6.5).  
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In neither sex was there a significant association between new donor status and any sub-component. 
The magnitude of effect was low on all occasions, with most coefficients below 0.5 (Table 6.5). 
Table 6.4: Coefficients (95% CI) of the effect of inter-donation interval on PCS and MCS scores and 
their sub-components in both sexes 
Symptom/Model Men Women 
Physical Functioning  N=21774 N=21575 
Randomised Group Only 0.001 (-0.032, 0.035) 0.021 (-0.012, 0.054) 
Baseline Characteristics 0.001 (-0.032, 0.034) 0.012 (-0.019, 0.043) 
Baseline Iron Variables -0.001 (-0.034, 0.032) 0.011 (-0.020, 0.043) 
Physical Role Functioning N=21572 N=21561 
Randomised Group Only -0.026 (-0.050, -0.003) 0.005 (-0.020, 0.031) 
Baseline Characteristics -0.026 (-0.050, -0.003) 0.002 (-0.024, 0.027) 
Baseline Iron Variables -0.028 (-0.052, -0.005) 0.001 (-0.024, 0.026) 
Bodily Pain N=21772 N=21567 
Randomised Group Only -0.012 (-0.050, 0.026) 0.030 (-0.012, 0.072) 
Baseline Characteristics -0.013 (-0.051, 0.024) 0.022 (-0.019, 0.064) 
Baseline Iron Variables -0.016 (-0.053, 0.022) 0.021 (-0.020, 0.062) 
General Health N=21779 N=21576 
Randomised Group Only -0.038 (-0.084, 0.009) 0.001 (-0.046, 0.047) 
Baseline Characteristics -0.037 (-0.082, 0.009) -0.012 (-0.057, 0.033) 
Baseline Iron Variables -0.039 (-0.085, 0.006) -0.013 (-0.058, 0.032) 
Vitality N=21769 N=21569 
Randomised Group Only -0.001 (-0.051, 0.049) -0.015 (-0.066, 0.037) 
Baseline Characteristics 0.001 (-0.049, 0.050) -0.022 (-0.072, 0.028) 
Baseline Iron Variables -0.001 (-0.051, 0.048) -0.024 (-0.073, 0.026) 
Social Role Functioning N=21768 N=21575 
Randomised Group Only 0.001 (-0.030, 0.032) 0.005 (-0.029, 0.040) 
Baseline Characteristics 0.001 (-0.030, 0.032) 0.003 (-0.031, 0.037) 
Baseline Iron Variables 0 (-0.031, 0.031) 0.002 (-0.032, 0.036) 
Emotional Role Functioning N=21747 N=21556 
Randomised Group Only 0.001 (-0.033, 0.034) 0.010 (-0.027, 0.048) 
Baseline Characteristics 0.001 (-0.032, 0.035) 0.009 (-0.028, 0.047) 
Baseline Iron Variables 0 (-0.034, 0.033) 0.009 (-0.028, 0.046) 
Mental Health N=21769 N=21569 
Randomised Group Only 0.024 (-0.025, 0.073) 0.028 (-0.023, 0.078) 
Baseline Characteristics 0.025 (-0.023, 0.073) 0.027 (-0.022, 0.076) 
Baseline Iron Variables 0.023 (-0.024, 0.071) 0.026 (-0.023, 0.075) 
PCS N=21755 N=21565 
Randomised Group Only -0.27 (-0.060, 0.005) 0.011 (-0.024, 0.046) 
Baseline Characteristics -0.028 (-0.059, 0.003) 0 (-0.033, 0.033) 
Baseline Iron Variables -0.030 (-0.061, 0.001) 0 (-0.033, 0.032) 
MCS N=21757 N=21566 
Randomised Group Only 0.018 (-0.029, 0.065) 0.010 (-0.040, 0.060) 
Baseline Characteristics 0.019 (-0.026, 0.065) 0.011 (-0.037, 0.059) 




Table 6.5: Coefficients (95% CI) of baseline variables on sub-components of the PCS and MCS for men and women. 
Variable Physical Functioning Physical Role 
Functioning 






Inter-Donation Interval6 -0.00 (-0.03, 0.03) 0.03 (0.01, 0.05) -0.02 (-0.02, 0.05) 0.04 (-0.01, 0.08) 0.00 (-0.05, 0.05) -0.00 (-0.03, 0.03) 0.00 (-0.03, 0.03) -0.02 (-0.07, 0.02) 
Age (years)7 -0.60 (-0.65, -0.54) -0.37 (-0.41, -0.33) -0.89 (-0.95, -0.82) -0.23 (-0.31, -0.14) 0.68 (0.59, 0.76) 0.26 (0.20, 0.31) 0.40 (0.34, 0.46) 1.14 (1.06, 1.23) 
Weight (kg)7 -0.51 (-0.57, -0.45) -0.16 (-0.21, -0.12) -0.37 (-0.43, -0.30) -1.17 (-1.26, -1.09) -0.59 (-0.68, -0.50) -0.07 (-0.13, -0.02) 0.03 (-0.03, 0.09) 0.00 (-0.09, 0.09) 
New Donor (Y/N) -0.05 (-0.29, 0.19) -0.06 (-0.22, 0.11) 0.06 (-0.21, 0.32) -0.18 (-0.50, 0.14) 0.12 (-0.23, 0.47) -0.19 (-0.41, 0.03) -0.02 (-0.26, 0.22) -0.20 (-0.53, 0.14) 
Iron Prescription Use (Y/N) -3.67 (-4.86, -2.48) -3.34 (-4.17, -2.50) -3.78 (-5.12, -2.43) -3.40 (-5.02, -1.77) -2.39 (-4.16, -0.62) -2.43 (-3.54, -1.32) -1.93 (-3.13, -0.73) -2.28 (-3.98, -0.57) 
Previous Anaemia Diagnosis (Y/N) -0.26 (-0.53, 0.01) -0.69 (-0.88, -0.50) -1.06 (-1.37, -0.76) -1.22 (-1.60, -0.85) -1.42 (-1.82, -1.01) -0.89 (-1.15, -0.64) -0.73 (-1.00, -0.45) -1.39 (-1.79, -1.00) 
2-Year Donations (n)7 0.11 (0.05, 0.18) 0.11 (0.07, 0.16) 0.22 (0.15, 0.29) 0.35 (0.27, 0.44) 0.38 (0.29, 0.47) 0.16 (0.10, 0.21) 0.21 (0.15, 0.27) 0.38 (0.29, 0.47) 
2-Year Low Hb Deferrals (n)7 -0.06 (-0.14, 0.02) -0.06 (-0.12, -0.01) -0.11 (-0.20, -0.02) -0.01 (-0.12, 0.10) -0.02 (-0.14, 0.10) 0.00 (-0.07, 0.08) -0.04 (-0.12, 0.03) -0.03 (-0.15, 0.08) 
R2  0.023 0.014 0.027 0.031 0.023 0.008 0.013 0.042 
Women 
Inter-Donation Interval6 0.01 (-0.02, 0.04) 0.00 (-0.02, 0.03) -0.02 (-0.02, 0.02) 0.01 (-0.03, 0.06) 0.02 (-0.03, 0.07) -0.00 (-0.03, 0.03) -0.01 (-0.05, 0.03) -0.03 (-0.07, 0.02) 
Age (years)7 -0.81 (-0.87, -0.76) -0.37 (-0.42, -0.33) -0.77 (-0.84, -0.69) 0.26 (0.18, 0.34) 0.94 (0.85, 1.03) 0.43 (0.37, 0.49) 0.61 (0.54, 0.67) 1.23 (1.15, 1.32) 
Weight (kg)7 -0.94 (-1.00, -0.88) -0.37 (-0.42, -0.22) -0.77 (-0.85, -0.70) -1.60 (-1.68, -1.52) -1.00 (-1.09, -0.91) -0.29 (-0.35, -0.23) -0.20 (-0.27, -0.13) -0.24 (-0.33, -0.16) 
New Donor (Y/N) -0.07 (-0.27, 0.12) 0.05 (-0.11, 0.21) 0.10 (-0.15, 0.36) -0.17 (-0.45, 0.11) 0.30 (-0.01, 0.61) -0.11 (-0.32, 0.11) -0.07 (-0.31, 0.16) 0.22 (-0.09, 0.52) 
Iron Prescription Use (Y/N) -0.98 (-1.65, -0.31) -0.95 (-1.49, -0.41) -1.54 (-2.42, -0.66) -1.80 (-2.77, -0.84) -0.35 (-1.42, 0.72) -0.79 (-1.52, -0.06) -0.49 (-1.29, 0.30) 0.07 (-0.98, 1.12) 
Previous Anaemia Diagnosis (Y/N) -0.11 (-0.24, 0.01) -0.40 (-0.50, -0.31) -0.81 (-0.97, -0.65) -1.15 (-1.32, -0.97) -1.82 (-2.01, -1.62) -0.72 (-0.85, -0.59) -0.76 (-0.90, -0.61) -1.33 (-1.52, -1.14) 
2-Year Donations (n)7 0.21 (0.15, 0.28) 0.27 (0.22, 0.32) 0.40 (0.31, 0.49) 0.45 (0.36, 0.55) 0.55 (0.45, 0.66) 0.33 (0.26, 0.40) 0.28 (0.20, 0.35) 0.42 (0.32, 0.53) 
2-Year Low Hb Deferrals (n)7 -0.02 (-0.06, 0.03) 0.01 (-0.02, 0.05) 0.05 (-0.01, 0.11) 0.06 (-0.00, 0.13) 0.04 (-0.03, 0.12) 0.01 (-0.04, 0.06) -0.02 (-0.08, 0.03) -0.01 (-0.08, 0.06) 
R2 0.053 0.016 0.028 0.057 0.046 0.018 0.022 0.044 
 
 
6 Per one week decrease 




In this chapter, I have investigated the INTERVAL trial’s secondary outcome – donor well-being 
measured by the physical and mental component summary scores of the Sf-36 questionnaire. I have 
also analysed effects of shorter inter-donation interval with the sub-components of the PCS and MCS, 
including assessing their associations with other baseline characteristics. This adds to previously 
published INTERVAL trial results which analysed PCS and MCS scores only as pre-specified outcomes. 
6.4.1 Trends of PCS, MCS, and sub-components during the INTERVAL trial 
The PCS, MCS, and sub-components displayed similar trends in most instances, with the baseline and 
two-year scores being similar, while the intermediary scores were lower. While it has been reported 
that the scores from the PCS and MCS and their sub-components are highly correlated between the 
Sf-36 and Sf-12 questionnaire, it is possible that the observed patterns were due to the different 
questionnaires. In particular, the questions in the Sf-12 questionnaire were not in the same order as 
they appeared in the Sf-36 (Appendix C and Appendix D). This may induce changes in how participants 
score questions as their mood and health perceptions may be influenced by the questions just 
answered. This pattern was not observed for Physical Role Functioning, Vitality, and Social Role 
Functioning in both sexes, and MCS in men only. However, in all cases the magnitude of difference 
was small, below 2, which is neither subjectively nor clinically meaningful. A clinically meaningful 
change corresponds to a difference of 3 points [244, 247, 258]. 
6.4.2 Effect modification on the relationship between inter-donation interval and well-being 
measures 
Previous INTERVAL results did not find a significant effect of shorter inter-donation interval on PCS 
and MCS [74]. The analysis of sub-components in this chapter found that shorter inter-donation 
interval affected only Physical Role Functioning in men, with a small decrease in the score.  
PCS, MCS and sub-components were nevertheless associated with a few baseline characteristics. In 
both sexes, higher age was associated with lower scores in Physical Functioning, Physical Role 
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Functioning, and Bodily Pain. This could be because higher age is often also associated with additional 
health complications. In contrast, higher age was associated with higher Social Role Functioning, 
Emotional Role Functioning, and Mental Health in both sexes. Higher weight was also associated with 
lower Physical Functioning, Physical Role Functioning, Bodily Pain, General Health. This is likely 
because higher weight is known to affect an individual’s physical abilities such as increased difficulty 
supporting their weight and reduced stamina. In women, higher weight was also associated with lower 
Vitality, Emotional Role Functioning, and Mental Health. 
In both sexes, the number of donations given in the past two years was significantly associated with 
higher scores in all subcomponents, which adds to the hypothesis that more committed donors are 
healthier than other populations. Use of iron supplementation or a previous diagnosis of anaemia was 
associated with lower scores in all sub-components in men, and most sub-components in women. This 
adds to the hypothesis in Chapter 5 that those on iron supplementation represent those already at 
risk of poorer health, and that there is a possibility that this could be extended to include those who 
have experienced diagnosed anaemia. As above, the magnitudes of these associations were very small, 
mostly below 0.5, and none indicating clinical significance. 
6.4.3 Implications 
INTERVAL’s key secondary outcome was the well-being of participants. It is important to ensure that 
increased donation does not affect a donor’s well-being, as they may not return to donate. The results 
from both the primary INTERVAL findings [74], which found little effect of shorter inter-donation 
interval on PCS and MCS, are further supported by the extended analyses in chapter. While some 
differences were observed in PCS, MCS and their sub-components over time, they were of low 
magnitude, and not of clinical significance. The same was found of associations with other baseline 
characteristics. The primary implication of this chapter is that it is likely that donors’ well-being would 
not be negatively affected by increased donation. 
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6.4.4 Strengths and Limitations 
The primary strength in this analysis is the use of the longitudinal data from INTERVAL trial, which 
were collected routinely every six months from a very large sample. In addition, the modelling 
framework adopted allowed the use of all information from all available time points to minimise 
selection biases and increase statistical power. Norm-based scoring was also used to aid 
interpretability. 
The primary limitation of this analysis is that the questionnaire was changed to the Sf-12 survey during 
the six-monthly follow-up. While the Sf-36 and Sf-12 PCS and MCS scores have been shown to be very 
highly correlated [255, 257, 258], the questions in the Sf-12 questionnaire did not appear in the same 
order in which they appeared in the Sf-36 questionnaire, and so this may affect responses. In addition, 
it has previously been found that participants sometimes struggle to interpret questions in the Sf-36 
and Sf-12 questionnaires. Specific difficulties reported included respondents’ inability to attach 
meaning to the distance they are asked in the walking questions (such as attaching meaning to a mile), 
and whether carrying groceries meant carrying a small amount from a local shop, or a heavy bag from 
a weekly shop, and have to give their best guess, which can be unreliable [261, 262]. In addition, as 
participants’ health over time changes, so does their perception of health [263]. This response shift 
pattern can be problematic as participants are not comparing their health to a uniform baseline. Some 
compare to their peers, their past selves, or a hypothesised general population, and this can result in 
very different interpretations of the physical functioning questions in particular [262, 264, 265]. 
Moreover, the mean score for the PCS, MCS, and all sub-components of was above 50 at all time points 
for participants in the INTERVAL trial. This shows that INTERVAL represented a healthier population 
than the general population and so results may not be generalisable to non-donor UK populations. 




Before assigning personalised inter-donation intervals, donor wellbeing should be considered to 
ensure that donor retention is not impacted. Results from this chapter found that there was minimal 
effect of the inter-donation interval on PCS, MCS and their sub-components in INTERVAL trial 
participants. There were statistically significant associations found for iron-related variables, age, and 
weight and the sub-components, however the magnitude of associations were still low and there was 
no convincing evidence that the magnitude of associations would be clinically significant. It is likely 
that for the majority of the UK blood donor population there would be minimal impact to their well-
being should a personalised donation interval recommend they come to donate more frequently than 




Chapter 7 – Discussion 
Summary 
The  aim of this thesis was to investigate different aspects of blood donor health (including well-being, 
iron levels and symptoms related to iron deficiency) and to summarise key characteristics of donors 
who may be able to safely give blood donations more frequently. Using data from the INTERVAL trial, 
which had as its key aim to maximise blood donations while minimising low haemoglobin deferrals, 
analyses were conducted to assess the effect of more frequent donation on ability to donate blood, 
experience of low haemoglobin deferrals, frequency of reporting post-donation symptoms 
(particularly those related to iron deficiency), and blood donor well-being. 
This chapter summarises the main findings from previous chapters, places them in the context of 
wider literature, examines the practical implications of findings, and suggests possible directions for 
further research. 
7.1 Summary of Findings 
7.1.1 Maximising Blood Donations While Minimising Low Haemoglobin Deferrals 
A key aim of this thesis was to identify characteristics of blood donors which would enable NHSBT to 
maximise blood donations from the UK blood donor population while minimising low haemoglobin 
deferrals. 
This thesis has identified the donor characteristics associated with more frequent donation, as well as 
those associated with low haemoglobin deferrals. It also assessed correlates of haemoglobin and 
ferritin levels, as the former determines low haemoglobin deferrals, and ferritin is a general measure 
of iron status which can be important for donor safety, especially when considering post-donation 
symptoms (Chapter 4). These analyses were supplemented by a systematic review of the literature 
(Chapter 2) on low haemoglobin deferrals to add to the evidence identified in a previous review, which 
was considered alongside the results from INTERVAL. 
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The systematic review confirmed previous findings and added to the evidence base of factors that 
affect low haemoglobin deferrals in blood donors. It confirmed the impact of previously known factors, 
including female sex, lower weight and older age in men on low haemoglobin deferral, and further 
strengthened the evidence for differences in low haemoglobin deferral by ethnic group, geographic 
location, and associations with ferritin levels. There was inconclusive evidence on the effect of new vs 
repeat donor status (Chapter 4).  
Additional factors which may impact low haemoglobin deferral in blood donors were identified as 
areas in need of further investigation. These included blood group, previous platelet donation, diet, 
smoking, time of day, genetic data, and rhesus status. The INTERVAL trial data were analysed to 
further assess the role of some of these factors. Male blood donors with a non-O blood type had a 
higher relative risk of low haemoglobin deferral than O blood-group donors. 
Correlates and moderators of the effects of randomised inter-donation interval on four outcomes 
were investigated using INTERVAL trial data (Chapter 4). These outcomes analysed included number 
of donations and low haemoglobin deferrals during the trial, as well as two year haemoglobin and 
ferritin levels. This chapter added to previously published INTERVAL results by considering outcomes 
which had not been previously examined and including a wider range of baseline characteristics. 
Baseline variables that had a significant association with the number of donations during the trial 
included red blood cell count, baseline MCH, haemoglobin, log ferritin, and two year history of 
donations for men, and age for women. For both sexes, randomised group had a highly significant 
effect – in men, a decrease in the inter-donation interval of one week amounted to a 0.4 unit increase 
in blood given over two years, and for women this was a 0.2 unit increase. Some characteristics were 
associated with both number of donations and low haemoglobin deferrals – number of donations in 
the past two years and baseline haemoglobin in both sexes, and baseline ferritin in men. Analyses of 
two year haemoglobin and ferritin levels found few characteristics with significant interactions effects 
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with randomised inter-donation interval. These were largely biomarkers which are not routinely 
collected.  
7.1.2 Post-Donation Symptoms and Iron Supplementation 
One key consideration when assigning inter-donation intervals to blood donors is donor retention. If 
blood donors experience symptoms post-donation, they may stop returning to donate even when 
considering committed repeat donors. GEE modelling investigated if more frequent donation could 
influence post-donation symptoms in donors, such as tiredness, fainting, restless legs syndrome, and 
pica, and whether iron supplementation could mediate the effect of randomised inter-donation 
interval on symptoms (Chapter 5). Iron supplementation has been shown to reduce symptoms on 
occasion including RLS, fatigue, and pica. These analyses added to previous literature by analysing a 
wider range of symptoms, some of which have not been studied before in a blood donor population, 
such as breathlessness and feeling faint.  
Decreasing the inter-donation interval significantly increased a donor’s risk of developing almost all 
symptoms studied in the trial for both sexes. The exceptions were chest pain and pica in men, and 
palpitations and restless legs syndrome in women, with no significant effect of randomised inter-
donation interval found. While a donor’s use of iron supplementation at baseline and iron during the 
trial were associated with symptoms, the effect of randomised group was not mediated by iron 
supplementation for any of the symptoms studied. 
7.1.3 Effects of More Frequent Donation on Well-Being 
An additional consideration when assigning inter-donation intervals to blood donors is the impact on 
their quality of life. The effect of iron deficiency without anaemia on well-being is not well established, 
and blood donors may be susceptible to this.  
Longitudinal analyses were conducted to investigate the impact of more frequent donation on well-
being – the key secondary outcome of the INTERVAL trial (Chapter 6). Well-being was assessed by the 
physical and mental component scores of the Sf-36 questionnaire at baseline and after two years, and 
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the Sf-12 questionnaire every six months. Previous analyses had found that the summary PCS and MCS 
scores were largely unaffected by inter-donation interval [74].  
This chapter added to the literature by studying the sub-components which comprise the PCS and 
MCS summary scores in addition to the summary scores, and expanded the literature base which 
currently contains just one study in a blood donor population which specifically analysed PCS and MCS, 
which found no significant effect of blood donation on well-being [233]. 
Results from these analyses concurred with the previous study, finding little effect of inter-donation 
interval on the Sf-36 scores. This was also true of the Sf-12 scores, and the subcomponent scores of 
the PCS and MCS. Inter-donation interval had a statistically significant effect in Physical Role 
Functioning for men only, and no other sub-components were significantly affected. Other correlates 
of the subcomponents included weight and age, and iron-status variables. However, few of these 
associations were clinically meaningful. 
7.1.4 Summary 
Overall, the findings from this thesis indicate that it is possible to identify characteristics of donors 
who may be able to donate more frequently than current NHSBT inter-donation intervals while 
minimising low haemoglobin deferrals. Many of these characteristics are routinely collected. However, 
an increase in post-donation symptoms is a possible consequence of more frequent donation and iron 
supplementation may not offset the increased risk of post-donation symptoms posed by more 
frequent blood donation. Effects of more frequent blood donation on well-being of blood donors are 
likely to be minimal.  
7.2 Strengths and Limitations 
The primary strength of the results presented in this thesis is that they are based on analyses from the 
largest pragmatic randomised controlled trial designed to assess blood donation intervals. Inferences 
based on comparisons of randomised inter-donation intervals in over 45000 participants are free from 
confounding issues. In addition, as most donors adhered to their randomised inter-donation interval, 
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a clear separation between groups was achieved, and the trial represented the geographical breadth 
of England [74]. The trial also recorded a comprehensive set of outcomes and had almost complete 
data for the two main outcomes – number of donations and number of low haemoglobin deferrals 
[186]. In addition, the longitudinal models used in the analysis of symptoms and PCS and MCS analyses 
allowed for all timepoints at which data was collected to be used in the analysis, strengthening the 
reliability and power of the analyses. 
One limitation of the analyses is the nature of self-reported data. This was relied upon in baseline data 
collection, in particular for dietary variables which regarded estimating the number of portions of food 
consumed in a typical week. This may not be reliable as many people would not stick to a regular 
schedule eating the same type of food with the same frequency each week, or have an accurate record 
of their food consumption, forcing them to make their best guess at a response. In addition, the 
symptoms analysed were self-reported. While some of these symptoms such as fainting are very 
unambiguous, others such as feeling more tired or breathless than usual are subjective, and different 
donors would have a different level of feeling the symptom to report that they had experienced it. 
Some questions in the Sf-36 questionnaire were also shown to be difficult for participants to interpret 
meaningfully, and it is possible that this could affect results [262]. There is also the limitation afforded 
by the trial setting – as donors were actively participating in a trial, compliance with the assigned inter-
donation intervals is likely to be higher than if donors were donating outside of the trial. In addition, 
the donors who participated in the trial were likely to be more altruistic and motivated to donate than 
the general population. Consequently, it is possible that the observed results from this thesis are of a 
higher magnitude than what would be observed if the inter-donation interval were varied in routine 
practice in England. Moreover, as the trial could not by design be blinded, it is possible that 
participants on the shorter inter-donation interval groups were more sensitive of changes to their iron 
status and post-donation symptoms. 
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7.3 Results in Context of Other Literature 
Previous analyses from INTERVAL data have shown that allocating donors to more frequent inter-
donation intervals did amount to an increase in blood collected during the study period for both sexes. 
No difference in quality of life, physical activity, or cognitive function was observed across randomised 
groups, however those on the more frequent intervals did experience an increase in symptoms and 
low haemoglobin deferrals, and a decrease in their two year haemoglobin and ferritin [74]. These 
findings were consistent in the two year  study, which also found that donors were more likely to be 
diagnosed with low iron levels by a doctor on the more frequent inter-donation groups [186]. 
The findings from this thesis extended the main trial findings [74], by assessing interaction effects to 
determine which characteristics which may be useful to define donors most able to tolerate donation 
at more frequent intervals, while minimising low haemoglobin deferrals and symptoms. A thorough 
investigation of the effect of randomised inter-donation interval on post-donation symptoms and 
well-being measures was also conducted.  
The observational associations findings from this thesis are consistent with previous findings in blood 
donor populations. The Danish Blood Donor Study began 2010 and recruited blood donors in Denmark 
to assess why some donors are healthier than others. It has recruited over 40,000 participants [266]. 
It has found that ferritin is one of the most significant predictors of haemoglobin and development of 
low haemoglobin in blood donors [189], that donation intensity is a key predictor of iron stores in 
blood donors [76, 191], and that there is little association between blood donation and self-reported 
quality of life [233]. The RISE study from the USA recruited 2425 blood donors into sex-specific first 
time/reactivated donor and frequent donor cohorts. These cohorts were followed up for between 15 
and 24 months to evaluate their iron status [84]. It also concluded that donation intensity is a key 
predictor of iron stores [84]. The Donor InSight study was conducted in the Netherlands in the form 
of a self-administered questionnaire on demographics, lifestyle nutrition, physical activity, medical 
history, reproductive factors, and donor motivation [267, 268]. While dietary variables were not 
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significant in the analyses from INTERVAL data, the Donor InSight study in the Netherlands found a 
positive association between consumption of heme iron, and a smaller association with non-heme 
iron, and ferritin levels, which was mediated by donors’ baseline ferritin. However it concluded that 
dietary advice was not effective [269]. Results from this study concurred with findings in this thesis 
that lifestyle factors contribute little to low haemoglobin deferral levels [270]. 
7.4 Implications.  
Blood donation in the UK and elsewhere is inherently an altruistic act. Donors donate blood to give 
something back to their community. It is the duty of the blood service to ensure that the generosity 
of blood donors does not come at a cost to their physical or mental wellbeing. When deciding how 
long a donor should wait to return for donation, the blood service need to balance the demand for 
blood (or the donor's medical benefit from donating) against any potential adverse consequences on 
donor health such as low haemoglobin or ferritin levels, post-donation symptoms, and the general 
impact on wellbeing. While the analyses from this thesis have shown that there is little risk afforded 
to donors with respect to post-donation symptoms (Chapter 5), or general wellbeing (Chapter 6) from 
more frequent blood donation, low iron stores remains a concern. For the blood service, the primary 
concern will be low haemoglobin deferral, and the demotivation that this causes in donors, even 
regular, committed donors. In certain groups, such as women, ethnic minorities, and those with lower 
haemoglobin levels at previous donation visits, this can be of particular concern (Chapter 2). However, 
there are also the consequences of iron deficiency, which may occur in the absence of a low 
haemoglobin deferral, as a single blood donation removes 240-260mg of iron. Consequences of iron 
deficiency can include restless legs syndrome, fatigue, and cognitive effects. It is therefore important 
to minimise donors’ risks of iron deficiency, which may not be captured in haemoglobin testing solely.  
While few symptoms of iron deficiency were recorded in INTERVAL, it is possible that this may be 
differential in the general donor population, and due to the self-reported and subjective nature of this 
reporting, it is possible that symptom levels may be higher than reported. 
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The results from this thesis provide some considerations to take into account when varying the inter-
donation interval for blood donors. The overarching objective is to integrate the considerations 
surrounding personalised donation intervals into a coherent whole – to be able to allow blood donors 
to donate more frequently should there be a need for more blood, while minimising the risk that the 
donor comes to harm. Information on factors that affect a donor’s ability to donate can be considered 
alongside the risk of the donor experiencing a deferral, post-donation symptom, or serious adverse 
event. Although overall blood demand has been decreasing recently, there exist groups of blood 
donors that are a priority for NHSBT such as BAME donors and those of rare blood groups, so a 
personalised donation policy may be relevant in the shorter term or in the future as demand for blood 
and demographics of the general and blood donor population change. 
7.4.1 Assignment of Personalised Donation Intervals 
Results from Chapter 2 on correlates of low haemoglobin deferrals can be readily used by the blood 
service to inform literature such as pamphlets given to blood donors before and after donation, and 
recommend that donors in groups more predisposed to low haemoglobin deferrals take measures to 
manage their iron status between donations, to minimise low haemoglobin deferrals in these groups.  
Chapter 4 demonstrated that there are some factors that affect a donor’s ability to donate blood at 
more frequent intervals, such as red blood cell count and occupation status, and so if the blood service 
wishes to maximise blood donations from the blood donor population it is easy to consider these. 
Some factors, affect both donation and low haemoglobin deferral numbers. These include the number 
of donations in the previous two years and ferritin levels. A balance between these two effects would 
need to be sought when deciding personalised donation intervals. If looking to predict haemoglobin 
and ferritin levels as part of this process, it would be necessary to perform more haemotology analyses 
than is currently routine practice, which comes at an additional cost to the blood service.  
In Chapter 5, it was found that iron supplementation did not change the effect of randomised group 
on a donor’s likelihood to develop symptoms due to more frequent donation. The implication of this 
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is that, while there may be other reasons why donors may be encouraged to take iron 
supplementation such as increasing haemoglobin levels to minimise low haemoglobin deferrals, in 
more frequent donation groups, it should not be expected that this will also reduce post-donation 
symptoms, nor mitigate against the increased risk of developing post-donation symptoms posed by 
more frequent blood donation.  
The results from Chapter 6 were largely non-significant, and it is possible that the only significant 
effect due to inter-donation interval was found by chance. Regardless, none of the variables studied 
were associated with a clinically meaningful change in the sub-components of PCS and MCS. It is 
therefore expected that changes to a donor’s overall quality of life due to more frequent donation 
would be minimal. This trend continued in the INTERVAL two year extension study, and thus NHSBT 
may look to prioritise minimising low haemoglobin deferrals and post-donation symptoms. 
7.4.2 Blood Collection During the Coronavirus Pandemic 
The findings from this thesis are relevant to clinical practice. With the current coronavirus pandemic, 
blood collection agencies will have additional challenges for donor recruitment and retention. In the 
beginning of the pandemic in China, the USA and Australia, blood donations dropped considerably due 
to both fear of infection and more limited donation opportunities due to lockdown restrictions [271-
275]. However, focused retention and recall of donors has been effective at maintaining and 
improving donor numbers after this initial fall in donations [276]. In addition, blood collection agencies 
in China and Australia have found that donors who receive clear communication about coronavirus 
adaptations to the service were more likely to donate during the pandemic [273, 277], and messages 
of this kind have been advised as a method to improve blood donor numbers [273]. However, it is 
possible that first time or reactivated donors who respond to the pandemic will not remain committed 
donors, and countries which are reliant on replacement donors may not see the same benefits [271]. 
Personalised donation intervals to maximise the supply of blood from existing voluntary donors could 
help blood collection agencies which struggle as the pandemic progresses to maintain blood supply. 
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 7.4.3 Ferritin Testing of Blood Donors 
A key consideration raised from this thesis is ferritin testing of blood donors. The Netherlands recently 
implemented a ferritin testing policy in blood donors, testing ferritin at a donor’s first, and every fifth 
donation [278]. Donors were deferred between 6 and 12 months based on ferritin levels, and 
retention rates following a low ferritin deferral were 80% in men and 60% in women. However, low 
haemoglobin deferral rates were lower following ferritin deferral. A small-sample study from REDS-III 
found that ferritin testing was viable, with no significant variation in ferritin concentrations found in 
plasma separated from whole blood after five days, which reduces the pressure on blood collection 
agencies [279]. Should ferritin-based deferral policies be considered, iron supplementation may play 
a role in mitigating low ferritin deferrals more than observed in low haemoglobin deferrals. The HIERS 
trial in the USA randomised participants to iron supplementation following blood donation, and found 
that both haemoglobin and ferritin recovery were more rapid in donors taking iron supplementations, 
especially amongst those with low ferritin [280]. It found that the greatest benefit to iron stores was 
up to four weeks after donation, and recommended donors take iron supplementation immediately 
following donation to better manage iron levels [281, 282]. Additional RCT evidence would be useful 
to confirm the effect of iron supplementation on haemoglobin and ferritin levels in a blood donor 
setting. 
7.4.4 BAME Donors and Rare Blood Groups 
Currently, NHSBT has a shortage of black donors in particular [283]. This is important, as those from 
the same ethnic group are more likely to be from the same blood groups, and minor blood groups 
from donors of a different ethnicity can trigger reactions during transfusion even if donors are 
matched in their main blood type [284]. Despite black donor numbers rising by 35% in three years, 
there are still not enough to meet the demand for transfusions amongst patients with sickle cell 
disease, which has a higher prevalence in the black and minority ethnic community [285, 286]. 
Moreover, the Ro Kell negative blood which is particularly important for treating sickle cell disease has 
seen demand rise by 50% since 2015/16 and black donors are around ten times more likely to possess 
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this subtype than white donors [287]. While previous NHSBT campaigns have been effective [288], 
studies have identified motivations and deterrents to blood donation among black communities. Fear, 
and distrust in the blood and health services were found to be deterrents to black donors [285]. Under-
representation of black donors remains a problem even in majority-black countries such as South 
Africa, where black donors make up 24% of the donor population compared to 83% of the general 
population. Altruism was cited as the single most popular motivator to donate by black South Africans, 
and altruism-based interventions have had the largest effect sizes in encouraging donation [285, 289]. 
However, warm glow (helping others because it makes one feel good), reluctant altruism (helping 
because one does not trust others will) have also been identified as important motivators, with first 
time and repeat donors responding differently to different messages based on altruism, and 
benevolence which emphasises both the gain for the donor and the recipient [28, 290]. Personalised 
inter-donation intervals could be used to address the gap in supply and demand for blood from black 
donors which may take time to address through novel recruitment strategies that address both the 
motivations and deterrents to blood donation within black communities. However, the demographics 
of the black donor population may be different to the INTERVAL trial population, and therefore some 
results from INTERVAL may not be directly applicable. 
7.5 Future Directions 
Extensions of the work in this thesis could include using the results from Chapter 4, Chapter 5, and 
Chapter 6 to assign personalised inter-donation intervals in practice. While the aim of maximising the 
blood supply in the UK blood donor population is not immediately relevant, there are rare blood 
groups which are a priority for NHSBT, such as the Ro subtype which continues to see increased 
demand despite comprising 2% of the NHSBT blood donor population [291]. Personalised inter-
donation intervals more frequent than the current NHSBT guidelines could be introduced for these 
blood donors. It would also be possible to overcome the primary limitation of the INTERVAL trial, that 
of the trial effect, and assess the impact of more frequent inter-donation intervals in routine practice. 
Ferritin testing could also be implemented in such a pilot scheme to help minimise low haemoglobin 
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deferrals and maintain donor health while donating more frequently. This could be combined with 
results from the COMPARE study on haemoglobin testing and STRIDES trial on vasovagal reactions to 
ensure donor safety [292].  
In addition to this, the findings from this thesis could be used to guide future research. Expanded 
modelling using the results from this thesis could be performed to account for relationships between 
biomarkers and symptoms. Related outcomes could also be analysed together, for example, by using 
a joint modelling approach to assess haemoglobin and ferritin levels. Moreover, consideration could 
be made for clustering of donors by centre, or clusters of symptoms experienced by the same 
individual. In addition, structural equation modelling, LCA modelling, or machine learning approaches 
could be used to construct a framework that treats all the outcomes from this thesis as inter-related, 
enabling the development of an overall “donor risk score” which balances the donor’s ability to donate 
while taking a holistic view of the potential consequences of donation. Outcomes from such modelling 
could be used to develop a more comprehensive understanding of donor health, and the impact of 
more frequent donation on donor health. 
Chapter 5 investigated many symptoms that had little or no previous investigation. Additional studies 
on the effects of blood donation on some of these symptoms could be beneficial to enhance the 
evidence base. In addition, while iron supplementation was reported in INTERVAL, it was not a part of 
the trial’s design. It is possible that the donors in INTERVAL who took iron supplementation were doing 
so due to previous history of iron deficiency or side-effects of blood donation. In addition, fewer than 
10% of INTERVAL participants took iron prescription at any point during the trial. Further study of iron 
supplementation in UK blood donors, such as a study with equal numbers of donors taking iron 
supplementation as those who did not, and ensuring via minimisation algorithms that the 
characteristics of donors in both groups were comparable, could be used to further investigate the 
mediation effect of iron supplementation on symptoms in blood donors, and to overcome the 
limitations of the INTERVAL data when used for this purpose.  
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It is important to note that findings from INTERVAL represent the UK blood donor population only. 
International studies carried out by blood services in other countries where the characteristics of the 
general population in terms of age, weight, ethnicity, donation history, and population health could 
present different results to those obtained using the INTERVAL data. In addition, the effect of varying 
the inter-donation interval could be different in countries where the inter-donation interval is 
different than the UK, and in countries which routinely recommend or offer iron supplementation to 
blood donors following blood donation. Such studies would be beneficial to set international 
guidelines on inter-donation intervals which could be referenced by blood services internationally 
should they experience variation in their blood supply and demand and wish to adjust their inter-
donation intervals accordingly. 
7.6 Conclusions 
The INTERVAL trial has shown that there are some subgroups of the UK population that may be able 
to donate blood more frequently than current minimum inter-donation intervals. These groups of 
donors include men and women with a higher baseline haemoglobin level and number of previous 
donations, as well as older women. However, increased donation did also lead to an increase in some 
post-donation symptoms including tiredness, breathlessness, and fainting or feeling faint. Iron 
supplementation was not able to mitigate the effect of randomised group, and so it is important to 
bear this in mind when assigning donors to shorter intervals. 
At the trial’s inception, it was envisioned that there would be a shortfall in the supply of blood due to 
the aging population and the fact that new donor numbers are falling. However, there has instead 
been a decrease in blood demand owing to better transfusion practices such as only using one unit of 
blood at a time, having lower haemoglobin thresholds to begin transfusion, and other patient blood 
management techniques. While this is encouraging for the blood service, it is worth noting that the 
majority of the most committed blood donors in the UK are from the baby boomer generation, and in 
10-15 years’ time, many of these donors will be unable to give blood due to health complications or 
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aging out of the donor population. While INTERVAL’s primary goal may no longer be immediately 
relevant, it is therefore possible that this work can be used in the future should the supply of blood 
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Appendix A: Systematic Review Search Strategy 
THE COCHRANE LIBRARY 
#1 MeSH descriptor Blood Donors, this term only 
#2 MeSH descriptor Cytapheresis explode all trees 
#3 (red cell* or RBC* or blood or platelet*) NEAR/6 (donor* or donat*) 
#4 (donor* or donat* or interdonat*) NEAR/10 (defer* or delay* or exclu* or reject* or "turn* 
away" or interval*) 
#5 (#1 OR #2 OR #3 OR #4) 
#6 MeSH descriptor Anemia explode all trees 
#7 MeSH descriptor Ferritins, this term only 
#8 MeSH descriptor Hemoglobins, this term only 
#9 MeSH descriptor Iron, this term only 
#10 (iron or anaemi* or anemi* or ferritin or ferrous):ti 
#11 (ferropaeni* or ferropeni* or Feosol or "Fer Iron" or "Fer-Gen-Sol" or "Fer-in-Sol" or Feratab 
or FeroSul or (Ferra NEAR/2 Caps) OR "Ferro-Bob" OR "Slow Fe" OR "Slow Release Iron") 
#12  iron NEAR/3 (store* or status or deficien* or deplet* or supplement* or tablet* or pill* or 
sulphate or sulfate) 
#13 (ferritin or iron or haemoglobin or hemoglobin or Hb or haematocrit or hematocrit or Hct) 
NEAR/3 (level* or low* or below or concentration* or cutoff or rais* or increas*) 
#14 ferrous NEXT (sulfate or sulphate or fumerate) 
#15 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14) 
#16 (#5 AND #15) 
 
MEDLINE (Ovid) 
1. BLOOD DONORS/ 
2. exp CYTAPHERESIS/ 
3. ((red blood cell* or red cell* or RBC* or blood or platelet* or plateletpheres*) adj6 (donat* or 
donor*)).tw. 
4. ((donor* or donat* or interdonat*) adj10 (defer* or delay* or exclu* or reject* or turn* away or 
interval*)).tw. 
5. or/1-4 




10. (iron or anaemi* or anemi* or ferritin or ferrous).ti. 
11. (iron adj3 (store* or storing or status or deficien* or deplet* or supplement* or tablet* or pill* or 
capsule* or sulphate or sulfate)).ab. 
12. ((ferritin or iron or haemoglobin or hemoglobin or Hb or haematocrit or hematocrit or Hct) adj3 
(level* or low* or below or concentration* or cutoff or rais* or increas*)).tw. 
13. (ferrous adj (sulfate or sulphate or fumerate)).ab. 
14. (ferropaeni* or ferropeni* or Feosol or Fer Iron or Fer-Gen-Sol or Fer-in-Sol or Fer-In-Sol or 
Feratab or FeroSul or (Ferra adj2 Caps) or Ferro-Bob or Slow Fe or Slow Release Iron).tw. 
15. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16. 5 and 15 
 
EMBASE (Ovid) 





4. ((red blood cell* or red cell* or RBC* or blood or platelet* or plateletpheres*) adj6 (donat* or 
donor*)).tw. 
5. ((donor* or donat* or interdonat*) adj10 (defer* or delay* or exclu* or reject* or turn* away or 
interval*)).tw. 
6. or/1-5 
7. exp IRON DEFICIENCY ANEMIA/ 
8. IRON DEFICIENCY/ 
9. HEMOGLOBIN/ 
10. IRON DEPLETION/ 
11. (iron or anaemi* or anemi* or ferritin or ferrous).ti. 
12. (iron adj3 (store* or storing or status or deficien* or deplet* or supplement* or tablet* or pill* or 
capsule* or sulphate or sulfate)).ab. 
13. (ferropaeni* or ferropeni* or Feosol or Fer Iron or Fer-Gen-Sol or Fer-in-Sol or Fer-In-Sol or 
Feratab or FeroSul or (Ferra adj2 Caps) or Ferro-Bob or Slow Fe or Slow Release Iron).tw. 
14. ((ferritin or iron or haemoglobin or hemoglobin or Hb or haematocrit or hematocrit or Hct) adj3 
(level* or low* or below or concentration* or cutoff or rais* or increas*)).tw. 
15. (ferrous adj (sulfate or sulphate or fumerate)).ab. 
16. or/7-15 
17. 6 and 16 
 
CINAHL (NHS Evidence) 
1.    BLOOD DONORS/ 
2.    exp CYTAPHERESIS/ 
3.   ((red blood cell* OR red cell* OR RBC* OR blood OR platelet* OR plateletpheres*) AND(donat* 
OR donor*)).ti,ab 
4.   ((donor* OR donat* OR interdonat*) AND (defer* OR delay* OR exclu* OR reject* OR turn* away 
OR interval*)).ti,ab 
5.   1 OR 2 OR 3 OR 4 
6.    ANEMIA, IRON DEFICIENCY/ 
7.    FERRITINS/ 
8.    HEMOGLOBINS/ 
9.   IRON/ 
10.  (iron OR anaemi* OR anemi* OR ferritin OR ferrous).ti 
11.  (iron AND (store* OR storing OR status OR deficien* OR deplet* OR supplement* OR tablet* OR 
pill* OR sulphate OR sulfate)).ab 
12.  (Feosol OR Fer Iron OR Fer-Gen-Sol OR Fer-in-Sol OR Fer-In-Sol OR Feratab OR FeroSul OR Ferra 
Caps OR Ferro-Bob OR Slow Fe OR Slow Release Iron).ti,ab 
13.  ((ferritin or iron or haemoglobin or hemoglobin or Hb or haematocrit or hematocrit or Hct) AND 
(level* or low* or below or concentration* or cutoff or rais* or increas*)).ti,ab 
14.  (ferrous AND (sulfate OR sulphate OR fumerate)).ab 
15.   6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 
16.   5 AND 16 
 
PUBMED (epublications only) 
(red cell[TI] OR red cells[TI] OR blood[TI] OR platelet[TI] OR platelets[TI] OR plateletpheresis[TI] OR 
defer*[TI] OR delay*[TI] OR interval* OR reject*[TI] or exclu*[TI] OR iron[TI] OR ferritin[TI] OR 
anemi*[TI] OR anaemi*[TI])  
AND (donor*[TI] OR donat*[TI] OR interdonat*) AND (publisher[sb] NOT pubstatusnihms)  
 
WHO INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM (including ClinicalTrials.gov, EU 
Clinical Trials Register & ISRCTN) 
188 
 
((donor OR donors OR donate OR donated OR donation OR donations OR donating OR 
interdonation) [in Title] AND  
((iron OR ferritin OR ferrous OR interval OR intervals OR deferral OR deferred) [in Interventions] OR 
(anemia or anemia or anaemic or anemic or iron deficient or iron deficiency or low hemoglobin OR 
low hematocrit) [in Condition])) 
 
TRANSFUSION EVIDENCE LIBRARY 
((red blood cell* OR red cell* OR RBC* OR blood OR platelet* OR defer* OR delay* OR exclu* OR 
reject* OR turn* away OR interval* OR iron OR ferritin OR anemi* OR anaemi*) [In Search All Text] 
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Period 
Description of Study 
Participants and Data 
Collected All M F 




New and repeat blood 
donors at blood donation 
centre over one year. Data 
collected on new/repeat 
donor status and 
haemoglobin levels 
Agnihotri 2010 India RBC 
CuSO4 and Hemocue 
(men), hemocue 
(women) 
12.5 6032 [6357] 90.00 6.8 2.7 47.2 
January 
2008 – June 
2009 
Voluntary and replacement 
donors recruited over one 
and half years. Data 
collected on age, and 
voluntary donor status 




Blood donors who visited 
donation centre over 1.5 
years had data analysed. 
Haemoglobin and weight 
data collected  
Al Shaer 2017 UAE RBC Hemocue 13.5/12.5 
128054 
[142431] 




Allogenic whole blood 
donors aged between 17 
and 65. Data collected on 


















Hb Deferrals (%)4  
Study 
Period 
Description of Study 
Participants and Data 
Collected All M F 
Almeida 2013 Brazil RBC 
Hemocue (pre-2003), 
HemataSTAT II (2003 
onwards) 





Donors who had more than 
one visit to the centre and 
who were not deferred on 
their first visit due to the 
screening. Donors included 
in study until first low HCT 
deferral. Data collected on 
age (over vs under 50), 
baseline HCT level, and 
time between donations. 
Arslan 2007 Turkey RBC Hemocue 13.5/12.5 
83899 
[94919] 
89.5 3.4 2.1 15.2 
2001-2005 Hospital blood bank donors 
aged 18-65. Data collected 
on education level and 
voluntary donor status 
Baart 2012  The Netherlands RBC Hemocue 13.5/12.5 
220946 
[220946] 5 
50.9 5.8 4.1 7.7 
2007-2009 Previous donors who visited 
a blood collection centre 
whose previous two 
donations were whole blood. 
Data collected on 
seasonality, age, previous 
Hb levels, time since 
donation, donation history 
and previous deferral, BMI, 
and blood volume. 
Baart 2014 Ireland RBC Capillary Hemocue 13.0/12.0 45301 57.22 4.97 2.4 8.4 
2008 - 2010 Donors who visited any 
blood donor centre between 
2008 and 2010 whose last 
two donations were RBC. 
Data collected on 
seasonality, age, previous 
Hb levels, time since 
donation, donation history 
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Study 
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Description of Study 
Participants and Data 
Collected All M F 
Baart 2016 Switzerland RBC Hemocue 13.0/12.0 53722 60.41 5.82 3.28 9.69 
2011 - 2013 Donors who visited any 
blood donor centre between 
2011 and 2013 whose last 
two donations were RBC. 
Data collected on 
seasonality, age, previous 
Hb levels, time since 
donation, donation history 
and previous deferral. 
Backman 2016 Finland RBC, P, A 
Fingerstick analysed 
with Hemocue 





Database of all donation 
attempts from January 2010 
to December 2014. Data 
collected on blood group, 
rhesus status, seasonality, 
and first time vs repeat 
donors. 




Donations were replacement 
(99.5%) and voluntary 
(0.5%). 
Bakrim 2018 Morocco RBC Sysmex 13/12 15323 54.44 8.48 3.05 14.46 
November 
2014 - May 
2016 
 
Donors aged between 18 
and 60 who attended donor 
centres or mobile blood 
drives. Data collected on 
sex, type of work, age, 
province, and donor status. 
Baquero 2018 Columbia RBC, P, E n/r 13.5/13 
139277 
[179851] 
n/r 5.63 n/r n/r 
2011-2017 Repeat donors who were 
deferred multiple times for 
low haemoglobin during 
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All prospective blood donors 
at university hospital 
between 01/01/1996 and 
31/12/2003.  
Bischke 2011  Denmark n/r n/r 13.5/12.5 219 [219]  65.3 16.4  7.0 30.0 
n/r Donors failing previous Hb 
test would have been 
offered iron tablets. 
Bryant 2009 USA RBC Fingerstick 12.5 3549 [3730]  53.0 9.2 n/r n/r 
10/27/2008 
– 4/10/2009 
Consented donors >18yrs 
old. Data reported on 
ethnicity, age, and whether 
the donor stood or sat 
before donation. 
Burkitbayev 2017 Kazakhstan RBC Hemocue 12/11 130887 n/r 3.5 n/r n/r 
January 
2015 - June 
2017 
 
All donors who reported to 
donate during the study 
period. 
Cable 2012 USA 
RBC, 
2RBC 
Copper suphate 12.5 9633 [9901] 48.45 9.54 3.135 15.715 
2007 - 2009 Donors who successfully 
donated at enrolment visit 
recruited to study. Grouped 
by gender and first 
time/repeat donor. Data 
collected on diet, smoking 
and reproductive history, 
gender, age (categorised), 
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Data analysed over a period 
of 12 months at a donor 
centre to see if temperature 
affects low HCT deferral 
rate. 
Charles 2010  Trinidad/Tobago RBC Copper sulphate 13.5/12.5 
8199 
[11346]  
66.6 10.9 3.4 24.7 
2005 Data collected on age and 
voluntary donor status. 
Chaudhary 1995  India RBC CuSO4 13.5/12.5  
12363 
[14269]  




All donors were unpaid 
voluntary relatives aged 18-
60. Data also collected on 
medical history 




Blood donors who attended 
blood bank between 
01/01/2012 – 31/12/2012 
Cortes 2005   Colombia RBC Hemocue 13.5/13.0 210  59.5 7.6 0 18.8 
April – June 
2004 
300 donors presenting to a 
blood centre between April – 
June 2004, differentiated by 
altitude of city of residence. 
Custer 2004  USA RBC Copper sulphate 12.5 
4987704 
[5607922]  
50.2 6.0 n/r 11.0 2004 
Data collected on donation 
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Description of Study 
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Collected All M F 
Custer 2012 USA 
RBC, 
2RBC, MC 
n/r 12.5 1064855 n/r 4.8 n/r n/r 
September 
2009 - July 
2011 
Donors with at least one 
successful donation and one 
additional presentation 
between September 2009 
and July 2011. Gives odds 
ratios for deferral by 
donation type, haemoglobin 
levels, IDI, previous 
donations, and age. 
Custer 2012/  
Mast 2010  











Donors from REDS study. 
Data collected on age, 
ethnicity, donor status, 
donor site, previous 
donation, education level. 
Custer 2014 USA 
RBC, 
2RBC, MC 




Donors who donated blood 
on their index visit and also 
donated at least once 
between 01/08/2009 – 
31/07/2012). Information on 
sex, donation interval, 
baseline Hb, ethnicity, age 
and BMI (all categorised) 




Low Hb deferred donors 
between August 2005 and 
March 2006 matched for 
gender with successive 
blood donors. Data collected 
on electrophoretic profile 
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Collected All M F 
De Clippel 2017 Belgium RBC 
Venuous Hb, compolab, 
haemospect 




Prospective study over five 
donor centres equipped with 
Compolab measurement 
device and compared with 
others. Data collected on 
sex and first time/repeat 
donors. 
De Kort 2019 The Netherlands RBC Hemocue n/r 
131215 
[138398] 
43.74 5.44 3.14 7.24 
2015 A single random visit in the 
study period for each donor 
was included in the study. 
Data collected on season, 
time of day, blood group, 
age, and number of visits in 
past 5 years 
Delage 2012 Canada 2RBC Blood analyser n/r 1163 n/r 2.32 n/r n/r 
August 2009 
onwards 
Donors from August 2009 
onwards, gives associations 
with low Hb deferral and 
ferritin, haemoglobin, age 
and donation frequency 
















RCT which randomised 
donors who were aged 18, 
fulfilled criteria for donation, 
had an e-mail address, and 
willing to attend static donor 
centre to donate blood at 
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Collected All M F 
Di Lorenzo 
2009/2011  





66.0 2.8 0.6  5.5  
2006 Donors presenting in one of 
18 blood centres or 2 
hospital units. Data collected 
on age, ethnicity, previous 
donations, sickle cell trait, 
human development index, 
and size of city. 






Two study periods defined. 
July-Decmber 2012 where 
minimum inter-donation 
interval (IDI) is 8 weeks, and 
July-December 2013 where 
IDI is increased to 12 
weeks.  
Duffy 2015 USA RBC n/r n/r 27347 n/r n/r n/r n/r 
2010 - 2014 Donor database compared 
between 2010 and 2014 
where IDIs are 8 and 12 
weeks respectively. 
Eder 2010  USA n/r Mixed 12.5 
7546213 
[7871268] 
49.3 7.7 1.4 13.9 
2008 
American Red Cross 
donors. Data collected on 
donor status and age. 
Gandhi 2012  USA RBC n/r 12.5 
35053 
[35053] 5 




Two hospital blood donation 
sites and one fixed site 
collection unit. Data 
collected on age, donation 
and deferral history, blood 
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One fixed site collection unit. 
Data collected on age, and 
repeat donor status. 
Goldman 2013 Canada RBC n/r 12.5 600 43 8.33 1.63 13.74 
January - 
May 2012 
Donors recruited between 
January and May 2012, with 
oversampling of younger, 
first-time donors. 










Donors who presented to 
blood banks during the 
study period. In this time the 
minimum haemoglobin 
requirement for men was 
raised from 12.5 to 13 g/dL 
and the minimum donation 
interval for women was 
gradually lengthened from 
56 days to 84. 





All donor visits to mobile 
blood collection sites 
between September 2008 
and September 2013. Two-
step screening process used 
for deferrals. Data collected 
on age and gender. 
Goncalez 2013  Brazil RBC 









Three Brazilian blood banks, 
data collected on repeat 
donor status, ethnicity, age, 
socio-economic status, 
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Collected All M F 
Gorakshakar 2013 India n/r 
Automated 
counter/copper sulphate 
n/r 500 79.8 15.6 8.4 43.7 
n/r 500 blood donors from 
Mumbai area included in 
study. Data collected on 
age, sex, number of 
donations in the previous 
year, past and present 
illness, whether ready to 
take iron supplement 
collected and used to predict 
number of donations. 




Donors recruited at a blood 
centre at a children’s 
hospital. 
Hillgrove 2011 Australia RBC Hemocue 12.8/11.8 
69686 
[69686]  




All donors attending in two 
states (New South Wales 
and South Australia). Data 
collected on age, donation 
and deferral history. 
Hoekstra 2007  Netherlands RBC 










Participants had to have 
donated twice during the 
study period. Data collected 
on weight and temperature. 
Kagu 2010  Nigeria n/r Hemocue 12.5 3724 [4032] n/r 10.9 n/r n/r 
April 2007 – 
April 2009 
Data collected on repeat 
donor status and donation 
site. 
Kamel 2011 USA RBC n/r 12.5 
1051720 
[1051720]  
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Voluntary and replacement 
donors from January 2011 
and December 2012. 
Information on low Hb 
deferral by sex and age 
Khuankaew 2014 Thailand RBC n/r 13.0/12.5 
55000 
[58693] 
n/r 6.72 n/r n/r 
2013 Donor data analysed from 
the year 2013. 
Klausa 2013 Poland RBC n/r 13.5/12.5 121 23.14 28.1 21.43 30.11 
25-10-2012 
- 04/01/2013 
Survey of donors from 25-
10-2012 and 04/01/2013 on 
dietary preferences. Deferral 
information on sex, first time 
vs repeat donors, and 
donors applying a special 
diet. 
Konings 2013 The Netherlands n/r n/r n/r 917 66.09 35.11 35 35.5 
2009 - 2013 Donors from southeast 
region of Sanquin 
Bloodsupply dataset 
between 2009 and 2013 
analysed. 
Kouao 2012  Ivory Coast RBC Hemocue 11.0 
22516 
[24363] 




Hospital blood bank. Data 
collected on weight, repeat 
donor status, and blood 
pressure. 
Kwenti 2016 Cameroon RBC Hemoglobinometer 13.0/12.0 1896 91.35 31.43 29.39 50 
01/01/2014 - 
31/12/2014 
Blood donors recruited 
between 01/01/2014 and 
31/12/2014. Blood group 
and rhesus status collected, 
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n/r 4.6 n/r n/r 
1981 - 1984 
 
Blood centre attendees. 
Data collected on age, 
donation history, exercise, 
occupation, previous 
deferral, past iron 
deficiency, and obstetric 
history 
Lee 2013 Hong Kong RBC Hemocue 13.0/11.5 801 49.13 24.47 25.06 23.89 
27/07/2009 -  
24/08/2009 
Consenting donors who 
donated between 
27/07/2009 and 24/08/2009. 
Data on donor weight, IDI, 
previous donations, and 
biomarkers. 
Lee 2016 Hong Kong n/r n/r 13.0/11.5 90643 43.28 11.42 8.06 13.99 
2014 - 2015 All first time donors in 2014 
and 2015 included. Age 
collected as categorical 
variable. 
Lim 1993  Singapore n/r n/r 12.5/12.0 
242167 
[278401] 




Attended Singapore Blood 
Transfusion Service. Data 
collected on race and 
menstruation history. 





First time donors between 
October 2013 and January 
2014.Age presented as 
categorical variable. 





Donors analysed between 
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Magnussen 2015b Denmark RBC 
Venuous analysed with 
Sysmex 





Malard 2018 Caribbean RBC Sysmex 13/12 20368 n/r n/r 3.4 15.9 
2015 All donor candidates who 
presented to a collection site 
in 2015. Data collected on 
donation interval, previous 
haemoglobin level, and 
number of previous 
donations 
Mangwana 2013 India RBC n/r n/r 
19878 
[22404] 
93.88 4.39 1.91 34.4 
01/01/2007 -
30/06/2010 
Donors who attended from 
01/01/2007 and 30/06/2010 





Female donors only, who 
had given at least one blood 
donation in the past two 
years recruited from March 
2009 to October 2010 into 
trial receiving iron or 
placebo pills post-donation. 
Primary outcome was ferritin 
levels after 12 weeks. Age 
and Hb levels recorded. 
Mast 2015 USA RBC n/r n/r 393 n/r n/r n/r n/r 
n/r Frequent blood donors from 
3 centres assigned to 
intervention groups of 
iron/placebo pills, iron status 
letters, and no action, and 
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Mathur 2012 India RBC CuSO4 and Hemocue 12.5 
30948 
[35339] 
n/r 14.19 n/r n/r 
September 
2005 - July 
2006 
Voluntary donors who 
attended between 
September 2005 and July 
2006. Compares CuSO4 
method with Hemocue. 
Meinia 2018 India RBC n/r 12.5 2106 [2195] 89.61 0.76 0.16 6.07 
June 2015 – 
May 2016 
Donors who presented 
during the study period. 
Mirrezaie 2011  Iran n/r Hemocue 12.5 2000  70.0 16.3 10.0 31.0 n/r 
Randomly selected donors. 
Munasinghe 2011  Sri Lanka RBC n/r n/r 6964 [7609] n/r 3.5 n/r n/r 2008-2010 Data collected on repeat 
donor status. 
Muon 2018 Portugal RBC 
Spectrophomotery 
 
13.5/12.5 739576 48.94 u/c5 u/c5 u/c5 
2007-2016 Donors who presented 
during the study period. 
Data collected on sex and 
time between donations 
Nadarajan 2010  Malaysia n/r 





n/r 2.1 n/r n/r 
2006 - 2008 
Data collected on repeat 
donor status and donation 
interval 




Includes donors whose first 
visit was between 
01/01/2007 – 31/12/2009 
and who donated at least 
twice during this period. 
Data collected on age and 
gender, as well as season 
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Nasserinejad 2015 The Netherlands RBC Photometer 13.5/12.5 5388 35.3 27.39 18.4 32.3 
01/01-2005 
- 31/12/2012 
New donors whose first visit 
was between 01/01-2005 
and 31/12/2012 and who 
made at least one visit after 
the first donation 
Nasserinejad 2016 The Netherlands RBC n/r 13.5/12.5 4461 34.79 9.26 5.28 11.38 
01/01-2005 
- 31/12/2012 
New donors whose first visit 
was between 01/01-2005 
and 31/12/2012 and who 
made at least one visit after 
the first donation. Data 
collected on age and 
gender, as well as season 
(summer vs winter) 





500 donors with a 
successful first donation 
between 06/06/2008 and 
07/07/2008 and with at least 
two donations followed for 
3.75 years 
Ngoma 2013 Japan RBC n/r 12.5/12.0 
218376 
[231361] 




Donors who attended two 
blood centres between 
March 2010 and March 
2011. Information given on 
deferral by age (categorical), 
gender, location, and first 
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Students aged 16-24 who 
donated in two blood 
centres from March 2010 to 
March 2011. Information 
given on deferral by age 
(categorical), gender, 
location, and first time vs 
repeat donors. 
O’Meara 2011  Switzerland RBC Cell counter 13.3/12.3 
160612 
[160612]  
46.2 2.4 n/r n/r 
1996 - 2009 Optional iron 
supplementation offered 
from 2004 onwards. Data 
collected on age. 
Oumeziane 2013 UAE RBC Hemocue 13.5/12.5 
88509 
[93230] 
90.44 4.18 2.46 216 
2010-2012 All prospective donors from 
2010-2012) 
Patiakas 2013 Greece RBC n/r n/r 
14358 
[16580] 
n/r 2.67 n/r n/r 
2007 - 2013 
 
Blood donors in past six 
years questioned. 
Compared donors who 
donated in hospital and out 
of hospital. 















Donors who presented 
during both study periods. 
Data collected on age, 
ethnicity, donor status and 
blood group 










Hospital blood collection 
unit. Data collected on first 
time and reactivated donors, 
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Prados Madrona 
2014 
Spain RBC Hemocue 
8.4/7.8 
mmol/L 
19916 48.68 24.01 7.16 0.4 
2005-2009 All donor presentations from 
2005-2009. Age collected as 
categorical variable 
Py 2014 France RBC n/r 13.0/12.0 2335869 53.71 2.13 0.74 3.33 
2010 Retrospective analysis of 
data from 2010. 





Data collected on donation 
history. 
Raka 2010 Macedonia RBC n/r n/r 
21331 
[21915] 
79.3 4.6 n/r n/r 
2009 
 
Raouf 2016 UAE RBC n/r n/r 
62300 
[74087] 





Four year retrospective 
study, comparing deferrals 
at fixed and mobile sites 
Rosochova 2011  Switzerland RBC 
Hemocue 
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Donor centres selected for 
inclusion based on state’s 
relative contribution to blood 
supply. At selected centres 
over 4 consecutive days 
RBC donors were recruited, 
apheresis donors recruited 
in one random day of the 
same week. Height, weight, 
and previous donor history 
collected. 
Samir 2015 Egypt RBC n/r 13.0/12.0 
32412 
[40765] 
74.36 10.52 n/r n/r 
2014 Retrospective analysis of 
donors in 2014. Presents 
graphical results of deferral 
by month. 
Saunders 2018 UK RBC Copper sulphate 13.5/12.5 1195 48.95 8.87 4.44 13.11 
n/r Single donation from each 
donor selected. 
Sebok 2007  USA n/r 
CoSU4 followed by 





n/r 7.8 1.0  13.8  
2002-2004 
Data collected on age, 
season, and temperature 
variability. 
Sharma 2013 India RBC n/r n/r 
18364 
[19125] 
95.91 2.64 1.62 26.94 
January – 
June 2011 
Donor data from January – 
June 2011 analysed. 
Information on voluntary vs 
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Shaz 2010  USA n/r 





52.8 8.9 1.2 15.7 
2004-2008 Voluntary donors who 
presented during the study 
period. Data collected on 
age and race 
Sohail 2017 Pakistan n/r n/r n/r 
40220 
[54292] 





Voluntary blood donors who 
presented during the study 
period. 
Sorensen 2019 Denmark RBC Sysmex 13.5/12.5 15567 53.53 n/r n/r n/r 
Unclear Donors who had donated 
more than twice. Information 
on genetic data presented 
with a model for risk of low 
haemoglobin deferral. 
Spencer 2016 USA RBC n/r 12.5 5017107 45.22 10 1.53 20 
2006 - 2009 Donors attending six donor 
centres between 2006 and 
2009. Odds ratios given for 
donor deferral by race, age, 
weight, two year donation 
history, location and time 
between 2RBc and RBC 
donation. 
Steele 2013 USA n/r n/r 12.5 
1009127 
[1219805] 
46.47 7.9 0.006 14.64 
2011 Donors who made their first 
donation in 2011 analysed. 
Gives analysis of deferral by 
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Stotzer 2013 Germany RBC n/r n/r 863 25.96 2.34 n/r n/r 
n/r Prospective study 
comparing iron replacement 
drug used by the blood 
service with a food 
supplement and no 
supplementation. 




donors were tested using 
two measurement methods. 
Deferral data given by sex 
and measurement method. 












Donors no more than 60 
years old. Data collected on 
age and voluntary donor 
status. 
Svirnoskaya 2012 Belarus RBC Hemocue 13.5/12.5 2031 [2902] 82.01 4.87 n/r n/r 
2009 - 2010 Donors who made their 20th 
donation between 2009 and 
2010. 
Timova 2014 Macedonia RBC n/r 13.5/12.5 2001 [2054] n/r 4.4 n/r n/r 
2013 Donors who attempted 
donation in 2013 
Timova 2015 Macedonia RBC n/r 13.5/12.5 2179 [2255] n/r 3.44 n/r n/r 
2014 Donors who attempted 
donation in 2014 





Blood banks and mobiles, 

















Hb Deferrals (%)4  
Study 
Period 
Description of Study 
Participants and Data 
Collected All M F 




Blood donors at a tertiary 
care hospital. Data collected 
on age, education, 
employment status, and 
occupation 
Valerian 2018 Tanzania RBC n/r n/r 
12934 
[14377] 




All donors who presented at 
the blood bank. Data 
collected on age, type of 
donor, and location of 
residence 
van den Berg 2016 South Africa RBC n/r n/r 4412 n/r 7.46 n/r n/r 
2 days Consecutive sampling. Odds 
ratios of deferral risk by 
race, gender, age, and 
ferritin levels reported. 
Van den Berg 2019 South Africa RBC 
copper sulphate 









Donors over the age of 18. 
Data reported on age, 
ethnicity, location, donor 
type, previous donation 
history, haemoglobin levels, 
and ferritin. 




Donor records from six 
months analysed.  
Wichmann 2013 Germany RBC Sysmex 13.5/12.5 4312 [4388] 56.93 2.76 1.09 5.16 
n/r Two mobile blood sites 
equipped with Hemospect 
and donors asked to give 



















Hb Deferrals (%)4  
Study 
Period 
Description of Study 
Participants and Data 
Collected All M F 
Wilkinson 1982  Ireland n/r CuSO4 12.25 
1763903 
[1763903]  
65.7 5.7 1.0 14.6 
1961 - 1980 
Aged 18-65. Data collected 
on repeat donor status. 





2010 for 18 
months 
Donor data from September 
2010 for 18 months 
(Ultracrit) and October 2008 
to March 2010 (Hemocue) 
analysed comparing monthly 
rate of deferral by 
measurement method. 
Zanella 1989  Italy n/r 
CuSO4 and automated 
cell counter 
13.5/12.5 14641 63.3 4.3 1.2 9.7 
1977 - 1987 Donors who made their first 
donation during the study 
period. Data collected on 
age, annual frequency of 
donations, Hb concentration 
at first visit. 
Ziemann 2006  Germany RBC 
Automated 
haemotology analyser 
13.5/12.5 81913  57.5 6.4 n/r n/r 
May 2003 – 
November 
2005 
Consecutive donors. Data 
collected on donation 
interval and iron 
supplementation. 
 
n/r = not reported;  1 RBC = red blood cells; P = platelets, A = apheresis, 2RBC = double red cell, MC = multicomponent, E = Erythroperesis, Ps = Plasma;   2 g/dL (values in 
parentheses are % haematocrit thresholds);   3 number of donation attempts excluding deferrals due to reasons other than low Hb [total number of donation attempts];   4 
where possible, the low Hb deferral rate is calculated as a percentage of the combined total number of Hb deferrals and accepted donations, i.e. deferrals due to other reasons 
were excluded in the calculation of the low Hb deferral rate; 5 Data presented in paper does not add up to totals presented;   6 the number of deferrals due to reasons other 
than low Hb could not be determined; the deferral rate is therefore given as a percentage of all donation attempts, including those deferred due to other reasons; 5 sex-specific 
deferral data available for RBC donors only 
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Appendix D: Sf-12 as used in INTERVAL 
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